



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 183912

TO: Ruixiang Li
Location: rem/4D59/4C70
Art Unit: 1646
April 6, 2006

Case Serial Number: 10/811198

From: P. Sheppard
Location: Remsen Building
Phone: (571) 272-2529

sheppard@uspto.gov

Search Notes

78733

Mg

183912

STIC-Biotech/ChemLib

From: Li, Ruixiang
Sent: Saturday, April 01, 2006 9:34 AM
To: STIC-Biotech/ChemLib
Subject: Sequence search of Application No.10/811,198

Please do a standard search on:

SEQ ID NO: 2 against both commerical and interference amino acid databases.

Thank you very much!

Ruixiang Li
GAU 1646
REM 4D59
Mail Box 4C70
(571) 272-0875

RECEIVED
APR - 3 2006
STIC-BIOTECH/CHEM LIBRARY
(STIC)

Searcher: _____
Searcher Phone: _____
Date Searcher Picked up: _____
Date completed: _____
Searcher Prep Time: _____
Online Time: _____

Type of Search
NA# _____ AA#: _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure #: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable
STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: _____
WWW/Internet: _____
Other (Specify): _____

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using SW model

Run on: April 4, 2006, 20:07:07 ; Search time 233 Seconds
1105.227 Million cell updates/sec

Title: US-10-811-198-2

Perfect score: 1944

Sequence: 1 MASTESSLLRLSGLSPGPGS.....CRWAATPQDSSCSTPRADRL 365

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs., 705528306 residues

Total number of hits satisfying chosen parameters:

2166443

Minimum DB seq length: 0

Maximum DB seq length: 20000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_05-80:
1: uniprot_sprot:
2: uniprot_trembl:
*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB ID	Description
1	194	100.0	365	1	P2RY4_HUMAN	P51582 homo sapien
2	194	100.0	365	2	Q5DT22_HUMAN	Q502W2 homo sapien
3	193	99.7	365	2	Q5DT22_HUMAN	Q502W2 homo sapien
4	193	99.5	365	2	Q4VB77_HUMAN	Q4VB88 homo sapien
5	193	99.5	365	2	Q4VB88_HUMAN	Q4VB88 homo sapien
6	159	82.2	361	1	P2RY4_RAT	Q35811 rattus norvegicus
7	156	80.3	361	1	P2RY4_MOUSE	Q9JJS7 mus musculus
8	117	60.5	230	2	Q5Y809_SUS_SCROFA	Q57466 meleagris gallopavo
9	112	58.0	374	2	Q5Y809_SUS_SCROFA	Q7ZZA4 brachydanio rerio
10	103	53.4	347	2	Q7ZZA4_BRARE	Q5b779 xenopus laevis
11	102	52.6	543	2	Q5b779_XENLA	P79928 xenopus laevis
12	100	51.5	537	1	P2RY8_XENLA	Q7Zwq7 xenopus laevis
13	100	51.8	537	2	Q7Zwq7_XENLA	Q4RP73 tetraodon natus
14	97	49.9	302	2	Q4RP73_TBMAN	P41231 homo sapien
15	96	49.6	377	1	P2RY2_HUMAN	P53833 mus musculus
16	96	49.5	373	1	P2RY2_MOUSE	Q4815 tetraodon natus
17	95	48.9	374	1	P2RY2_BRARE	Q5Y232 rattus norvegicus
18	94	48.4	373	2	Q5Y235_BOVIN	Q5Y235 sus scrofa
19	91	46.8	349	2	Q6PB52_XENTR	Q6P852 xenopus trophiculus
20	82	42.3	165	1	P2RY4_CHIGR	P58826 cricetus carolinus
21	80	41.6	164	1	Q5DXK1_PIG	Q5dkx1 sus scrofa
22	80	41.3	310	2	Q4SEL5_TEING	Q4815 bovis taurinus
23	66	34.1	125	1	Q6QH9_BOVIN	P47900 homo sapiens
24	64	33.0	373	1	P2RY1_HUMAN	P49652 meleagris gallopavo
25	63	32.5	362	1	P2RY1_TBMAN	P49962 gallus gallus
26	62	32.3	362	1	P2RY1_CHICK	P49902 cavia porcellus
27	62	32.3	373	1	P2RY1_CAVPO	P48042 bos taurus
28	62	31.9	373	1	P2RY1_BOVIN	Q9de05 rata erinaceus
29	62	31.9	357	2	Q9de05_RAJER	P49651 rattus norvegicus
30	61	31.7	373	1	P2RY1 RAT	P2RY1_MOUSE
31	61	31.6	373	1	P2RY1_MOUSE	P49650 mus musculus

CC agonist-dependent desensitization and loss of surface P2RY4. This CC phosphorylation does not involve PKC, nor other calcium activated CC kinases.

->A: Belongs to the G-protein coupled receptor 1 family.

CC - SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.

CC	EMBL: X918963; - ; Genomic DNA.	FT MUTAGEN	339	339	A-339
CC	EMBL: X40223; AAC0347.1; - ; Genomic DNA.	FT MUTAGEN	344	365	S->A: Greatly reduces agonist-induced desensitization and loss of cell surface receptors; when associated with A-333 and A-334.
CC	EMBL: X96597; CAA54515.1; - ; Genomic DNA.	FT MUTAGEN	356	365	Missing: No effect on agonist-induced phosphorylation, no functional effect.
CC	HSSP; P24996; 1DDP.	FT CONFFLICT	86	96	Missing: No functional effect.
CC	Ensembl; ENSG00000186912; Homo sapiens.	FT CONFFLICT	234	234	L -> V (in Ref. [2]).
CC	HGNC; HGNC:8542; P2RY4.	FT SEQUENCE	365	AA:	S -> A (in Ref. [2]).
CC	MIN; 30038; - .	Score 1944;	100	0%;	Score 1944;
CC	DR; GO:0005887; C: integral to plasma membrane; TAS.	Best Local Matches	100	0%;	DB 1;
CC	DR; GO:0015065; F: uridine nucleotide receptor activity; TAS.	Mismatches	0	0;	Length 365;
CC	DR; GO:002004; P: positive regulation of cytosolic calcium ion concentration; TAS.	Indels	0	0;	Pred. No. 1..1e-131;
CC	DR; InterPro; IPR000276; GPCR_Rhodopsin.	Gaps	0	0;	Gap 0;
CC	DR; InterPro; IPR002226; G_protein_coupled_receptor_P2_purinceptor.				
CC	DR; InterPro; IPR00018; P2Y_purinceptor.				
CC	DR; Pfam; Pfam00001; 7tm_1..1.				
CC	DR; PRINTS; PR00237; GPCR_RHODOPSN.				
CC	DR; PRINTS; PR01066; P2Y4_PNOCOPR.				
CC	DR; PRINTS; PR01157; P2Y_PNOCOPR.				
CC	DR; PROSITE; PS00237; G_PROTEIN_RECEP_F1..1;				
CC	DR; PROSITE; PS000262; G_PROTEIN_RECEP_F1..2; 1.				
CC	DR; G_protein_coupled_receptor_Phosphorylation; Polymorphism; Receptor; Transducer; Transmembrane.				
CC	FT TOPO_DOM 1 34 Extracellular (Potential).				
CC	FT TRANSMEM 35 61 1 (Potential).				
CC	FT TOPO_DOM 62 72 Cytoplasmic (Potential).				
CC	FT TRANSMEM 73 95 2 (Potential).				
CC	FT TOPO_DOM 96 112 Extracellular (Potential).				
CC	FT TRANSMEM 113 131 3 (Potential).				
CC	FT TOPO_DOM 132 154 4 (Potential).				
CC	FT TRANSMEM 155 174 Extracellular (Potential).				
CC	FT TOPO_DOM 175 196 5 (Potential).				
CC	FT TRANSMEM 197 222 Cytoplasmic (Potential).				
CC	FT TOPO_DOM 223 246 Extracellular (Potential).				
CC	FT TRANSMEM 247 269 6 (Potential).				
CC	FT TOPO_DOM 270 287 7 (Potential).				
CC	FT TRANSMEM 288 309				
CC	FT TOPO_DOM 310 365				
CC	FT MOD_RES 333 333 Cytoplasmic (Potential).				
CC	FT MOD_RES 334 334 Phosphoserine (Probable).				
CC	FT DISULFID 108 185 Phosphoserine (Probable).				
CC	FT VARIANT 168 168 By similarity.				
CC	V -> M (in dbSNP:1152186).				
CC	/PTId=VAR_011854.				
CC	FT VARIANT 178 178 N -> T (in dbSNP:1152187).				
CC	/PTId=VAR_011855.				
CC	FT VARIANT 191 191 P -> L (in dbSNP:1152188).				
CC	/PTId=VAR_011856.				
CC	S->A: No effect.				
CC	Missing: Abolishes agonist-induced desensitization and loss of cell surface receptors.				
CC	ACRWAAPQDACAACAA; Greatly reduces agonist-induced desensitization and loss of cell surface receptors; when associated with A-333 and A-334.				
CC	SSLVSLPENSQRWAAATPODSSEST->KALAVVALPDA				
CC	PT MUTAGEN 333 359 NUCLEOTIDE SEQUENCE.				
CC	PT MUTAGEN 333 333 RNP (MAY-2005) to the EMBL/GenBank/DDBJ databases.				
CC	PT MUTAGEN 333 365 RN Brown_A; Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.				
CC	PT MUTAGEN 333 333 RN [2]				
CC	PT MUTAGEN 333 333 RN NUCLEOTIDE SEQUENCE.				
CC	PT MUTAGEN 333 333 RN TISSUE=PCR rescued clones;				
CC	PT MUTAGEN 333 333 RN MEDLINE=22389257; Peingold_E.A.; Grouse_L.H.; Derge_J.G.; Schulz_G.D., Klausner_R.D., Collins_P.S., Wagner_L., Shemesh_C.M., Schaefer_C.P., Bhat_N.K., Altschul_S.F., Zeeberg_B., Buetow_K.H., Hopkins_R.P., Jordan_H., Moore_T., Max_S.I., Wang_J., Hsieh_F., Diatchenko_L., Marusina_K., Farmer_A.A., Rubin_G.M., Hong_L.,				

Db	121	CSVLPFTCISVRYLGICHPKRALWKGRPRIAGLICLAWLVVACCLVPNLLFFTTSTKG	180	DR PROSITE; PS50262; G PROTEIN RECEPTOR_F1_2; 1. KW G-protein coupled receptor; Receptor; Transmembrane.
Qy	181	TTVLCHDTTRPPEFDHYVFHSSAVNGLFLGSPVCLTVLGIMARRLYQPLPGSAQSSR	240	Query Match 99.5%; Score: 1935; DB: 2; Length: 365;
Db	181	TTVLCHDTTRPPEFDHYVFHSSAVNGLFLGSPVCLTVLGIMARRLYQPLPGSAQSSR	240	Best Local Similarity 99.5%; Pred. No. 4.7e-131; Matches 363; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy	241	LRSLRITAVVLTIVAVCFVPHITRITYYLARLLPADCRLVNIINVYKTRPLASANSC	300	Qy 1 MASTESSLURSLGSQGPSSSEVLDCWDEDKFELLPUVSYAVWFLGLGLNAPTLWLF 60 1 MASTESSLURSLGSQGPSSSEVLDCWDEDKFELLPUVSYAVWFLGLGLNAPTLWLF 60
Db	241	LRSLRITAVVLTIVAVCFVPHITRITYYLARLLPADCRLVNIINVYKTRPLASANSC	300	Db 61 IFRLRPWDDATYNFHIALSDTLIVLSPLIYIYAAHHWPFGTEICKFVRFLFYNNLY 120 61 IFRLRPWDDATYNFHIALSDTLIVLSPLIYIYAAHHWPFGTEICKFVRFLFYNNLY 120
Qy	301	LDPVLYLTLGDKYRQLRQLGGKEQPRITAASSLVLSPEDSSCRWAATPDQSSCSTP	360	Qy 121 CSVLFCLTCISVHRYLGICHPKRLWRGRPLAGLCLAWLWVVGCLVNPNLFFTTTSNKG 180 121 CSVLFCLTCISVHRYLGICHPKRLWRGRPLAGLCLAWLWVVGCLVNPNLFFTTTSNKG 180
Db	301	LDPVLYLTLGDKYRQLRQLGGKEQPRITAASSLVLSPEDSSCRWAATPDQSSCSTP	360	Db 121 CSVLFCLTCISVHRYLGICHPKRLWRGRPLAGLCLAWLWVVGCLVNPNLFFTTTSNKG 180
Qy	361	RADRL 365	Qy 181 TTVLQHDTRPPEFDHYFESSAIVGCLLFGCPVCLTVLGIMARRLYQPLPGSAQSSR 240 181 TTVLQHDTRPPEFDHYFESSAIVGCLLFGCPVCLTVLGIMARRLYQPLPGSAQSSR 240	
Db	361	RADRL 365	Db Qy 241 LRSLRITAVVLTIVAVCFVPHITRITYYLARLLPADCRLVNIINVYKTRPLASANSC 300 241 LRSLRITAVVLTIVAVCFVPHITRITYYLARLLPADCRLVNIINVYKTRPLASANSC 300	
Qy	[1]	NCBI_TaxID=9606;	Db DT 241 LRSLRITAVVLTIVAVCFVPHITRITYYLARLLPADCRLVNIINVYKTRPLASANSC 300 241 LRSLRITAVVLTIVAVCFVPHITRITYYLARLLPADCRLVNIINVYKTRPLASANSC 300	
RN			DE Pyrimidinergic receptor P2Y4. Name=P2R4; OS Homo sapiens (Human); Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; OC Homo. NCBI_TaxID=9606;	
RP			Qy 361 RADRL 365 Db 361 RADRL 365	
NUCLEOTIDE SEQUENCE			RESULT 5	
RC			Q4VB8B_HUMAN PRELIMINARY; PRTR; 365 AA.	
TISSUE=PCR rescued clones;			ID Q4VB8B_HUMAN PRELIMINARY; AC Q4VB8B_	
MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;			AC DT 13-SEP-2005 (TREMBLrel. 31, Last sequence update) AC DT 13-SEP-2005 (TREMBLrel. 31, Last annotation update)	
RA Strasbourg R.L., Feingold E.A., Grouse L.H., Derge J.G., RA Klausner R.D., Collins F.S., Wagner L., Sherman C.M., Schuler G.D., RA Altschul S.F., Zeeberg B., Bustow K.H., Schaefer C.F., Bhat N.K., RA Hopkins R.F., Jordahl H., Moore T., Max S.I., Wang J., Hsieh F., RA Diachenko L., Mansina K., Farmer A.A., Rubin R., Hong L., RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., RA Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C., RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mulahay S.J., RA Bosak S.A., McEvaw P.J., McKernan K.J., Malek J.A., Gunarane P.H., RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., RA Pahey J., Helton E., Ketteman M., Madan A., Rodriguez S., Sanchez A., RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., RA Schnier A., Schein J.E., Jones S.J.M., Marra M.A., RA "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences"; RA Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).	RA MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899; RA STRASBURG R.L., FEINGOLD E.A., GROUSE L.H., DERGE J.G., RA KLAUSNER R.D., COLLINS F.S., WAGNER L., SHERMAN C.M., SCHULER G.D., RA ALTSCHUL S.F., ZEEBERG B., BUSTOW K.H., SCHAEFER C.F., BHAT N.K., RA HOPKINS R.F., JORDAHL H., MOORE T., MAX S.I., WANG J., HSIEH F., RA DIACHENKO L., MARNSINA K., FARMER A.A., RUBIN R., HONG L., RA STAPLETON M., SOARES M.B., BONALDO M.F., CASAVANT T.L., SCHEETZ T.E., RA DE PYRIMIDINERGIC RECEPTOR P2Y4. RA GN NAME=P2R4; RA OS HOMO SAPIENS (HUMAN); RA EUKARYOTA; METAZOA; CHORDATA; CRANIATA; VERTEBRATA; EUTELEOSTOMI; RA MAMMALIA; EUTHERIA; EUARCHONTOGLIERES; PRIMATES; CATARRHINI; HOMINIDAE; RA OC HOMO. RA NCBI_TAXID=9606;			
NUCLEOTIDE SEQUENCE			RN [1] NUCLEOTIDE SEQUENCE.	
RC			RC TISSUE=PCR rescued clones;	
TISSUE=PCR rescued clones;			RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;	
NIH NGC Project;			RA RA Strasbourg R.L., Feingold E.A., Grouse L.H., Derge J.G., RA RA Klausner R.D., Collins F.S., Wagner L., Sherman C.M., Schuler G.D., RA RA Hopkins R.F., Jordahl H., Moore T., Max S.I., Wang J., Hsieh F., RA RA Diachenko L., Mansina K., Farmer A.A., Rubin R., Hong L., RA RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., RA RA Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C., RA RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., RA RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., RA RA Schnier A., Schein J.E., Jones S.J.M., Marra M.A., RA RA "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences"; RA RA Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).	
NUCLEOTIDE SEQUENCE			RT RN [2] NUCLEOTIDE SEQUENCE.	
RC			RT DR Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. (By similarity). CC -1- SUBCELLULAR LOCATION: Integral membrane protein (By similarity). DR EMBL; B036069; AAH90693.1; - mRNA. RA InterPro; IPR000276; GPCR_Rhodopsin. RA InterPro; IPR002286; P2_Purinoceptor. RA InterPro; IPR000018; P2Y4_Purinoceptor. DR Pfam; PF00001; 7cm 1; 1. DR PRINTS; PS00237; GPCERHODOPSIN. DR PRINTS; PRO1066; P2Y4_PRNOCTR. DR PRINTS; PRO1157; P2Y4_PRNOCTR. DR PROSITE; PS00237; G PROTEIN RECEP_F1_1; UNKNOWN_1.	
NUCLEOTIDE SEQUENCE			RT RT Generation and initial analysis of more than 15,000 full-length human	

and mouse cDNA sequences.";
 [2] Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).

RN RP NUCLEOTIDE SEQUENCE.
 RN STRAIN=Sprague-Dawley; TISSUE=Brain;
 RC RX
 RC MEDLINE=98421785; PubMed=9751165;
 RC Wabb T.E., Henderson D., Roberts J.A.; Barnard E.A.;
 RC NIH MGC Project;
 RC Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.
 RC "Molecular cloning and characterization of the rat P2Y4 receptor."
 RL -!- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).
 CC DR -!- FUNCTION: Receptor for ATP and UTP coupled to G-proteins that
 activate a phosphatidylinositol-calcium second messenger system.
 CC DR Not activated by ADP or UDP.
 CC DR -!- SUBCELLULAR LOCATION: Integral membrane protein.
 CC DR -!- TISSUE SPECIFICITY: Widely expressed at low levels. In brain,
 higher expression in the pineal gland and ventricular system.
 CC DR -!- PTM: Phosphorylation of Ser-329 and Ser-330 is a key step in
 agonist-dependent desensitization and loss of surface P2Y4. This
 phosphorylation does not involve PKC, nor other calcium-activated
 kinases (By similarity).
 CC DR -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
 CC DR -!- This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 use as long as its content is in no way modified and this statement is not
 CC removed.

PRINTS: PR01237; GPCR_RHODOPSIN.
 PRINTS: PR01066; P2Y4_PPNOCPR.
 PRINTS: PR01157; P2Y_PPNOCPR.
 PROSITE: PS00237; G PROTEIN RECEP_F1_1; UNKNOWN_1.
 PROSITE: PS00262; G PROTEIN RECEP_F1_2; 1.
 DR DR G-protein coupled receptor; Transducer; Transmembrane.
 DR DR G-protein coupled receptor; Receptor; Transducer; Transmembrane.
 KW KW
 SQ SEQUENCE 365 AA; 40947 MW; 68EA0ED3CCA19FL CRC54;

Query Match Score 99.5%; Score 1934; DB 2; Length 365;
 Best Local Similarity 99.7%; Pred. No. 5_6e-111;
 Matches 364; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MASTESSLRLSLGSPGGSSEYELDCWDFEDDFKFLILLPVSYAVVFVYLGLGLNAPTLWLF 60
 Db 1 MASTESSLRLSLGSPGGSSEYELDCWDFEDDFKFLILLPVSYAVVFVYLGLGLNAPTLWLF 60

Qy 61 IFLRLRPNDATATMFMHLSDTLVYLSPPTLIYYAAAHNHMPGTEFLCKFVRFLYNNY 120
 Db 61 IFLRLRPNDATATMFMHLSDTLVYLSPPTLIYYAAAHNHMPGTEFLCKFVRFLYNNY 120

Qy 121 CSYFLFLTCISVRYLGICHPFLRWRGPRLAGLCLAVNLIVAGCLIPNLFPTVTSNKG 180
 Db 121 SSYFLFLTCISVRYLGICHPFLRWRGPRLAGLCLAVNLIVAGCLIPNLFPTVTSNKG 180

Qy 181 TTVLCHDTTRPEEFDHVHFSSAVMGLLFGVPCLVLYCYGLMARRLYQPLPGSAOSSR 240
 Db 181 TTVLCHDTTRPEFDHVHFSSAVMGLLFGVPCLVLYCYGLMARRLYQPLPGSAOSSR 240

Qy 241 LSRLRATTAVVLTIVAYCFVPPFHITRITYLALARDECRVLNIVVYKVTRPLASANSC 300
 Db 241 LSRLRATTAVVLTIVAYCFVPPFHITRITYLALARDECRVLNIVVYKVTRPLASANSC 300

Qy 301 LDPLVLYLTGDKYRQLRQLCGGGKPORTAASSLALVSLPDSSCRWAATPDSSCSCTP 360
 Db 301 LDPLVLYLTGDKYRQLRQLCGGGKPORTAASSLALVSLPDSSCRWAATPDSSCSCTP 360

Qy 361 RADRL 365
 Db 361 RADRL 365

RESULT 6
 ID P2RY4 RAT STANDARD; PRT; 361 AA.
 AC 035811;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 10-MAY-2005 (Rel. 41, Last annotation update)
 DE P2Y Purinoreceptor 4 (P2Y4).
 GN Name=P2RY4; Synonyms=P2Y4;
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Gires; Rodentia; Sciurognathi;
 OC Muridae; Murinae; Murinae; Rattus.
 OC NCBI TaxID=10116;
 RN NUCLEOTIDE SEQUENCE.
 RC STRAIN=Sprague-Dawley; TISSUE=Liver;
 RA Bogdanov Y.D., Wildman S., King B.F.; Burnstock G.;
 RL Submitted (AUG-1997) to the EMBL/GenBank/DBJ databases.

Query Match 82.2%; Score 1597; DB 1; Length 361;
 Best Local Similarity 82.7%; Pred. No. 9.1e-107;
 Matches 302; Conservative 20; Mismatches 39; Indels 4; Gaps 1;
 Sq 1 MASTESSLRLSLGSPGGSSEYELDCWDFEDDFKFLILLPVSYAVVFVYLGLGLNAPTLWLF 60
 Db 1 MTSAASLLFTSLGPSPSSGDG---DCRFNEEFPKILLPMNSYAVVFVGLALNAPTLWLF 56

Qy 61 IFLRLRPNDATATYMFHIALSDFLVLISPLTUYIYYYAAHHNHWPFGTICKEVRFLYWNLY 120
 :|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
 Db 57 LFLRLRPNDATATYMFHIALSDFLVLISPLTUYIYYYAAHHNHWPFGTICKEVRFLYWNLY 116
 :|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
 Rx 121 CSYLFELTCISVRYLGCHPLRALKRPLAGLICLAVMLVYAGCLVPLFFUTTSNKG 180
 :|||:|||:|||:|||:|||:|||:|||:|||:|||:
 Db 117 CSYLFELTCISVRYLGCHPLRALKRPLFASLLCIGVLYVAGCLVPLFFUTTNANG 176
 :|||:|||:|||:|||:|||:|||:|||:
 Qy 181 TTVLCHDTTRPEEFDTHTVHFFSSAVMGILFGVPLCLVLYCYGMLARLQDGSASSR 240
 :|||:|||:|||:|||:|||:|||:|||:|||:
 Db 177 TTILCHDTLPEEPDTAVYVYFSSAVMVLFGPLLTIVCYGMLARLQDGSASSR 236
 :|||:|||:|||:|||:|||:
 Qy 241 LRSLRITAAVLVTFYAVCFVPPFHITRTTYXLLARLLEADCRVINTVYKTKTRPLASANC 300
 :|||:|||:|||:|||:|||:|||:
 Db 237 LRSLRITAAVLVTFYAVCFVPPFHITRTTYXLLARLLEADCRVINTVYKTKTRPLASANC 296
 :|||:|||:|||:|||:
 Qy 301 LDPVLYLTGDKYRQLRQLCGGGKPKDORTAASSLALVSPLPEDSSCRMATPQDSSCSTP 360
 :|||:|||:|||:
 Db 297 LDPVLYLTGDKYRQLRQLCGGGKPKDORTAASSLALVSPLPEDSSCRMATPQDSSCSTP 356
 :|||:
 Qy 361 RADRL 365
 |||:
 Db 357 EGDRL 361
 |||:
 *RESULT 7

P2RY4 MOUSE STANDARD: PRT; 361 AA.
 ID P2RY4_MOUSE STANDARD: PRT; 361 AA.
 AC Q9JJS7; DT 28-FEB-2003 (Rel. 41, Created)
 - DT 28-FEB-2003 (Rel. 41, Last sequence update)
 - DT 10-MAY-2005 (Rel. 47, Last annotation update)
 DE P2Y purinoreceptor 4 (P2Y4);
 GN Name=p2ry4; Synonyms=p2y4;
 OS Mus musculus (Mouse); Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Rodentia; Gires; Rodentia; Sciurognathi; OC Muridae; Muridae; Murinae; Mus.
 RN [1] - TAXID=10090;
 RN [1] - NUCLEOTIDE SEQUENCE.
 RX MEDLINE=2129/SVJ; PubMed=11290369; DOI=10.1016/s0014-2999(01)00875-5;
 RA Suarez-Huerta N., Pouillon V., Boeynaems J.-M., Robaye B.;
 RT "Molecular cloning and characterization of the mouse p2y4 nucleotide receptor."
 RL Eur. J. Pharmacol. 416:197-202 (2001).
 RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
 RC STRAIN=C57BL/6J; TISSUE=SKIN;
 RX MEDLINE=22234683; PubMed=1466851; DOI=10.1038/nature01266;
 RA Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
 RA Nikaido I., Osato N., Saito R., Suzuki H., Yamamoto I., Kiyosawa H.,
 RA Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schenbach C., Gojobori T.,
 RA Baldarelli R., Hill D.P., Bult C., Rume D.A., Quackenbush J.,
 RA Schriml L.M., Karapin A., Matsuda H., Batalov S., Beisel K.W.,
 RA Blake J.A., Brard D., Brusick V., Chotoku L., Corban L.F., Cousins S.,
 RA Dalla B., Dragan T.A., Fletcher C.F., Forrest A., Frazer K.S.,
 RA Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,
 RA Grimmel S., Gusbin C., Hirokawa N., Jackson I.J., Jarvis E.D.,
 RA Kanai A., Kawaji H., Kawasawa Y., Kedzierski R.M., King B.L.,
 RA Konagaya A., Kuruchkin I.V., Lee Y., Lenhard B., Lyons P.A.,
 RA Maggio D.R., Malottais L., Okido T., Pavan W.J., Perera G., Pesole G.,
 RA Nagashima T., Numata K., Okido T., Pontius J.U., Oi D., Ramachandran S.,
 RA Petrovsky N., Pillai R., Pontius C.A., Reed J.C., Reid J., Ringwald M.,
 RA Ravasi T., Reed J.C., Reed D.J., Reid J., Setou M., Shimada K.,
 RA Sandelin A., Schneider C., Semple C.A., Setou M., Shimada K.,
 RA Sultan R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,
 RA Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
 RA Wilming L.G., Wyshaw-Boris A., Yanagisawa M., Yang I., Yang L.,
 RA Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,
 RA Hirozane-Kishikawa T., Kondo H., Nakamura M., Sakazume N., Sato K.,
 RA Shiraki T., Waki K., Kawai J., Arakawa T., Aizawa K., Fukuda S.,

RA Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,
 RA Miyazaki A., Sakai K., Sasaki D., Shiba K., Shinagawa A.,
 RA Yasumori A., Yoshino M., Waterson N., Lander E.S., Rogers J.,
 RA Birney E., Hayashizaki Y.,
 RT "Analysis of the mouse transcriptome based on functional annotation of
 RL Nature 420:56-573 (2002)."
 CC -1- FUNCTION: Receptor for ATP and UTP coupled to G-proteins that
 CC activate a phosphatidylinositol-calcium second messenger system.
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein.
 CC -1- TISSUE SPECIFICITY: Expressed in the liver, intestine, stomach,
 CC bladder and lung.
 CC -1- PTM: Phosphorylation of Ser-329 and Ser-330 is a key step in
 CC agonist-dependent desensitization and loss of surface P2RY4. This
 CC phosphorylation does not involve PKC, nor other calcium-activated
 CC kinases (By similarity).
 CC -1- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
 CC -1- This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.
 CC -1-
 DR EMBL; AJ277752; CAB91041.1; - ; Genomic_DNA.
 DR EMBL; AK076364; BAC36314.1; - ; mRNA.
 DR EMBL; AK076364; BAC36314.1; - ; mRNA.
 DR Ensembl; ENSMUSG0000004359; Mus musculus.
 DR MGII; MGI:1926694; P2ry4.
 DR MGII; MGI:1926694; C:Integral to membrane; TAS.
 DR GO; GO:0016021; F:Pyrimidine nucleotide binding; IC.
 DR GO; GO:0019103; F:Pyrimidine nucleotide receptor activity; IDA.
 DR GO; GO:0045030; F:GTP-activated nucleotide receptor activity; IDA.
 DR GO; GO:0030321; P:transorbital chloride transport; IDA.
 DR InterPro; IPR000276; GPCR_Rhodopsin.
 DR InterPro; IPR002286; P2_Purinceptor.
 DR InterPro; IPR000018; P2Y_purinocptor.
 DR Pfam; PF00001; 7cm¹; 1.
 DR PRINTS; PRO0027; GPCR_RHODOPSIN.
 DR PRINTS; PRO1056; PAXYPROIOCPTR.
 DR PRINTS; PRO1157; PYPURINOCPTR.
 DR PROSITE; PS00237; G PROTEIN_RECCEP_F1_1-1.
 DR PROSITE; PS50262; G PROTEIN_RECCEP_F1_2-1.
 KW G-protein coupled receptor; GlycoProtein; Phosphorylation; Receptor; Transducer; Transmembrane.
 FT TOPO_DOM 1 30
 FT TRANSMEM 31 58
 FT TRANSMEM 31 58
 FT TRANSMEM 59 68
 FT TRANSMEM 69 91
 FT TOPO_DOM 92 108
 FT TOPO_DOM 109 127
 FT TRANSMEM 128 149
 FT TRANSMEM 150 170
 FT TRANSMEM 171 192
 FT TRANSMEM 193 218
 FT TRANSMEM 219 242
 FT TRANSMEM 243 265
 FT TRANSMEM 266 283
 FT TRANSMEM 284 305
 FT TRANSMEM 306 361
 FT MOD_RES 329 329
 FT MOD_RES 330 330
 FT CARBONYL 175 175
 FT DISULFID 104 181
 SQ SEQUENCE 361 AA; 41034 MW; 3EBBA84B65BCDA20 CRC64;
 Query Match 80-3%; Score 1561; DB 1; Length 361;
 Best Local Similarity 80-8%; Pred. No. 3.5e-104;
 Matches 295; Conservative 20; Mismatches 46; Indels 4; Gaps 1;

Qy 1 MASTESSLLRLGLGSGPSSEVELDCWFEDDEKFETPLPSYAYVFLVGLGINAPTLWLF 60
 DB 1 MTSDASLFLTSLGSPSSGSDG---DCCKNEBBKPTILLPLPSYAYVFLVGLGINAPTLWLF 56

Page 7

Qy 1 MASTESSLLRLSLGLSPPGSSEVELDWFDDFKFILLPVSYAVVEVFLGLLNAPTLWLF 60
 Db 6 MATLHPSPPLTULP-PLKNTNTDSYENGFKEILIPSYSGMGLNAPLTAIWIF 64

Qy 61 IFRLRPWDAATYTMFHIALSDTLYLSLPTLIIYAAHHNMPPGTEICKFVRFPLYWNLY 120
 Db 65 IAKMRPWPPTVYMFNLASDLYLSLPTLIVYADQNNMPFGVALCKURVLFVANLY 124

Qy 121 CSVLFLTCISYERYLGICHPRLRNGPRLAGLCLAVAMLUVAGCLVPLLEFTTSNKG 180
 Db 125 SSILFLTCISYRYRGCHPTTLRCMNKAHVIALCNLVSVMCLCPVNLMEVTVSPKV 184

Qy 181 TTVLCHDTTRBEPFDHYVHESSAVAGLLEFGVCPCLTLCYCMLMARRLYQL-PGAAQS-- 237

Db 185 NGTICHDITLPEEFDKYVESTGIMCILFGPCLLACYGGLMAREBLMKPLVNGHOTLP 244

Qy 238 SSRRLSLRTIAVLTVFVCPVPFHITRTRIYLALEADGRVINTVNVYKVTRPLASA 297

Db 245 SYKKRSKTIKVIVMIAFACPMPFHITRTRIYARILGVNCYALANVINTFYKIRPLASA 304

Qy 298 NSCLOPVLJLJTGDKYRQI-----RQLC-----GGGKPQPTTAASSLAVSI 340

Db 305 NSCIDPILYFLANDRTRRLIRTVERSSWHERRCMHTNHPGPHEPEPMTTGPILPVVSX 364

Qy 341 PEDSS 345

Db 365 BETOS 369

RESULT 12

P2RY8_XENLA	STANDARD;	PRT;	537 AA.
ID P79928			
AC P79928			
DT 01-NOV-1997	(Rel. 35, Created)		
DT 01-NOV-1997	(Rel. 35, Last sequence update)		
DT 10-MAY-2005	(Rel. 47, Last annotation update)		
DE P2Y Purinoreceptor 8 (P2Y8).			
GN Name=P2Y8;			
-OS Xenopus laevis (African clawed frog).			
-OC Bokaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
-OC Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae;			
-OC Xenopodinae; Xenopidae; Xenopus; Xenopus.			
-NCBI_TaxID=8355;			
-RN RP			
-CC NUCLEOTIDE_SEQUENCE.			
-CC TISSUE=Neural Place;			
-RX MEDLINE_PUB_ID=9728734; PubMed=9139711; DOI=10.1074/jbc.C72.19.12583;			
-RA Bogdanov Y.D.; Dale L.; King B.F.; Whittuck N.; Burnstock G.;			
-RT "Early expression of a novel nucleotide receptor in the neural plate of Xenopus embryos.";			
-RL J. Biol. Chem. 272:12583-12590(1997).			
-1- FUNCTION: Receptor for extracellular ATP, UTP, CTP, GTP and ITP. The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. May play a key role in the early development of neural tissue.			
-1- SUBCELLULAR_LOCATION: Belongs to the G-protein coupled receptor 1 family.			
-CC This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.			
-CC DR X99953; CAA88213.1; - mRNA.			
-CC DR HSSP; P34996; 1DDD.			
-CC DR InterPro; IPR002816; GPCR_Rhodopsin.			
-CC DR InterPro; IPR000018; P2Y4_Purinoceptor.			
-CC DR InterPro; IPR000018; 7Ct1_1.			
-CC DR PRINTS; PRO0237; GPCRHODOPIN.			
-CC DR PRINTS; PRO01066; F2Y4PRNOCPQR.			
-CC DR PRINTS; PRO1157; P2YPDRNOCPQR.			

DR PROSITE; PS00237; G PROTEIN RECEP_F1-1; 1.
 DR PROSITE; PS50562; G PROTEIN RECEP_F1-2; 1.
 G protein coupled receptor; Glycoprotein; Receptor; Transducer;
 KW Transmembrane.

FT TOPO_DOM 1 49
 FT TRANSMEM 50 70
 FT TRANSMEM 71 79
 FT TRANSMEM 80 100

FT TOPO_DOM 101 118
 FT TRANSMEM 119 139
 FT TRANSMEM 140 161
 FT TRANSMEM 162 182

FT TOPO_DOM 183 210
 FT TRANSMEM 211 231
 FT TRANSMEM 232 254

FT TRANSMEM 255 275
 FT TRANSMEM 276 292

FT TOPO_DOM 293 316
 FT TOPO_DOM 317 537

FT CAREOHD 26 26
 FT DISULFID 29 29

FT DISULFID 116 193

SQ SEQUENCE 537 AA; 62024 MW; B2CF24812F3C19F2 CRC64;

Query Match
 Best Local Similarity 51.8%; Score 1007.5; DB 1; Length 537;
 Matches 190; Conservative 50; Mismatches 83; Indels 17; Gaps 4;

Qy 20 SSEYVLDGMFDEDKFIFILLPVSYAVVFVGLGLNAPTLWLFIFURPMDATATYMFHLAL 79
 Db 28 TNDTIDCIVDFEGKFPLPVSVTSAVFMGLPNTIAWMFIKRPNTWFMFLNL 87

Qy 80 SDTLYVLSLPTLIIYXXAANHNPCTEICKFDPFLYNYCSLFLTICSVANVYLICH 139
 Db 88 SDTLYVLSLPTLVYYADKNNNWPGGEVILCKVRFLFYANLYSSLFLCTCSVYRGVCH 147

Qy 140 PLRALRWRGPRLAGLCLAVMWLVAGCLVPLNLPFTTSNSKGTVLCHDQTTRPEEFDHVH 199

Db 148 PTSLRBRNPKAHVYUCLVWLSVTLVCLVPLNLPFTVSPKVNTICHTTRPDRPARTY 207

Qy 200 FSSAVMGLLFGVYCLVTLVCLVYCLGMLRRLQPL-PGSQAS--SSRLRSRRTIAVVLTVPAV 256

Db 208 YSTAMCCLPFGIPLITAGCYGMLTRMELMKPVSGNQOTLPSTKRSKTSIIIVMAFAI 267

Qy 257 CFYPRHITRTIYLLARBLLEADCRVNLINIVYKTRPLASANCLDPYLILTCDKYRQ 316
 Db 268 CFMPFHITRTLTYYARLGIKCYALVNVYTKVTRPLASANCDPLYFLANDRYRR 327

RESULT 13

Q1ZWQ7_XENLA	XENLA PRELIMINARY;	PRT;	537 AA.
ID Q1ZWQ7			
AC Q1ZWQ7_			
DT 01-JUN-2003	(TREMBLrel. 24, Created)		
DT 01-MAR-2004	(TREMBLrel. 24, Last sequence update)		
DT 01-MAR-2004	(TREMBLrel. 26, Last annotation update)		
DE P2ry4-prov protein.			
GN Name=p2ry4-prov;			
-OS Xenopus laevis (African clawed frog).			
-OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Butelostomi;			
-OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae;			
-OC Xenopodinae; Xenopidae; Xenopus; Xenopus.			
-NCBI_TaxID=8355;			
-RN RP			
-CC NUCLEOTIDE_SEQUENCE.			
-CC TISSUE=Neural Place;			
-RX MEDLINE_PUB_ID=9728734; PubMed=9139711; DOI=10.1074/jbc.C72.19.12583;			
-RA Bogdanov Y.D.; Dale L.; King B.F.; Whittuck N.; Burnstock G.;			
-RT "Early expression of a novel nucleotide receptor in the neural plate of Xenopus embryos.";			
-RL J. Biol. Chem. 272:12583-12590(1997).			
-1- FUNCTION: Receptor for extracellular ATP, UTP, CTP, GTP and ITP. The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. May play a key role in the early development of neural tissue.			
-1- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.			
-CC This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.			
-CC DR X99953; CAA88213.1; - mRNA.			
-CC DR HSSP; P34996; 1DDD.			
-CC DR InterPro; IPR002816; GPCR_Rhodopsin.			
-CC DR InterPro; IPR000018; P2Y4_Purinoceptor.			
-CC DR InterPro; IPR000018; 7Ct1_1.			
-CC DR PRINTS; PRO0237; GPCRHODOPIN.			
-CC DR PRINTS; PRO01066; F2Y4PRNOCPQR.			
-CC DR PRINTS; PRO1157; P2YPDRNOCPQR.			

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

QY 140 PLRALRGPRPLAGLCLAVMLVAGCIVPNLFFVFTSNKGTVLCHDTTRPBEEDHYVH 199
 :|:||:|:||:|:||:|:||:|:||:|:||:|:||:|:||:|:||:|:
 Db 120 PIKALNLYKPRHSYLVCSWAVVIVCVPNLIFVTTSRDNTLCHDTSEFLQVN 179
 :|:||:|:||:|:||:|:||:|:||:|:||:|:||:|:
 Qy 200 FSSAVMGLLFGPVCLTVLGMLRYQPLEGSAQ---SSSSRLSLRSTAVLTVPF 255
 :|:||:|:||:|:||:|:||:|:||:|:||:|:
 Db 180 YCSVVMYTFGLPFLTVCYCLMARTCRPVGLSSRQGAVSYQTKTLKJIMVLMPA 239
 :|:||:|:||:|:||:|:||:|:||:|:||:|:
 Qy 256 VCFVPFHTRTYYLARILEADCRVINVNVVYKVTRPLASANSCLDPVLYLTGDKYRR 315
 :|:||:|:||:|:||:|:||:|:||:|:||:|:
 Db 240 MCFVPPFHTRTYYVARLAKPSCTDNAINFTYKIRPLVCVNSCDPILKFLAGDSYR 299
 :|:||:|:||:|:||:|:||:|:||:|:
 Qy 316 QL 317
 Db 300 RL 301

RESULT 15
 ID P2RY2_HUMAN STANDARD; PRT; 377 AA.
 AC P4121; Q9EMB8;
 DT 01-FEB-1995 (Rel. 31, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DE P2U purinoreceptor 2 (P2Y2) (P2U purinoreceptor 1) (P2U1) (ATP receptor)
 DB (Purine nucleotide receptor 2)
 GN Name=p2ry2; Synonyms=P2R01;
 OS Homo sapiens (Human)
 OC Bacteria; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 Homo. NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX TISSUE=Airway epithelium;
 MEDLINE=9211846; PubMed=159738;
 RA Parr C.E., Sullivan D.M., Pardiso A.M., Lazarowski E.R., Burch L.H.,
 Olsen J.C., Erb L., Weisman G.A., Boucher R.C., Turner J.T.;
 RT "Cloning and expression of a human P2U nucleotide receptor, a target
 for cystic fibrosis pharmacotherapy";
 Proc. Natl. Acad. Sci. U.S.A. 91:3275-3279(1994).
 [2]
 RP SEQUENCE REVISION.
 RX MEDLINE=95108098; PubMed=7809171;
 RA Sullivan D.M., Pardiso A.M., Lazarowski E.R., Burch L.H.,
 Olsen J.C., Erb L., Weisman G.A., Boucher R.C., Turner J.T.;
 RT "Cloning and expression of a human P2U nucleotide receptor, a target
 for cystic fibrosis pharmacotherapy";
 Proc. Natl. Acad. Sci. U.S.A. 91:13067-13067(1994).
 [3]
 RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
 RC TISSUE=Placenta;
 RA Puhl H.L., Ikeda S.R., Aronstam R.S.;
 RT "cDNA clones of human proteins involved in signal transduction
 sequenced by the Guthrie DNA resource center (www.cDNA.org)." ;
 RL Submitted (JUL-2002) to the ENSEMBL/GenBank/DBJ databases.
 [4]
 RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
 RC TISSUE=Kidney, and Leukocyte;
 MEDLINE=22388237; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 Klausner R.D., Collins F.S., Wagner L., Shemesh C.M., Schuler G.D.,
 Altshul S.F., Zeeberg B., Bustow K.H., Schaefer C.F., Bhat N.K.,
 Hopkins R.F., Jordan H., Moore T., Max S. I., Wang J., Hsieh F.,
 Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 Stapleton M., Soares M.B., Bandal M.F., Casavant T.L., Scheetz T.E.,
 Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 Raha S., Loquelinano N.A., Peters G.J., Abramson R.D., Mallah S.J.,
 Bosak S.A., McElwain P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 Villalon D.K., Muoz D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,

RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 Rodriguez A.C., Grinblat J., Schwartz J., Myers R.M.,
 Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 Scheiner A., Schein J.R., Jones S.J.M., Marras M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 and mouse cDNA sequences";
 Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 CC -1- FUNCTION: Receptor for ATP and UTP coupled to G-proteins that
 activate a phosphatidylinositol-calmodulin second messenger system.
 CC The affinity range is UTP = ATP > ATP-gamma-S > 2-methylthio-ATP
 CC = ADP.
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein.
 CC -1- TISSUE SPECIFICITY: Spleen, testis, kidney, liver, heart and
 CC brain.
 CC -1- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
 CC -1- SIMILARITY: It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.
 CC EMBL; U07225; AAC04923.1; - ; mRNA.
 DR EMBL; AY136753; AAC01279.1; - ; mRNA.
 DR EMBL; BC012104; AAH12104.1; - ; mRNA.
 DR HSSP; BC028135; AAH28135.1; - ; mRNA.
 DR HSSP; P31996; 1DDD.
 DR Ensembl; ENSG00000175591; Homo sapiens.
 DR HGNC; HGNC:8541; P2RY2.
 DR H-InvDB; HIX0009916; - .
 DR MIM; 600041; - .
 DR GO; GO:0005887; C:integral to plasma membrane; TAS.
 DR GO; GO:0004872; P:receptor activity; TAS.
 DR GO; GO:0006873; P:cell ion homeostasis; TAS.
 DR InterPro; IPR002286; P2_Purinceptor.
 DR InterPro; IPR000356; P2_Purinceptor.
 DR Pfam; PF00017; tm_1..1.
 DR PRINTS; PR00237; GPCRRAHDOPSN.
 DR PRINTS; PR05534; P2YPRNOCPT.
 DR PRINTS; PR01157; PYYPYRNOCPT.
 DR PROSITE; PS00037; G_PRORBIN_RBCBP_F1_1..1.
 DR PROSITE; PS00062; G_PRORBIN_RBCBP_F1_1..1.
 DR G-protein coupled receptor; Glycoprotein; Transmembrane; Receptor; Transducer;
 KW Transmembrane.
 FT TOPO_DOM 1 32 Extracellular (Potential).
 FT TRANSMEM 33 59 1 (Potential).
 FT TRANSMEM 71 93 2 (Potential).
 FT TOPO_DOM 60 70 Extracellular (Potential).
 FT TRANSMEM 111 129 3 (Potential).
 FT TRANSMEM 130 152 Cyttoplasmic (Potential).
 FT TRANSMEM 153 172 4 (Potential).
 FT TOPO_DOM 173 194 Extracellular (Potential).
 FT TRANSMEM 195 220 Cyttoplasmic (Potential).
 FT TOPO_DOM 221 246 6 (Potential).
 FT TRANSMEM 247 269 Extracellular (Potential).
 FT TOPO_DOM 270 287 Cyttoplasmic (Potential).
 FT TRANSMEM 309 328 By similarity.
 FT TOPO_DOM 310 377 N-Linked (Glycan). . . (Potential).
 FT CARBOHYD 9 9 N-Linked (Glycan). . . (Potential).
 FT CARBOHYD 13 13 N-Linked (Glycan). . . (Potential).
 FT DISMFID 106 183 R->S (in Ref. 4; AAH12104).
 FT CONFLICT 312 312 R->G (in Ref. 1).
 FT CONFLICT 350 350 E->G (in Ref. 1).
 FT CONFLICT 359 359 S->F (in Ref. 1).
 SQ SEQUENCE 377 AA; 42290 MN; EBS572A572A29AC6 CRC64;

Query Match 49.6%; Score 965; DB 1; Length 377;
 Best Local Similarity 59.1%; Pred. No. 2.5e-61;
 Matches 185; Conservative 40; Mismatches 86; Indels 2; Gaps 1;

QY 22 EVELDCWFDDEFKFLILLPVSYAVVFLUGLNAPTLWLFRLRPDATAFMHIALSD 81
 Db 20 ELGYRCRFNEDFKYVLLPISYGIVCVLGLCLNAVALYIPICRKTNASTYMEHLASD 79
 QY 82 TLYVLSPLTLLYYAAHHNHPFGTICKFVRFLYWNLYCSVILFLTCISVHRYLGICPL 141
 Db 80 ALYAASPLLVVYARGDHMPSTVLCRFLFTNLVCSIFLTCISVHRCIGVLEPL 139
 QY 142 RALRNGCPRLAGLCLAYWLVAGLVLPPNLFVTTISNKGETVLCHDTRPEEFDHYHFS 201
 Db 140 RSLRNGRARYARRVAGVVNLVLAQPVLYFVITISARGGRVTCHDTSAPELFRVAYS 199
 QY 202 SAVMGLLFGYPCLTVCLVCGIMARLYQPLGSAOSSRL - RSLRTIAVLTFAVCFV 259
 Db 200 SVMGLLGFPAVFLVCCYUMLARLLKPAYGTSGGLPAKRKSVRTAVVLAFLACFL 259
 QY 260 PFHITRTIYYLARLLEADCRVLNIVNVVKTRPLASANSCLDPVLYLITGDKYRRQRQ 319
 Db 260 PFHVTRTLTSFRSLDLSCTLNAINMAYKTRPLASANSCLDPVLYFLAGQLVYRARD 319
 QY 320 LCGGGKQPRTAA 332
 Db 320 AKPPPTGSPATPA 332

Search completed: April 4, 2006, 20:14:09
 Job time : 235 secs

Page 2

```

; GENERAL INFORMATION:
; APPLICANT: Conley, Pamela B.
; APPLICANT: Jantzen, Hans-Michael
; APPLICANT: Ramakrishnan-DuBridge, Vanitha
; APPLICANT: Julius, David
; APPLICANT: Hollópetér, Gunter
; APPLICANT: COR Therapeutics, Inc.
; TITLE OF INVENTION: P2Y12 Receptor
; FILE REFERENCE: 44481-5053-US
; CURRENT APPLICATION NUMBER: US/09/745,842
; CURRENT FILING DATE: 2000-12-26
; PRIOR APPLICATION NUMBER: US 60/171,622
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 374
; TYPE: PRT
; ORGANISM: Meleagris gallopavo
; FEATURE:
; OTHER INFORMATION: Turkey P2Y nucleotide
US-09-745-842-15

Query Match Score 1127.
Best Local Similarity 59.3%; Pred. No. 2
Matches 208; Conservative 56; Mismatch
Db 9 LRSIQLSP-----GPGGSSEVLDQWFL
Db 5 VRMFSLAPPTPPTPWLGANTTAAEAKCVF
Qy 59 LFIFRLRPDATAATYMFENALSDTLYVLSP
Db 65 IFVSRMRPNNATYMFENALSDTLYVFSLP
Qy 119 LYCSVLFICISVERYLGLCIPRLARLWRGP
Db 125 LYSSLEFLTCISVERYMGLCIPRLSLKWKYT
Qy 179 KGTIVLCHDTRPERFDHVTYHFFSSAVMGILF
Db 185 KDNSPLCLHDITKPEFEFDHVTYHSSIMALLP
Qy 236 QSSSRLSLRSLATVYLTVFACFCYFPFHITRT
Db 245 VPSTVKCRSLKMIIVLVTVPACFCYFPFHITRT
Qy 296 SANSCDLPVLYLLTDKYRQLRQLUGGGKPK
Db 305 SINSCLDPVLYLLTDKYRQLRQLR--GAAQO

RESULT 4
US-09-745-842-17
Sequence 17, Application US/09745842
; GENERAL INFORMATION:
; APPLICANT: Conley, Pamela B.
; APPLICANT: Hollópetér, Gunter
; APPLICANT: COR Therapeutics, Inc.
; TITLE OF INVENTION: P2Y12 Receptor
; FILE REFERENCE: 44481-5053-US
; CURRENT APPLICATION NUMBER: US/09/745,842
; CURRENT FILING DATE: 2000-12-26
; PRIOR APPLICATION NUMBER: US 60/171,622
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 377

```

TYPE: PRT
FEATURE: Homo sapiens
OTHER INFORMATION: P2Y2 purinergic receptor; p2ur
US-09-745-842-17

Query Match 49.6%; Score 965; DB 2; Length 377;
Best Local Similarity 59.1%; Pred. No. 3.2e-64;
Matches 185; Conservative 40; Mismatches 86; Indels 2; Gaps 1;

Qy .22 EVELDCWFDDEPKILLPSVAVFGLGILNPLTMFLPIFLRPLDATATMFLHLSDF 81
Db 20 ELGYRCRNFEDFCKVLLPSVGVCLGICLNAAVALYFLCRLKTNNTTMMFLHNSD 79

Qy 82 TLYVLSLPLTLIYTYYAHHMPFGTEICKVFLRFLTCISVHRLGICPL 141
Db 80 ALYAASLPLLVYYARGDHWPFSFLVCKLVRFLFTYNNCSILFLTCISVHRLGIVRPL 139

Qy 142 RALWRGRPLLAGLCLAYMLVAGCLVNLFFUTTSNGKTTVLCHDTTRPERFDHYHFS 201
Db 140 RSLRWGRARYARAVAGAVVNLACOAVPLYFTTSARGGRVTCHDSSAPEFSRFAYS 199

Qy 202 SAVMGLLGVPCLTVLTYGMLARRYLPLPGSAQSSRL - RSLRITAVLTVFAVCV 259
Db 200 SAVMGLLGVPAPVAVLVCVYLARRLLPAVGTSGGLEPARKSVRTIAVLAFL 259

Qy 260 PFFHTRTYYLARILLEADCRVINIVVYKVTRPLASANSLDPVLYLTGDKYRQLRQ 319
Db 260 PFFHTRTYYLXSPRSLDLSCHTINAINMAYKVTRPLASANSLDPVLYLFLAGRLVRFARD 319

Qy 320 LCGGGKPKPRTAA 332
Db 320 AKPPTGPATPA 332

RESULT 5
US-08-513-974B-373
; Sequence 373, Application US/08513974B

GENERAL INFORMATION:
; APPLICANT: Hinuma, Shuji
; APPLICANT: Hosoya, Masaki
; APPLICANT: Fujii, Ryō
; APPLICANT: Ohtaki, Tetsuya
; APPLICANT: Fukusumi, Shōji
; APPLICANT: Ohgi, Kazuhiro
; TITLE OF INVENTION: G PROTEIN COUPLED RECEPTOR PROTEIN,
; NUMBER OF SEQUENCES: 380
; CURRENT APPLICATION DATA:
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
; STREET: 130 Water Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk.
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Parent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/513,974B
FILING DATE: 14-SEP-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/JP95/01599
FILING DATE: 10-AUG-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 7-093989
FILING DATE: 19-AUG-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 7-057186

PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 7-007177
FILING DATE: 20-JAN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-326661
FILING DATE: 28-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-270017
FILING DATE: 02-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-236357
FILING DATE: 30-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-189274
FILING DATE: 11-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-169273
FILING DATE: 11-AUG-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-189272
FILING DATE: 11-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Resnick, David S.
REGISTRATION NUMBER: 34,235
REFERENCE/DOCKET NUMBER: 45753
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-523-3400
TELEFAX: 617-523-6440
INFORMATION FOR SEQ ID NO: 373:
SEQUENCE CHARACTERISTICS:
LENGTH: 373 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
US-08-513-974B-373

Query Match 49.4%; Score 960.5; DB 2; Length 373;
Best Local Similarity 53.7%; Pred. No. 6.9e-64; Mismatches 46; Gaps 3;
Matches 188; Conservative 46;

Qy 22 EVELDCWFDDEPKILLPSVAVFGLGILNPLTMFLPIFLRPLDATATMFLHLSD 81
Db 20 ELGYRCRNFEDFCKVLLPSVGVCLGICLNAAVALYFLCRLKTNNTTMMFLHNSD 79

Qy 82 TLYVSLEPLTYYAHNNHPFGTEICKFVFLFWNLYCSEVLFTCISVRYLGICHPL 141
Db 80 SLYAASLPLLYYYARGDHWPFSFLVCKLVRFLFTYNNCSILFLTCISVHRLGIVRPL 139

Qy 142 RALWRGRPLLAGLCLAYMLVAGCLVNLFFUTTSNGKTTVLCHDTTRPERFDHYHFS 201
Db 140 HSLRNGRARTARRVAAVVWLVLAQAVPLYFTTSARGGRVTCHDSSAPEFSRFAYS 199

Qy 202 SAVMGLLGVPCLTVLTYGMLARRYLPLPGSAQSSRL - RSLRITAVLTVFAVCV 259
Db 200 SAVMGLLGVPFSVLLCYLMARLLPKPAYGTGCLPRRKSTRTIALVLAFLCFL 259

Qy 260 PFFHTRTYYLARILLEADCRVINIVVYKVTRPLASANSLDPVLYLTGDKYRQLRQ 319
Db 260 PFFHTRTYYLXSPRSLDLSCHTINAINMAYKVTRPLASANSLDPVLYLFLAGRLVRFARD 319

Qy 320 LCGGGKPKPRTAA 335
Db 320 AKPPTGPATPA 336

RESULT 6
US-09-102-710B-3
; Sequence 3, Application US/09102710B

```

; Patent No. 6479630
; GENERAL INFORMATION
; APPLICANT: Coleman, Roger
; APPLICANT: Au-Young, Janice
; APPLICANT: Stuart, Susan G.
; TITLE OF INVENTION: A NOVEL HUMAN PURINERGIC P2U RECEPTOR
; FILE REFERENCE: PF-0038-1 DIV
; CURRENT APPLICATION NUMBER: US/09/102,710B
; CURRENT PILING DATE: 1998-06-22
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PERL Program

SEQ ID NO 3
LENGTH: 374
TYPE: PRT
ORGANISM: Rattus norvegicus
FEATURE:
NAME/KEY: misc feature
OTHER INFORMATION: RNU09402
US-09-102,710B-3

Query Match 49.1%; Score 955; DB 2; Length 3
Best Local Similarity 53.2%; Pred. No. 1..8e-63;
Matches 185; Conservative 50; Mismatches 99; Indels 1
Qy 22 EYELDCWPDDEFKPLLPYSAYVFVGLGINAPTLWLFRLRPMDF
Db 20 ELGYKCRPNEDFKYVLLPYSYGIVCVLGLCLNVVAVLYIFCLRKLTWN
Qy 82 TLYVLSIPTLIIYYAAHHNWPFGTBLICKFVRLFLYNNLYCSVLFLTC
Db 80 SIYASLPLVYVYQAQGDWPFSTVLCYRFLFTNLVYCSILFLTC
Qy 142 RALRWGRPLLAGLCLAVWLVAGGLVPLVNLFFVTSNKGTVLCHDT
Db 140 HSLRWGHARYARRVAAVWVVLACQTPLVYFVTSVVRGTRITCHDT
Qy 202 SAVMGLLGVPCLVTVGLMLRQLPQPG-SAOSSSRSLRSRIT
Db 200 SYMGLLEPAVPPSISLVCYVLMARRLKPKAYGTTGPRAKKSVRTV
Qy 261 FHTRTITYLARLLEADCRVLNIVVVKYTRPLASANSCLDPVLYI
Db 260 FHVTRTLYSFRSIDLSCHTLNAINMAYKTRPLASANSCLDPVLYF
Qy 321 CGGGKPQR-TAASSL-----VSLEPDSCRWAATPQD
Db 320 KPATPEPTPSQQARKLGLFRPNRTDTVRDLSISSDSRRTSTPAC

RESULT 7
US-08-442-134A-2
; Sequence 2, Application US/08442134A
; Parent No. 5596088
GENERAL INFORMATION
; APPLICANT: Boucher, Richard C.
; APPLICANT: Weisman, Gary A.
; APPLICANT: Turner, John T.
; APPLICANT: Harden, Thomas K.
; APPLICANT: Parr, Claude E.
; APPLICANT: Sullivan, Daniel M.
; APPLICANT: Erb, Laura
; APPLICANT: Lustig, Kevin D.
TITLE OF INVENTION: DNA Encoding the Human P2U Receptor
TITLE OF INVENTION: Null Cells Expressing P2U Receptor
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Bell, Seitzer, Park & Gibson
STREET: Post Office Drawer 34009
CITY: Charlotte
STATE: No. 5596088th Carolina
COUNTRY: USA
ZIP: 28224
COMPUTER READABLE FORM

```

MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.3.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/442,134A
 FILING DATE: 16-MAY-1995
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Sibley, Kenneth D.
 REGISTRATION NUMBER: 31,665
 REFERENCE/DOCKET NUMBER: 5470-7-1A
 TELECOMMUNICATION INFORMATION:
 TELEFAX: 919-420-2200
 INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 375 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-442,134A-2

	Query	Match	Score	Length	DB	Score	Length	DB	Score	Length	DB
Qy	22	EVEELCDWFEDDFERPLLPYSAYVVFGLGLNAPTLWLFERLPRWDATATYMFHLASD	59.5%	41;	Pred. No.	6.4e-62;	934:	DB 1:	Length	375:	3;
Db	20	ELGYCRCRENFDEKYLPLPYSGIVCYGLCLNAVGFLYFLCRKUWNASTYMFHLAVSD	59	85;	Indels	4;		Gaps			
Qy	82	TLYVLSPLTLYTAHNNEWPGTEICKVFRFLFVYMLYCSVPLTCISVHRYLIGICHPL	141								
Db	80	ALYAAASPLPLVYYTARGDWPFSTVLCVKVRFLYTNYLCSILFLTCISVHRCIGVLRLP	139								
Qy	142	RALWRGRPRPLAGLCLCLAYWLVYAGCLVPNLFLFYTTSNGKGTIVLGHDTTRPEEFQHVFHS	201								
Db	140	RSLRWRGRAYARRYAGAWVVLVLAQCAQPLYFVFTSARG-PLTCHDSAPELTSRVFAYS	198								
Qy	202	SAYVGLLGSPVCLNTLYCYGLMARRLYQPLPGSAQQSSRL--RSLRTIAVVLTVFAVCYFV	259								
Db	199	SVMGLLFAVPLFAVLYCYVLMAARRLLKEAYGSGGLPAKRSVRSVTAVLLAVLAFALCPL	258								
Qy	260	PFHTITTYLARLLEDRVLTNTVNVVVKUTREPLASANSCLDPVLYLLTGDKYRQLRO	319								
Db	259	PFATVTTLYSPRSIDLSCHTLMANMAYKVTR-LASANSCLDPVLYFLAGQLVRVPARD	317								
Qy	320	LCGGGKPOPTAA	332								
Db	318	AKPPGPSPATPA	330								

RESULT 8
 US-08-442,581B-2
 Sequence 2, Application US/08444581B
 Patent No. 5607816
 GENERAL INFORMATION:
 APPLICANT: Boucher, Richard C.
 APPLICANT: Weisman, Gary A.
 APPLICANT: Turner, John T.
 APPLICANT: Herden, Thomas K.
 APPLICANT: Parr, Claude E.
 APPLICANT: Sullivan, Daniel M.
 APPLICANT: Erb, Laura
 APPLICANT: Lustig, Kevin D.
 TITLE OF INVENTION: DNA Encoding the Human P2U Receptor and
 TITLE OF INVENTION: Null Cells Expressing P2U Receptors
 NUMBER OF SEQUENCES: 8
 CORRESPONDENCE ADDRESS:
 ADDRESSE: Bell, Selzer, Park & Gibson
 STREET: Post Office Drawer 34009
 CITY: Charlotte
 STATE: No. 5607836th Carolina

COUNTRY: USA
 ZIP: 28234
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PcenIn Release #1.0., Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/444,581B
 FILING DATE: 19-MAY-1995
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/442,134
 FILING DATE: 16-MAY-1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Sibley, Kenneth D.
 REFERENCE/DOCKET NUMBER: 31,665
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 919-881-3175
 TELEFAX: 919-881-3175
 INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 375 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-444-581B-2

Query Match 48.0%; Score 934; DB 1; Length 375;
 Best Local Similarity 58.5%; Pred. No. 6.4e-62;
 Matches 183; Conservative 41; Mismatches 85; Indels 4; Gaps 3;

Qy 22 EVELDCWPFDEDFKILLPSYAVVFVLLGLNAPLWIFIURPDATAFMFLAUSD 81
 Db 20 ELGYRCRNFNEDFKVLLPSYGVCLGLCNAVGLYFLCRKLTNNSTTMFLAUSD 79

Qy 82 TLYVLSPPLIYYAAHHNWPFGTEICKFVRFYWNLYCSVLFLTCISVHRYLGICPL 141
 Db 80 ALTAASLPILVYYARGDWFPSFLVLCUVEFYTNYCISFLTCISVHRLGVRLP 139

Qy 142 RALRGGRPLLAGLCLAYLIVAGCLVPLNLFVFTTSNGKTTVLCHDTRPEEFDHYHFS 201
 *Db 140 RSLRWGRARYARRVAGATVVLACQAVPLFYVTTISARG-PLTCHDSAPELFSRFTAYS 198

Qy 202 SAVMGLLGPVCPCLTYCGLMARRYQPLPGAQSSSLR--RSLRTAVVLTFAVCFF 259
 Db 199 SVNIGLIPPAVPFAVLIVCYLMARLLPKPAYGSGGLPRAKRSVRTAVLAVFALCFL 258

Qy 260 PEHTTRTYLLARLLEADCRVNTVNYYKVTRPLASANSCLDPVLYLTGDKYRROLRQ 319
 Db 259 PPHTRTYLLYSFRSLDSCHTLNAINMAYKVTR-LASANSCLDPVLYFLAGRLVRFARD 317

Qy 320 LCGGGKPQRTAA 332
 Db 318 AKPTGKSPATPA 330

RESULT 9
 US-08-446-088A-2
 Sequence 2, Application US/08446088A
 GENERAL INFORMATION:
 APPLICANT: Boucher, Richard C.
 APPLICANT: Weisman, Gary A.
 APPLICANT: Turner, John T.
 APPLICANT: Harden, Thomas K.
 APPLICANT: Parr, Claude E.
 APPLICANT: Sullivan, Daniel M.
 APPLICANT: Erb, Laura
 APPLICANT: Lustig, Kevin D.
 TITLE OF INVENTION: DNA Encoding the Human P2U Receptor and Null Cells Expressing P2U Receptors

NUMBER OF SEQUENCES: 8
 CORRESPONDENCE ADDRESS:
 ADDRESSEES: Bell, Seltzer, Park & Gibson
 STREET: Post Office Drawer 34009
 CITY: Charlotte
 STATE: No. 5691156th Carolina
 COUNTRY: USA
 ZIP: 28234
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/446,088A
 FILING DATE: 19-MAY-1995
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Kenneth D. Sibley
 REGISTRATION NUMBER: 31,665
 REFERENCE/DOCKET NUMBER: 5470-71C
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 919-420-2200
 TELEFAX: 919-881-3175
 INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 375 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-446-088A-2

Query Match 48.0%; Score 934; DB 1; Length 375;
 Best Local Similarity 58.5%; Pred. No. 6.4e-62;
 Matches 183; Conservative 41; Mismatches 85; Indels 4; Gaps 3;

Qy 22 EVELDCWPFDEDFKILLPSYAVVFVLLGLNAPLWIFIURPDATAFMFLAUSD 81
 Db 20 ELGYRCRNFNEDFKVLLPSYGVCLGLCNAVGLYFLCRKLTNNSTTMFLAUSD 79

Qy 82 TLYVLSPPLIYYAAHHNWPFGTEICKFVRFYWNLYCSVLFLTCISVHRYLGICPL 141
 Db 80 ALTAASLPILVYYARGDWFPSFLVLCUVEFYTNYCISFLTCISVHRLGVRLP 139

Qy 142 RALRGGRPLLAGLCLAYLIVAGCLVPLNLFVFTTSNGKTTVLCHDTRPEEFDHYHFS 201
 Db 140 RSLRWGRARYARRVAGATVVLACQAVPLFYVTTISARG-PLTCHDSAPELFSRFTAYS 198

Qy 202 SAVMGLLGPVCPCLTYCGLMARRYQPLPGAQSSSLR--RSLRTAVVLTFAVCFF 259
 Db 199 SVNIGLIPPAVPFAVLIVCYLMARLLPKAYGSGGLPRAKRSVRTAVLAVFALCFL 258

Qy 260 PEHTTRTYLLARLLEADCRVNTVNYYKVTRPLASANSCLDPVLYLTGDKYRROLRQ 319
 Db 259 PPHTRTYLLYSFRSLDSCHTLNAINMAYKVTR-LASANSCLDPVLYFLAGRLVRFARD 317

Qy 320 LCGGGKPQRTAA 332
 Db 318 AKPTGKSPATPA 330

RESULT 10
 US-08-559-524A-3
 Sequence 3, Application US/08559524A
 GENERAL INFORMATION:
 APPLICANT: Conley, Pamela B.
 APPLICANT: Jantzen, Hans Michael
 TITLE OF INVENTION: NOVEL PURINERGIC RECEPTOR
 NUMBER OF SEQUENCES: 14
 CORRESPONDENCE ADDRESS:
 ADDRESSEES: MORGAN, LEWIS & BOCKIUS LLP
 STREET: 1800 M Street, N.W.

CITY: Washington
 STATE: D.C.
 COUNTRY: USA
 ZIP: 20036-5869

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/559,524A
 FILING DATE: 15-NOV-1995
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Adler, Reid G.
 REGISTRATION NUMBER: 30,988
 REFERENCE/DOCKET NUMBER: 044481-5010-00-US

TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-467-7000
 TELEFAX: 202-467-7176
 INFORMATION FOR SEQ ID NO: 3:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 375 amino acids
 TYPE: amino acid
 STRANDEDNESS:
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-559-524A-3

Query Match 48.0%; Score 934; DB 1; Length 375;
 Best Local Similarity 58.5%; Pred. No. 6.4e-62;
 Matches 183; Conservative 41; Mismatches 85; Indels 4; Gaps 3;

Qy 22 EVELDCWFEDDFKFLPVSAYVFEVGLGNAPTLWFLFRLRPKWDATATYMFHIALSD 81
 Db 20 ELGYRCRFNEDFKYVLPVSTGVCVLGLCNAGLYIFLCLRLKTWNASTYMFHIALSD 79

Qy 82 TLYVLSIPLTLYAAHNHWPEGTECKFVFLFTNLYCSVLFTCISRYLGICHL 141
 Db 80 ALYAASPLPVNTTARGDAMPSTVLCVLFETYNTLYCSILFTCISVHRC/GYLRLPL 139

Qy 142 RALWKGRPRLAGLCLAVWLVAGCLVPLNFVTSNKGTIVLCHDTTRPBEFDHYVHFS 201
 Db 140 RSLRNGRARYARRVAGAWVNLQAPVLYFVTTSAARG-PLTCHTDSAPELFSRFVAYS 198

Qy 202 SAVMGLFGVPCLTVLVCYGLMARRYQPLPGSAQSSRL--RSLRITAVLTTFAVCFV 259
 Db 199 SVMGLLFGVPCLTVLVCYMLRBLKPAVGTSCLPRARKSYRTIAVLAVALCFL 258

Qy 202 SAVMGLFGVPCLTVLVCYGLMARRYQPLPGSAQSSRL--RSLRITAVLTTFAVCFV 259
 Db 199 SVMGLLFGVPCLTVLVCYMLRBLKPAVGTSCLPRARKSYRTIAVLAVALCFL 258

Qy 260 PFFHTRTYYLARLLLEADCRVINTVVVYKVTRPLASANSCLDPVLYLGDKYRQLRQ 319
 Db 259 PFFHTRTYYLARLLLEADCRVINTVVVYKVTRPLASANSCLDPVLYLGDKYRQLRQ 317

Qy 320 LOGGGKQPRTAA 332
 Db 318 AKPTGSPSPATPA 330

RESULT 12
 US-09-947-922-3
 Sequence 3, Application US/0947922
 Patent No. 6680373

GENERAL INFORMATION:
 APPLICANT: Conley, Pamela B.
 ADDRESS: Jantzen, Hans-Michael
 TITLE OF INVENTION: NOVEL PURINERGIC RECEPTOR
 NUMBER OF SEQUENCES: 14
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: MORGAN, LEWIS & BOCKIUS LLP
 STREET: 1800 M Street, N.W.
 CITY: Washington
 STATE: D.C.
 COUNTRY: USA

RESULT 11
 US-08-749-707-3
 Sequence 3, Application US/08749707
 Patent No. 6033582

GENERAL INFORMATION:
 APPLICANT: Conley, Pamela B.
 ADDRESS: Jantzen, Hans-Michael
 TITLE OF INVENTION: NOVEL PURINERGIC RECEPTOR
 NUMBER OF SEQUENCES: 14
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: MORGAN, LEWIS & BOCKIUS LLP
 STREET: 1800 M Street, N.W.
 CITY: Washington
 STATE: D.C.
 COUNTRY: USA

ZIP: 20036-5869
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/947,922
 FILING DATE: 07-Sep-2001
 CLASSIFICATION: Unknown>
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/08/749,707
 FILING DATE: 15-Nov-1996
 ATTORNEY/AGENT INFORMATION:
 NAME: Adler, Reid G.
 REGISTRATION NUMBER: 30,988
 REFERENCE DOCKET NUMBER: 044481-5010-01-US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-467-7000
 TELEFAX: 202-467-7176
 INFORMATION FOR SEQ ID NO: 3:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 375 amino acids
 TYPE: amino acid
 STRANDEDNESS: <Unknown>
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 SEQUENCE DESCRIPTION: SEQ ID NO: 3:
 US-09-947-922-3

Query Match Score 934; DB 2; Length 375;
 Best Local Similarity 58.5%; Pred. No. 6.4e-62;
 Matches 183; Conservative 41; Mismatches 85; Indels 4; Gaps 3;

Qy 22 EVELDCWFDEDFKFILLPSIAYVFLGIGLNAPTLWLFIFRKPWDATATMFMHLASD 81
 Db 20 ELGRCRNFEDFKTLLPISGVIVCLGLCNAVGLYIFLCLRLTWNASTTMFLAISD 79

Qy 82 TLYVLSPLTIIYYAAAHNHWPFGTEICKFVRELFYNNLYCSVLFITCSVHRYLGICPL 141
 Db 80 ALYAAASPLVLYYYARGDHWPESTVLCKLVRFELTYNNLYCSVLFITCSVHRCIGVLRPL 139

Qy 142 RALEWGRPRIAGLCLCLAWLIVAGGLPVLNPKFTTSNKGTPTVILCHTRPEEPDHYVFS 201
 Db 140 RSLRWGRARYARRYAGAVWVVLACQAPVLYFTTSARG-PLTCHDTSAPLFSSRFVYS 198

Qy 202 SAVMGLLFGVPCLYTLCYGLMARRLYQPLPSAQSSRL--RSLRITAIVLTVFAYCFV 259
 Db 199 SVMGLLFAFPATVLCVLMARLLKRAYTSGGLPRAKRKSVRTAVLAVFALCFL 258

Qy 260 PFHTRTTYYLARLIEADCRVLTNVYKVTRPLASANSCLDPVLYLTGDKYRQLRQ 319
 Db 259 PFHVTRTLYSFRLSDLSCHTLNAINMAYKVTR-LASANSCLDPVLYFLAGQLVRFRD 317

Qy 320 LCGGGKQPRTAA 332
 Db 318 AKPPGSPATPA 330

RESULT 13
 US-09-745-842-14
 Sequence 14, Application US/09745842
 Patent No. 6762029
 GENERAL INFORMATION:
 APPLICANT: Conley, Pamela B.
 APPLICANT: Jantzen, Hans-Michael
 APPLICANT: Julius, David
 APPLICANT: Hollopeter, Gunter
 APPLICANT: COR Therapeutics, Inc.
 TITLE OF INVENTION: P2Y12 Receptor
 FILE NUMBER: 44481-5053-US
 CURRENT APPLICATION NUMBER: US/09/745,842
 CURRENT FILING DATE: 2000-12-26
 PRIOR APPLICATION NUMBER: US 60/171,622
 PRIOR FILING DATE: 1999-12-23

NUMBER OF SEQ ID NOS: 21
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO 14
 LENGTH: 373
 TYPE: PRT
 ORGANISM: Homo sapiens
 FEATURE:
 OTHER INFORMATION: P2Y1 purinergic receptor: p2yr
 US-09-745-842-14

Query Match Score 641.5; DB 2;
 Best Local Similarity 40.0%; Pred. No. 3.3e-40;
 Matches 140; Conservative 60; Mismatches 121; Indels 29; Gaps 9;

Qy 17 GPGSS-----EVELDCWFDEDFKFILLPSIAYVFLGIGLNAPTLWLFIR 63
 Db 20 GPGEWGNSTVASTAAVSSSEFKCALKTGFOFYLPAYVILVPTIGLGNNSVAlWMFVPH 79

Qy 64 LRPDATATMFMHLASDLYVLSLPTLIYAAHNHPFGTEICKFVPRFLFWNLYCYSV 123
 Db 80 MKWGSISVYMLVNLAFPEVYLPALIPIYPTKTBWFGDMCKQPFITNLYGSI 139

Qy 124 LFLLTCISVYRLGICHLPLRALMGRPLAGLICLAA--VWLWVACLVNPFLFFVTS-NRG 180
 Db 140 LFLLTCISAHRYSGVVPKSL--GRLKCKNAICISVWLIVVAISPLFVSYSTGVRN 197

Qy 181 TTIVLCHDTTRPREFDHTYHESSAVWGLLFGVPCLVLTIVCYGLMRL-YQPLPSAQSSS 239
 Db 198 KTTICDTSDETLRSPTYSMCTVAMFCVPLVILGCGYLVRALYKDLD--NSPL 254

Qy 240 RLSSLRITAIVLTVFAYCFVPHITTYYLRL--LEADCRVLNINVVVKYTRPLAS 296
 Db 255 RRSSVYLIVLTVFAYSIYIPHMKTOMTRPLRDFQTPMCAFNDRYVATYQTRGLAS 314

Qy 297 ANSCLDPVLYLTGDKYRQL---ROLCGGGKQPRTAASSLALVSLP 342
 Db 315 LNSCDVPILYFLAGDTFRLSRATRASRSEANLQSKEDEMTNLPE 364

RESULT 14
 US-08-559-524-4
 Sequence 4, Application US/08559524A
 Patent No. 5871963
 GENERAL INFORMATION:
 APPLICANT: Conley, Pamela B.
 APPLICANT: Jantzen, Hans-Michael
 TITLE OF INVENTION: NOVEL PURINERGIC RECEPTOR
 NUMBER OF SEQUENCES: 14
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: MORGAN, LEWIS & BOCKIUS LLP
 STREET: 1800 M Street, N.W.
 CITY: Washington
 STATE: D.C.
 COUNTRY: USA
 ZIP: 20036-5869

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/559,524A
 FILING DATE: 15-NOV-1995
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Agler, Reid G.
 REGISTRATION NUMBER: 30,988
 REFERENCE DOCKET NUMBER: 44481-5010-00-US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-467-7000
 TELEFAX: 202-467-7176
 INFORMATION FOR SEQ ID NO: 4:
 SEQUENCE CHARACTERISTICS:

LENGTH: 373 amino acids
 TYPE: amino acid
 STRANDEDNESS:
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-359-524A-4

Query Match 31.9%; Score 621; DB 1; Length 373;
 Best Local Similarity 43.4%; Pred. No. 1.1e-38;
 Matches 126; Conservative 53; Mismatches 103; Indels 8; Gaps 4;

Qy 33 EKFILLPSYAVVFLGGLNAPPLWIFIFRLRPDATAATMPEHLSDTLYVLSLPTLI 92
 Db 49 FQFYLPVAVTIVPGLNSVATWNEFRNKPGSISVMENLALADFLYVLTIPALI 108

Qy 93 YYAAHNHHWPSTTEICKFVLFLTVNLICSYLCSULFLTCISVHRYLGICHPLRMRGRPLRA 152
 Db 109 FYYFNKTDWIFGDAMCKLQRFHHTNLYGSITLFLTCISAHRSGVYVPLKSLGRLKCKNA 168

Qy 153 GLCLCAWLVLYAGCLVYNLFFVTTIS-NKGITVLCHDTRPPEFDHTYFHSSAVMGLLFGV 211
 Db 169 VYISVIVWLIVVGISPILFISGTGIRKNRKTCTTSDEYLRSFPIYSMCTTVAMFCV 228

Qy 212 PCLVTLVCGLMARL-YQPLPGSAQSSSRURSLRTIAVLTIVFAVCVPFHTRTYYL 270
 Db 229 PLVTLGCGYLVRLAKYKDLD--NSPLRKRSVLYLIVLIVTFAVSYIPHTYMTKTMNLR 285

Qy 271 ARL--LEADCRVLYINVVYKTRPLASANSCLDPVLYLLTGDKYRQL 317
 Db 286 ARLDQTPEMCAFNDRVYATQVTRGLASLNSCDPLYFLAGDTFRRL 335

Search completed: April 4, 2006, 20:15:48
 Job time : 48 secs

RESULT 15

US-08-749-707-4
 Sequence 4, Application US/08749707
 Patent No. 6063582

GENERAL INFORMATION:
 APPLICANT: Conley, Pamela B.
 APPLICANT: Jantzen, Hans-Michael
 TITLE OF INVENTION: NOVEL PURINERGIC RECEPTOR
 NUMBER OF SEQUENCES: 14
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: MORGAN, LEWIS & BOCKLUS LLP
 STREET: 1800 M Street, N.W.
 CITY: Washington
 STATE: D.C.
 COUNTRY: USA
 ZIP: 20036-5869

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/749,707
 FILING DATE: 15-NOV-1996
 CLASSIFICATION: 536
 ATTORNEY/AGENT INFORMATION:
 NAME: Adler, Reid G.
 REGISTRATION NUMBER: 30,988
 REFERENCE/DOCKET NUMBER: 044481-5010-01-US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-467-7000
 TELEX/FAX: 202-467-7176
 INFORMATION FOR SEQ ID NO: 4:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 373 amino acids
 TYPE: amino acid
 STRANDEDNESS:
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-749-707-4

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: April 4, 2006, 20:10:27 ; Search time 41 Seconds

(without alignment)
856.564 Million cell updates/sec

Title: US-10-811-198-2

Perfect Score: 1944

Sequence: 1 MASTESSLRLSLGLSPGPGS.....CRWAAATPQDSSCSTPRADRL 365

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 20000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_90;*

1: pir1;*

2: pir2;*

3: pir3;*

4: pir4;*

RESULT 1

S68679

G-protein-coupled receptor - human

C;Species: Homo sapiens (man)

C;Date: 15-Feb-1997 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004

C;Accession: S68679

R;Stam, N.J.; Klomp, J.; van de Heuvel, M.; Olijve, W.

PEBS Lett. 384, 260-264, 1996

A;Title: Molecular cloning and characterization of a novel orphan receptor (P(2P)) exp:

A;Reference: PMID:8617367

A;Accession: S68679

A;Status: Preliminary

A;Molecule type: DNA

A;Residues: 1-365 <STA>

A;Cross-references: UNIPROT:P51582; UNIPARC:UPI000002E776; EMBL:X96597; NID:91296631; 1

C;Superfamily: ATP receptor_P2u

C;Keywords: G protein-coupled receptor

SUMMARIES

Result No. Score %

Query Match Length

DB ID

Description

Result No.	Score	Query	Match	Length	DB ID	Description
1	1544	100.0	365	2	S68679	G protein-coupled receptor_P2u
2	965.5	49.5	373	2	A47556	APP receptor_P2u - P-2U nucleotide receptor
3	934	48.0	375	2	A54946	G protein-coupled receptor
4	641.5	33.0	373	2	JC4737	G protein-coupled receptor
5	628	32.3	362	2	S33733	P2Y receptor - bovine
6	621	31.9	373	2	JC4162	G protein-coupled receptor_P2Y6
7	598	30.2	355	2	JC4810	G protein-coupled receptor
8	596	30.1	328	2	I50241	G protein-coupled receptor
9	501.5	25.8	308	2	T09908	intron 17 Purinergic heptahelical receptor
10	479.5	24.7	344	2	JC5549	P2Y5 receptor
11	450.5	23.2	370	2	I48705	protease activating receptor thrombin receptor
12	423	21.8	399	2	I51667	protease-activating receptor
13	411.5	21.2	420	2	S66518	delta opioid receptor
14	403	20.7	397	2	I38532	delta opioid receptor
15	400	20.6	372	2	A37912	thrombin receptor
16	397.5	20.4	425	2	S17148	alpha-thrombin receptor
17	388.5	20.0	427	2	A43448	thrombin receptor
18	388	20.0	432	2	S6563	delta opioid receptor
19	385	19.8	372	2	B45610	delta opioid receptor
20	383	19.7	361	2	JN0654	G protein-coupled receptor
21	382.5	19.7	362	2	I56517	angiotensin II receptor
22	381.5	19.6	398	2	A40191	mu opioid receptor
23	379.5	19.5	392	2	I56553	opioid receptor mu
24	378.5	19.5	400	2	I56553	mu opiate receptor
25	377	19.4	372	2	B48227	delta opioid receptor
26	376.5	19.4	398	2	I56517	mu opioid receptor
27	371.5	19.1	342	2	I56517	platelet-activating factor receptor
28	371.5	19.1	398	2	A57510	mu opioid receptor
29	370.5	19.1	359	2	JCS277	G protein-coupled receptor

RESULT 2

A47556
 ATP receptor P2u - mouse
 C;Species: Mus musculus (house mouse)
 C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 09-Jul-2004
 C;Accession: A47556
 R;Lustig, K.D.; Shau, A.K.; Brake, A.J.; Julius, D.
 Proc. Natl. Acad. Sci. U.S.A. 90, 5113-5117, 1993
 A;Title: Expression cloning of an ATP receptor from mouse neuroblastoma cells.
 A;Reference number: A47556; PMID:7685114
 A;Accession: A47556
 A;Status: Preliminary
 A;Molecule type: mRNA
 C;SuperFamily: ATP receptor P2u
 C;Keywords: transmembrane protein

Query Match 49.5%; Score 962.5; DB 2; Length 373;
 Best Local Similarity 53.7%; Pred. No. 1.1e-77;
 Matches 183; Conservative 46; Nismatches 97; Indels 19; Gaps 3;

Qy 22 EVELDCWFDDEFKFTILLPVSAYVFLGLGNAPTLWLFIFRLRFDATYMFHLDSD 81
 Db 20 ELGYKCRFNEFKTYLILPVSYGVVCLGLCLNVALYLIFLGRKTWNASTYMFHLDSD 79

• Qy 82 TLYVLSPLTIIYYAAAHNRHEPFEGTECKFYRFLFYTWNLYCSVLFCTCSYHRYLGICPL 141
 Db 80 SLYAASLPILLVYYARGDHWFSTVLCYRFLFYTNYCSILEFTCTCSYHRCIGVLPBL 139

Qy 142 RALYGRPLLAGLCLAVWLVAGLVPNLEFYTTSNKGTIVLCHDTTRPEEFHVFHS 201
 Db 140 HSLRNGRARYARRYAVWWVILVLAOAIPVLYFTTTSVRGTRITCHDSARELFSHFVAYS 199

Qy 202 SAVMGILFGVCPCLVLYCYGMARRELYQPLPGSAQSSRSL--RSIERTIAVLTFAVCYV 259
 Db 200 SVMLGLFAVPSVILVCYTLMARRLKPKAYTTGGLPRAKRKSRTIALVLAFLCPL 259

Qy 260 PFHTTRTIYYLARLIEADCRVNLNTVYKVTRPLASANSCLDPVLYLTGDKYRQLRQ 319
 Db 260 PFHTTRTLYYSFRSLDSCHTLNAINMAYKTRPLASANSCLDPVLYFTLAGQRQLVRFARD 319

Qy 320 LCGGGKQP-----RTAASSLLAVLVSUPEDSSCRWAATPQDS 355
 Db 320 AKPPTEPTPSQARRKLGLHRPNRTRVKDQ---SVSSDDERRTESTPAGS 366

RESULT 3
A5446
 P-2U nucleotide receptor - human
 C;Species: Homo sapiens (man)
 C;Date: 11-Nov-1994 #sequence_revision 11-Nov-1994 #text_change 17-Mar-1999
 C;Accession: A5446
 R;Parr, C.E.; Sullivan, D.M.; Paradiso, A.M.; Lazarowski, E.R.; Burch, L.H.; Olsen, J.C.
 Proc. Natl. Acad. Sci. U.S.A. 91, 3275-3279, 1994
 A;Title: Cloning and expression of a human P-2U nucleotide receptor, a target for cystic fibrosis
 A;Reference number: A5446; PMID:84211846; PMID:8159758
 A;Accession: A54946
 A;Status: Preliminary
 A;Molecule type: mRNA; protein
 A;Residues: 1-375 <PAR>
 A;Cross-references: UNIPARC:UPI0000145104; GB:U07225
 A;Note: parts of this sequence were confirmed by protein sequencing
 C;Genetics: GDB:P2RY2; HP2U; P2U
 A;Cross-references: GDB:362713; OMIM:600041
 A;Map position: 11q13.5-11q14.1
 C;Superfamily: ATP receptor P2u
 C;Keywords: G protein-coupled receptor; transmembrane protein

Query Match 48.0%; Score 934; DB 2; Length 375;
 Best Local Similarity 58.5%; Pred. No. 3.6e-75;
 Matches 183; Conservative 41; Nismatches 85; Indels 4; Gaps 3;

P;258,336/Binding site: phosphate (Ser) (covalent) (by protein kinase A) #status predicted
 P;333,339/Binding site: phosphate (Thr) (covalent) (by protein kinase C) #status predicted
 P;333,339/Binding site: phosphate (Ser) (covalent) (by protein kinase C and calmodulin-depen-
 Query Match 33.0%; Score 641.5; DB 2; Length 373;
 Best Local Similarity 40.0%; Pred. No. 3.1e-49; Mismatches 60; Indels 29; Gaps 9;
 Matches 140; Conservative 60;

Qy 17 GPGSS-----EVLDCWDE-DFKEFLIPVSYAVFVUGLGNAPTLWLFIR 63
 Db 20 GPGSGWGSTAVASSSFKAUTKTKGQFYLLPAVYLVLFGLENSVAIWMFVTH 79
 Qy 64 LRPWDATATMFLALSDTLVLSPLTIIYAAINHWPGETICKFVFLFYNNLYCSV 123
 Db 80 MKPWSGISYVMMNTALADPEVYLPVTPALIPIYFNKTDWIPEGDACKLQDRIIFHNLV 139
 Qy 124 LFLLTCISVHYLGICHPRLRGRPRLAGILCLAA-VWLVAGGLVPNLFVFTTS-NKG 180
 Db 140 LFLLTCISVHYSGVYVPLKSL-GRLKRNACISVLUWVVAISPLFYSSTGVRRN 197
 Qy 181 TTIVLHDITTEPEEFDHVWHESSAVNGLFLQPVCLTVLVCYGLMARRL-YOPLGSQQSS 239
 Db 198 KTICTCYDTSDVEYLFSYFYSMCTVAMPFCVPLVILGCYGLTVRALTYKDLD--NSPL 254
 Qy 240 RLRSRTIAVLTIFAVCFVPPHTRTIYTILRL--LEADCRLVNINVVKVTRPAS 296
 Db 255 RRKSYLVVPLTIVLTFAVSYVPHMKTMLRQLRDFQTAMCANDRIVATYQVTRGAS 314
 Qy 297 ANSCLDPVYLLTGDKYRQL---ROLCGGGKPOPTTAASSLAVLVSPLPE 342
 Db 315 LNSCVDPLYFLAGDTFRLSLRATRASRSEANLQSKEDMTLNLLPE 364

RESULT 5
 S33733 G protein-coupled receptor - chicken
 C.Species: Gallus gallus (chicken)
 C.Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 09-Jul-2004
 *C.Accession: S33733
 R.Webb, T.E.; Simon, J.; Krishelk, B.J.; Bateson, A.N.; Smart, T.G.; King, B.P.; Burnstock
 PBB Leit., 124, 219-225, 1993
 A.Cross-references: UNIPROT:P349996; UNIPARC:UPI00000405D4; EMBL:X73268; NID:g395084; PID
 C.Superfamily: ATP receptor P2u
 A.Reference number: S33733; PMID:93285340; PMID:8509924
 A.Accession: S33733
 A.Molecule type: mRNA
 A.Residues: 1-362 <WEB>
 A.Cross-references: UNIPROT:P349996; UNIPARC:UPI00000405D4; EMBL:X73268; NID:g395084; PID
 C.Superfamily: ATP receptor P2u
 C.Keywords: G protein-coupled receptor; transmembrane protein
 Query Match 32.3%; Score 628; DB 2; Length 362;
 Best Local Similarity 39.4%; Pred. No. 4.8e-46; Mismatches 62; Indels 16; Gaps 7;
 Matches 137; Conservative 62;

Qy 4 TESSLRLSGLSPGPSSSEVLDLWDEDDFKFPLPVSYAVFVUGLGNAPTLWLFIR 63
 Db 13 TQPBLLAG-GWAAGNATRCSLT---KTFGFQFTLPTVILVITGFFGNSVAIWMFVTH 68
 Qy 64 LRPDATATMFLALSDTLVLSPLTIIYAAINHWPGETICKFVFLFYNNLYCSV 123
 Db 69 MRPWGSGISYVMMNTALADPEVYLPVTPALIPIYFNKTDWIPEGDACKLQDRIIFHNLV 139
 RBSLT 7
 G Protein-coupled P2 receptor - rat
 C.Species: Rattus norvegicus (Norway rat)
 C.Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
 C.Accession: 155450
 R.Chang, K.; Hanaka, K.; Kumada, M.; Takuwa, Y.
 J. Bio. Chem. 270, 26152-26159, 1995
 A.Title: Molecular cloning and functional analysis of a novel P2 nucleotide receptor.
 A.Reference number: I55450; MUID:7532819
 A.Accession: I55450
 A.Status: Preliminary; translated from GB/EMBL/DDBJ

Qy 124 LEFLTCISVHYLGICHPRLRGRPRLAGILCLAA-VWLVAGGLVPNLFVFTTS-NKG 182
 Db 129 LEFLTCISVHYLGICHPRLRGRPRLAGILCLAA-VWLVAGGLVPNLFVFTTS-NKG 188
 Qy 183 VLGHDTRPFEFDHYVHFSSAVNGLFLQPVCLTVLVCYGLMARRL-YOPLGSQAQSSRL 241
 Db 189 ITCTCYDTSDVEYLFSYFYSMCTVAMPFCVPLVILGCYGLTVRALTYKDLD--NSPL 245
 Qy 242 RSURTIAVLTIVPRAVCFVPPHTRTIYTILRL--LEADCRLVNINVVKVTRPLASAN 298

A; Molecule type: mRNA
A; Residues: 1-328 <RES>
A; Cross-references: UNIPROT:Q63371; UNIPARC:UPI0000131003; GB:D63665; NID:9106607; PIDN:10 RSLGSPGPSSSEVLDCNFDEDPKFLILLPVSAYVFGLNAPTLWLFIRFRPWA 69
C; Superfamily: ATP receptor P2u
C; Keywords: G protein-coupled receptor

Query Match 30.2%; Score 588; DB 2; Length 328;
Best Local Similarity 42.2%; Pred. No. 1.5e-44;
Matches 136; Conservative 37; Mismatches 128; Indels 18; Gaps 6;

Qy 5 ESSLRLSGLSPGPSSSEVLDCNFDEDPKFLILLPVSAYVFGLNAPTLWLFIRL 64
Db 4 DNGTQAGPLP-----TCVIRDFKRLPPSVLVLGVPLAVNCVIAQICASR 55

Qy 65 RWDDATYMFHIALSDTLYVLSLPLTIIYVYAAHNTWPGTEICKVPRFLFYWNLYCSTV 124
Db 56 RTLRSAYTMLALADLYACSLPLIYTARGDHWFGDIACLVRFLYANHGSI 115

Qy 125 FUTCISVRYLGICHPLRHL--GRPLLAGLCLAVLWVAGCLVLPNLFPVTSNKGT 181
Db 116 FUTCISVQRYLQICLHPPLAP--WHKRGGRBAAWVUCGWVWVTAQCLPTAAATGORN 173

Qy 182 TVLCHDPTRPPEFDHYKFSSAVMGILGFVPCLVTHYCGMARRL-YOPLP-GSAQSS 239
Db 174 RYTYCDLSSPPLSTRYLPGMALTVGWTFSLPFITKAYLAVRSTPGVCPVLETAAVYKGTRPPFASAN 233

Qy 240 RRSRLTIAVLTVEFAVCFPHITITIYKARILLE-ADCRVNIINVYKVTRPLASAN 298
Db 234 RSKAARMVAVVVAEVFTSPVSCPVLETAAVYKGTRPPFASAN 293

Qy 299 SCIDPVLVLLTDGYRQLRQL 320
Db 294 SVIDPILFFYFQOKPRQPHDL 315

RESULT 9
150241 G protein-coupled receptor 6H1 - chicken
N; Alternate names: purinoreceptor 6H1
C; Species: Gallus gallus (chicken)
C; Date: 13-Sep-1996 #text_change 09-Jul-2004
C; Accession: 150241; JC4618
R; Kaplan, M.H.; Smith, D.I.; Sundick, R.S.
J. Immunol. 151, 628-636, 1993
A; Title: Identification of a G protein coupled receptor induced in activated T cells.
A; Reference number: 150241; PMID:91329058; PMID:8393036
A; Accession: 150241
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-308 <KAP>
A; Cross-references: UNIPARC:UPI0000055A6B; GB:L06109; NID:9304383; PID:1304383
R; Community, D.; Parmentier, M.; Boeynaems, J.M.
Biochem. Biophys. Res. Commun. 222, 303-308, 1996
A; Title: Cloning, functional expression and tissue distribution of the human P2Y6 receptor
A; Reference number: JG4800; MUID:96222498; PMID:8670200
A; Accession: JG4800
A; Molecule type: mRNA
A; Residues: 1-328 <COM>
A; Experimental source: UNIPROT:Q15077; UNIPARC:UPI000005041C; EMBL:X97058
R; Hammet, F.; Southey, M.C.; Somers, G.R.; Hutchins, A.M.; Venter, D.J.
Submitted to the EMBL Data Library, March 1996
A; Reference number: H01373
A; Accession: G02514
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-4,328 <COM>
A; Cross-references: UNIPARC:UPI000161B0; EMBL:U52464; NID:91407632; PIDN:AAB03572.1; F;15-40/Domain: transmembrane #status predicted <TM1>
C; Genetics:
A; Gene: P2Y6
C; Superfamily: ATP receptor P2u
C; Keywords: glycoprotein; Placenta; receptor; transmembrane protein
F;26-32/Domain: transmembrane #status predicted <TM2>
F;63-86/Domain: transmembrane #status predicted <TM3>
F;104-122/Domain: transmembrane #status predicted <TM4>
F;193-216/Domain: transmembrane #status predicted <TM5>
F;241-264/Domain: transmembrane #status predicted <TM6>
F;283-309/Domain: transmembrane #status predicted <TM7>
F;5,17-21/Domain: transmembrane #status predicted <TM8>
Query Match 25.8%; Score 501.5; DB 2; Length 308;
Best Local Similarity 36.9%; Pred. No. 6.6e-37;
Matches 108; Conservative 56; Mismatches 124; Indels 5; Gaps 4;

Qy 23 VELDCWWDDEDFPKLIPVPSAYVFGLNAPTLWLFIRFRPDATAVYKHLAISDT 82
Db 2 VSSNCSTEDFSKTYLXGCVFSMVFLGCVNETTTMLNLAISDL 61

Query Match 30.1%; Score 586; DB 2; Length 328;
Best Local Similarity 42.5%; Pred. No. 2.3e-44;

A; Map Position: 1p36.1-1p34.3
 C; Superfamily: vertebrate rhodopsin

Query Match 20.6%; Score 400; DB 2; Length 372;

Best Local Similarity 31.2%; Pred. No. 8.1e-28;
 Matches 112; Conservative 57; Mismatches 138; Indels 52; Gaps 11;

Qy 16 PGPGS-SEVELDCWFDFDKFILLPVSYAVVFLGLNAPTLWLFIRLRFWDATATM 74

Db 38 PPGSAASSL-----AIAITALYSAVAGVLGNVLMFGIVRYTOKTAANIYI 88

Qy 75 FHLALSDTLYVLSPLPTLIIYYAAHNHWPGTICKEVRELFFWNLICSVSLFLTCISVHY 134

Db 89 FNLALADALATSTLPQSAYKIMET-WPFGELLKCAVLSIDYNNMFTSIFTLTMSVDRY 147

Qy 135 LGICHPLRALKGRPLLAGLCLAVVAGLVPNLFFVTTSNKGTTVLCHDTRPEEF 194

Db 148 IAVCHPVKAALDRTPAKAKLINICIVWIAASGYGVPMVMAVTRPRGAVVC----- 198

Qy 195 DHVYHRS-----AYNGLLFGVPCLVLTVCYGMARRL-YQPLFGSAQSSRL 241

Db 199 -MLQFSPSPSWWDTTKICVFLFAFPVPIILITVCGMLLRLSRVRLUSGSKEKDRL 256

Qy 242 RSL-RTIAVULTVFAVCFVPHITRITYYLARLLEADCYLVNIVVYKTRPLASNSC 300

Db 257 RRITRMLVYVGAFLVCAPIHTIFVWTLIDRDRPLVVAHLHCl---ALGYNSS 312

Qy 301 LDPUVYLTGDKYRQLRQLCGG-GKQPQRTAASSLLAVSLPEDSCR--WAATPQD 354

Db 313 LNPVLYAFLDENPKRCRCPQLCRKPCGRPDPS-----FSRPREATERVACTPSD 364

Search completed: April 4, 2006, 20:14:54
 Job time : 42 secs

GenCore version 5.1.7
 Copyright (c) 1993 - 2006 Bioceleration Ltd.
 OM protein - protein search, using sw model
 Run on: April 4, 2006, 20:26:42 ; Search time 25 seconds
 (without alignments)
 444.452 Million cell updates/sec

Title: US-10-811-198-2

Perfect score: 1944

Sequence: 1 MASTESSLLRSLGLSPGGS.....CRWAATPQDSSCSTPRADRL 365

Scoring table: BL0SUMM2

Gappen 10.0 , Gapext 0.5

Searched: 180808 seqs, 30441898 residues

Total number of hits satisfying chosen parameters:

180808

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database	Published Applications AA New:*
1:	/SIDSS5/ptodatt/2/pubpat/US08_NEW_PUB.pep:*
2:	/SIDSS5/ptodata/2/pubpat/US06_NEW_PUB.pep:*
3:	/SIDSS5/ptodata/2/pubpat/US07_NEW_PUB.pep:*
4:	/SIDSS5/ptodata/2/pubpat/PCN_NEW_PUB.pep:*
5:	/SIDSS5/ptodata/2/pubpat/US05_NEW_PUB.pep:*
6:	/SIDSS5/ptodata/2/pubpat/US10_NEW_PUB.pep:*
7:	/SIDSS5/ptodata/2/pubpat/US11_NEW_PUB.pep:*
8:	/SIDSS5/ptodata/2/pubpat/US60_NEW_PUB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Score	Match	Length	DB ID	Description
1	1944	100.0	365	6	US-10-995-561-545	Sequence 545, App
2	641.5	33.0	373	7	US-11-127-877-46	Sequence 46, App
3	641.5	33.0	373	7	US-11-122-874-6	Sequence 6, App
4	515	26.5	367	7	US-11-157-931-6	Sequence 6, App
5	514	26.4	337	7	US-11-222-874-6	Sequence 2, App
6	510	26.2	339	7	US-11-157-930-4	Sequence 4, App
7	403	20.7	397	7	US-11-073-175-145	Sequence 145, App
8	397	20.4	485	6	US-10-121-234-934	Sequence 934, App
9	388.5	20.0	370	6	US-10-130-773-446	Sequence 446, App
10	378.5	19.5	400	7	US-11-127-877-55	Sequence 55, App
11	377.5	19.4	346	7	US-11-157-930-2	Sequence 2, App
12	375	19.3	368	6	US-10-920-561-716	Sequence 6, App
13	375	19.3	415	7	US-11-117-058-2	Sequence 2, App
14	367	18.9	357	7	US-11-261-135-2	Sequence 2, App
15	362.5	18.6	380	6	US-10-130-773-443	Sequence 443, App
16	361	18.6	359	6	US-10-176-787-2	Sequence 2, App
17	360	18.5	359	6	US-10-995-561-712	Sequence 712, App
18	360	18.5	359	6	US-10-995-561-716	Sequence 716, App
19	350	18.5	359	7	US-11-127-877-65	Sequence 65, App
20	360	18.5	388	6	US-10-995-561-713	Sequence 713, App
21	360	18.5	394	6	US-10-995-561-714	Sequence 714, App
22	360	18.5	394	6	US-10-995-561-715	Sequence 715, App
23	345.5	17.8	254	6	US-10-055-877-228	Sequence 248, App
24	345.5	17.8	254	6	US-10-055-877-327	Sequence 327, App
25	345.5	17.8	254	6	US-10-055-877-340	Sequence 340, App

Sequence 83, Appli
 Sequence 5, Appli
 Sequence 67, Appli
 Sequence 6, Appli
 Sequence 838, Appli
 Sequence 837, Appli
 Sequence 242, Appli
 Sequence 9, Appli
 Sequence 546, Appli
 Sequence 17, Appli
 Sequence 67, Appli
 Sequence 2, Appli
 Sequence 1, Appli
 Sequence 26, Appli
 Sequence 60, Appli
 Sequence 4, Appli
 Sequence 64, Appli
 Sequence 2, Appli
 Sequence 4, Appli
 Sequence 2, Appli
 Sequence 225, Appli
 Sequence 237, Appli
 Sequence 27, Appli

ALIGNMENTS

RESULT 1
 US-10-995-561-545
 ; Sequence 545, Application US/10995561
 ; Publication No. US20050272054A1
 ; GENERAL INFORMATION:
 ; APPLICANT: CARGILL, Michele et al.
 ; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
 ; TITLE OF INVENTION:
 ; FILE REFERENCE: CL001559
 ; CURRENT APPLICATION NUMBER: US/10/995,561
 ; CURRENT FILING DATE: 2004-11-24
 ; SOFTWARE: FastSBQ for Windows Version 4.0
 ; SEQ ID NO: 545
 ; LENGTH: 365
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-10-995-561-545

Query Match 100.0%; Score 1944; DB 6; Length 365;
 Best Local Similarity 100.0%; Pred. No. 1..7e-165;
 Matches 365; Conserv 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MASTESSLLRSLGLSPGGSSEVEDDCWPDBDFKILLPVSAYVFLVGLGNAPLWLF 60
Db	1	MASTESSLLRSLGLSPGGSSEVEDDCWPDBDFKILLPVSAYVFLVGLGNAPLWLF 60
Qy	61	IFRLRPWDATATTMHLALSDTLYTLSPPLIYTAHNWMPFGTEICKFVRFLFWNL 120
Db	61	IFRLRPWDATATTMHLALSDTLYTLSPPLIYTAHNWMPFGTEICKFVRFLFWNL 120
Qy	121	CSVLFLTCISVHRYLGICHPLRLWRGRPLAGILCLAVLVIGCLVPLFFYTTSNKG 180
Db	121	CSVLFLTCISVHRYLGICHPLRLWRGRPLAGILCLAVLVACLVPLFFYTTSNKG 180
Qy	181	TIVLCHDTRPPEPDHYFPHSSAYMGLLGVPCLNLYCYGLMARRLYQPLPGSQSSR 240
Db	181	TIVLCHDTRPPEPDHYFPHSSAYMGLLGVPCLNLYCYGLMARRLYQPLPGSQSSR 240
Qy	241	LRSLTIAVLTIVACVCFPHITRITYLARLEADCRVLTIVVVKTRPLASANC 300
Db	241	LRSLTIAVLTIVACVCFPHITRITYLARLEADCRVLTIVVVKTRPLASANC 300

Db	82	WLFIRD KSGT PANVFLMHLAVADLSCVLVLPTRLVYHFGNHWPFGEIAICRLTGFLFYL	141
Dy	118	NLYCSVPLTCISVHRVYLGICHPLRAWRPRPLAGILCLLAVWAGCIVLNLLFVTTTS	177
Db	142	NNAYASIVELTCISADRFELAIVHPVKSLKLRRPLYAHLLACAFWVWVAVAMAPLLSPQTV	201
Dy	178	NKGTIVLICHDTTRPPEFDHYVHFSASWAGLFFGVPCLVTLVYCGLMARRLYQPLGSAQS	237
Db	202	QTNNHTVCLQLVR-EKASHHALLSVLAV--AFTEPFPTTVCYCLLITRSRQL--RVKEV	255
Dy	238	SSRLRSRTIAVLTIVPAVCYFPFHTRIYIL-ARLLEADCRTVINTVVYKVTRPLAS	296
Db	256	RKTAKVRMIAVLAFLVUCVPPHYSRSTVYLVHTSHGASCATRILLANRITSCLTS	315
Dy	297	ANSCLDPVLYLITGDKYTRQL-ROLGS---GGKP--QPTTAASSLALVS	339
Db	316	LNGALDPMYFFFVAEPRHALCNLICGCKRLKGPPSPEGCTNESLSAKS	365

RESULT 5
S-11-222-874-2
Sequence 2, Application US/11222874
Publication No. US20060052329A1
GENERAL INFORMATION:
APPLICANT: Bayar AG
TITLE OF INVENTION: REGULATION OF HUMAN P2Y1-LIKE G PROTEIN-COUPLED RECEPTOR
FILE REFERENCE: LIO131 Foreign Countries
CURRENT APPLICATION NUMBER: US/11/222,874
CURRENT FILING DATE: 2005-09-09
PRIOR APPLICATION NUMBER: US/10/344,728
PRIOR FILING DATE: 2003-03-14
PRIOR APPLICATION NUMBER: US 60/224,989
PRIOR FILING DATE: 2000-08-14
NUMBER OF SEQ ID NOS: 6
SOFTWARE: PatentIn version 3.1
SEQ ID NO 2
LENGTH: 337
TYPE: PRT
ORGANISM: Homo sapiens

Query Match	26.4%	Score	514;	DB	7;	Length	337;
Best Local Similarity	35.1%	Pred. No.	2.3e-38;				
Matches	101;	Conservative	64;	Mismatches	119;	Indels	4;
						Gaps	2;
30	DED--FKFILLPVSAYYVFVLGIGLNAPTLWLFIFRKPWDATATMFHLALSDTLYLVS	87					
26	DENPLKRYHPLPYIGIIFLVGFPGNAVIVSTYIFKRPWKSSTIMLNACTDLYLTS	85					
88	LPTLTYYAAHHNHPFGTBCKEVRLFLYFVNWLCSVHRYLGICHPLRAIRWG	147					
86	LPPFLHYAASGEWNHFQDFEMDPEHFRSFHNFYSSFLPTCESIFRCVTHPMSCFSIH	145					
148	RPRLAGLCLAVLWVAGCLVNPMLFYTTSNKGTTVLCHDITRPEEPDHVPHSSAVMGL	207					
146	KTRCAAWAACWWVITSLVAVIPMTFLITSTNRTNRSAACLDLTSDELNLTICKYNLLTAT	205					
208	LPGVPLCLTVLCYGLMARRYQPLPGSAQSSRRSLRSARTIAVVLTVFAVCVPFHTRTI	267					
206	TFCPLPLVTCYTTIHTLTLGL-QTDSCLKQAKRLLTLLAFYVCFLPFHILRVI	263					
268	YTLRILLEADCRPLNTVNVVYKVTRPLASANSCLDPYLILTGDKYRR	315					
264	RRESLUSISCSLENQIHEAYIVSPLAALNTFGNLILYVVSDNQQ	311					

SULT 6
-11-157-930-4
Sequence 4, Application US/11157930
Publication No. US2005026482A1
GENERAL INFORMATION:
APPLICANT: Xiao, Yonghong
TITLE OF INVENTION: Regulation of Human CysLT2-like GPCR

1 TITLE OF INVENTION: Protein
1 FILE REFERENCE: 04974.00058
1 CURRENT APPLICATION NUMBER: US/11/157,930
1 CURRENT FILING DATE: 2005-06-22
1 PRIOR APPLICATION NUMBER: US/09/828,478
1 PRIOR FILING DATE: 2001-04-09
1 PRIOR APPLICATION NUMBER: 60/195,196
1 PRIOR FILING DATE: 2000-04-07
1 PRIOR APPLICATION NUMBER: 60/254,876
1 PRIOR FILING DATE: 2000-12-13
1 NUMBER OF SEQ ID NOS: 16
1 SOFTWARE: FastSBQ for Windows Version 4.0
1 SEQ ID NO 4
1 LENGTH: 339
1 TYPE: PRT
1 ORGANISM: Homo sapiens
1
1

Query Match	Score	DB	Length	Details
Query Match	26.2*		Score 510; DB 7; Length 339;	
Best Local Similarity	37.1*		Pred. No. 5.3e-38;	
Matches 119; Conservative	52;	Mismatches 136;	Indels 14;	Gaps 7;
Qy	27	CWFDEDKFPIILPVSVAVVFLVGLGINAPTLWIFIRPRPWDATYMPHFLASDTLYVL	86	
Db	23	CQQETPLENMLFASFYFLDFILALVGNTLWIPDRKSGTGPANVFLHFLAVADLSCSV	82	
Qy	87	SLPTLIYXXAAHNHWPGFTEICKFVRFLFVNNLYCSTVFLTCISVHRYLGICHPLRLRW	146	
Db	83	VLPTRLVHFESNHWPGFGEIACRLTGFIFLYMNYASIVFLTCISADRFLAIVHPVKSLLK	142	
Qy	147	GRPLLAGLCLAVWLVYAGCLVPLNLFVFTTTSNKGGTTVICHDTTRPPEFDHYHFESSAVMG	206	
Db	143	RRLPYAHLACAFLWVVAWAVAPLLYSPQTVQTNHTVCLQLXR-EKASHHALVSLAV--	199	
Qy	207	LLFGVPCVLVILVCGIMARRVYQPLPSSAQSSSRLRSRRTIAVLTFAVCYFPFHITRT	266	
Db	200	-AFTPPFITTCTYLILRSRQGL - RVEBKLTKTRVMIAVLAFLVCFVBYHVNRS	256	
Qy	267	IYVL-ARLLEPADCRLVNLNVVYKVTRPLASANSCLDPVLYLTGDKYRQL-RQLCG--	322	
Db	257	VVLYHYRSHRGASCATORILALANRITSCSLTSNLGALDPIMTFVVAEKFPRHALCNLLCGKRR	316	
Qy	323	--GGKP--QPTAAASLLAVS	339	
Db	317	LKGPPPSFECKTNBSSLAKS	337	

SEQ ID NO:145	Length: 397	TYPES: PRT	ORGANISM: Homo sapiens	MS-11-072-175-145
Best Local Similarity	20.7%	Score	403;	DB 7;
	32.1%	Pred.	No.	2-18-28;

Matches 95; **Conservative** 57; **Mismatches** 124; **Indels** 20; **Gaps** 9;

RESULT 9

US-10-330-773-446
; Sequence 446, Application US/10330773
; Publication No. US200604262A1
; GENERAL INFORMATION:
; APPLICANT: David W. Morris B
; INVENTION: Novel Compositions and Methods in Cancer
; TITLE OF INVENTION: Novel Compositions and Methods in Cancer
; FILE REFERENCE: 529452001300
; CURRENT APPLICATION NUMBER: US/10/330,773
; CURRENT FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 981
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 446
; LENGTH: 370
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-330-773-446

Query Match 20.0%; **Score** 388.5; **DB** 6; **Length** 370;
Best Local Similarity 33.7%; **Pred.** No. 3..7e-27;
Matches 95; **Conservative** 45; **Mismatches** 111; **Indels** 31; **Gaps** 9;

Qy . 37 LIPVSYAVFVGLGNAPTLWLFIRLPRNDATYMEHLLSDTLYLSPLTLYYA 96
Db 96 LIPAYILIVFVFGPANAVTLWLFTRTSCTTVFTF-NLIAIDFLFCVTLPEKIAHL 154

Qy . 97 AHNHWPFGTETCKPVRFELFYNNLYCSVLFLTCISVHRYLGICHPLRWRGRPR--LQLG 154
Db 155 NGRNWVSEVLVCRATTIVFGNNYCSILLACISINRYLAIVHPF---YGLPKHTALV 210

Qy . 155 LCLAWLVVAGCLVNPILFFVTSN---KGTTFLCHDTTRPBE---FDHYHFSSEWNG 206
Db 211 TCGHWFATVFLMLP--FFPLIQEYLYQDPTTCHDVNTCESSPFLQYTFSLAFF 268

Qy . 207 LUFGPCLVLTVCXGLMARRLYQPLPSAQSSSRRLSRLTIAVLLTVFAVCVFPFHRT 266
Db 269 FL--IPFLILKCAAIRTL---NAYDHRWLWYKAASLLLIVFTICFAPSNTILLI 320

Qy . 267 IYIARLLEADCRVLNIVVVVKVTRPLASANSCLDPVYL 308
Db 321 IHH-----ANYYNNNTGFIYLALCGSLSNSCLDPFLYFL 356

RESULT 10

US-11-127-877-55
; Sequence 55, Application US/11127877
; Publication No. US20050287565A1
; GENERAL INFORMATION:
; APPLICANT: Merchiers, Pascal G.
; INVENTION: Amyloid-Beta Protein Production
; FILE REFERENCE: P27, 800-B USA
; CURRENT APPLICATION NUMBER: US/11-127,877
; PRIORITY: 2004-05-12
; PRIOR APPLICATION NUMBER: 60/570,352
; PRIORITY FILING DATE: 2004-05-12
; PRIORITY FILING DATE: 2004-08-24
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 55
; LENGTH: 400
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-127-877-55

Query Match 19.5%; **Score** 378.5; **DB** 7; **Length** 400;

Matches 95; **Conservative** 29.9%; **Mismatches** 136; **Indels** 31; **Gaps** 8;

RESULT 8

US-10-821-234-934
; Sequence 934, Application US/10821234
; Publication No. US20050255114A1
; GENERAL INFORMATION:
; APPLICANT: Labat, Ivan
; INVENTION: Striche-Crain, Birgit
; APPLICANT: Andramani, Susan
; APPLICANT: Tang, Y. Tom
; TITLE OF INVENTION: Methods for Diagnosis and Treatment of Preeclampsia
; FILE REFERENCE: 821A
; CURRENT APPLICATION NUMBER: US/10/821,234
; CURRENT FILING DATE: 2004-04-07
; PRIOR APPLICATION NUMBER: US 60/4462,047
; PRIOR FILING DATE: 2003-04-07
; NUMBER OF SEQ ID NOS: 1704
; SOFTWARE: pt_SEQ_Genes Version 1.0
; SEQ ID NO: 934
; LENGTH: 485
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-821-234-934

Query Match 20.4%; **Score** 397.5; **DB** 6; **Length** 485;
Best Local Similarity 29.9%; **Pred.** No. 7.8e-28;
Matches 97; **Conservative** 60; **Mismatches** 136; **Indels** 31; **Gaps** 8;

Qy . 36 ILLPVSYAVVFLVGLGNAPTLWLFIRLPRNDATYMEHLLSDTLYLSPLTLYYA 95
Db 163 LFVPSVYTGVEVSLPNTIMIAVVFILKMKVPPAVVYMLHATDVLVPSVLFKISYY 222

Qy . 96 AHNHWPFGTETCKPVRFELFYNNLYCSVLFLTCISVHRYLGICHPLRWRGRPLGIL 155
Db 223 FSGSDWQGSELCRFTAAFCNMNTASILMTVISDRFLAVVYPMQSLWRTRGASF 282

Qy . 156 CLAVW-LVAGCL-----VPLNFFVTTSNKTFLCHDTTRPPEP-HYVHESSA 203
Db 283 CLAVWLAIAQGVPLVLIKEQTQVGPNNIT-----CHDVNLNETLEGYZAYFSA 333

Qy . 204 VNGLLFVPCLVTCXGLMARRLYQPLPSAQSSRRRLSRLTIAVLLTVFAVCVFPFH 263
Db 334 FSAVFFFPLIISTCVTSIIRCLSS--SAYANRSKSKRSLFLSAAVCFIICGPTNV 391

Qy . 264 TRIIYY-LARLLEADCRVLNIVVVVKVTRPLASANSCLDPVYLTKDXYRROLR-Q-L 320
Db 392 LIAIHSFLSHSTSTEAYF----AYLLCVCVSSISSCIDPLIYASSECQRTVYSIL 446

Qy . 321 CGGGKPORTAAASSLAVSLPDS 344
Db 447 CCKESSDPSSTNSQGMASKNDT 470

Best Local Similarity 32.3%; Pred. No. 3.1e-26;
Matches 95; Conservative 52; Mismatches 128; Indels 19; Gaps 6;

Qy 36 ILLPVSYAVVFGLGNLAPTLWTFIRPDATAFMHIALSDTIVLVLSPITLVY 95
Db 71 ITIMALYSIVCVGFLFGNLFMVMVIVRMTYKMTANIVIFNLALADATSLPFSQTY 130

Qy 96 AAHNEWPFGIECKPFRFLPYWNLYCSVFLTCISVHRVLGICHPRLARWRGRPLAGIL 155
Db 131 LM-GTWPGFTLKVIVSIDYNNMFTSIFLCTMSVDTIAVCPVKALDFPRNAKII 189

Qy 156 CLAWLVLVAGCLVPNLFLFTTSNKGTTWLCHDTRPEEFDHYYHF----SSAVMGLFG 210
Db 190 NVCNWILSSAIGLPMPMATTKRGQSIDLT----FSHPTWYWEILVKICVFIFAFI 244

Qy 211 VPCLVLTVCYGLMARRL--YQPLGSAQSSRSRSL-RTIAVVLTFAVCFVPHITRTI 267
Db 245 MPVLLITVCYGLMILRKLSVRMLSGSKEDRNURMVLVYVVAVEFVCMWTHIYVII 304

Qy 268 YYLARLLEADCRVNIIVVYKVTRPLASANSCLDPVLYLTGDKYRQLRQLC 321
Db 305 KALVTPET----TFQTWSWHFCIALGYTNSCLNPVLYAFLDENFKRCFRFEC 353

RESULT 11
US-11-157-930-2
i Sequence 2, Application US/11157930
i Publication No. US20050266482A1
i APPLICANT: Xiao, Yonghong
i TITLE OF INVENTION: Regulation of Human CysLT2-Like GPCR
i TITLE OF INVENTION: Protein
i FILE REFERENCE: 0474-00458
i CURRENT APPLICATION NUMBER: US/11/157, 930
i CURRENT FILING DATE: 2005-05-22
i PRIOR APPLICATION NUMBER: US/09/828, 478
i PRIOR FILING DATE: 2001-04-09
i PRIOR APPLICATION NUMBER: 60/195, 196
i PRIOR FILING DATE: 2000-04-07
i PRIOR APPLICATION NUMBER: 60/254, 876
i PRIOR FILING DATE: 2000-12-13
i NUMBER OF SEQ ID NOS: 16
i SOFTWARE: FastSEQ for Windows Version 4.0
i SEQ ID NO: 2
i LENGTH: 346
i TYPE: PRT
i ORGANISM: Homo sapiens

Query Match Score 377.5; DB 7; Length 346;
• Best Local Similarity 29.2%; Pred. No. 3.3e-26;
• Matches 99; Conservative 73; Mismatches 126; Indels 41; Gaps 12;

Qy 12 LGLSPGPSSSEVELDCWFD-----EDEKFILLPSYAVF---VIGIGINAPTLWL 59
Db 6 MSLQPSISVSNEPNPGTFSNNNSRNCTENPREFPPIVLLIFEWGVNLGLS----I 60

Qy 60 FIPRLRPWDATA---YMFHIALSDTIVLVLSPITLVYAHNNHWFEGTEICKFVRFIFY 116
Db 61 YVF-LQPYKKSTSIVNFMNLASIDLIFISTLPPRADYIYLRGSNWFGLACRIMSYSL 119

Qy 117 WNLYCSTVFLTCISVHRVLGICHPRLARWRGRPLAGLCLAVWVAGCIVPNLFFVTT 176
Db 120 VNMISSTYFLTLCHDTRPEFDHY----VHSSAVMGLFGVPLCYLVCYGMARRY 179

Qy 177 SNKGTTVFLTCISVHRVLGICHPRLARWRGRPLAGLCLAVWVAGCIVPNLFFVTT 176
Db 180 QN-GSVTSC----LELNYLKQKLTQMYTAIVGCL--LPEFFTSLCYLTLRVLK 230

Qy 230 -PLPSGAQSSSPRLSRSLRTIAVLTFAVCFVPHITRTIYTLLAECDRVNIVVY 288
Db 231 VEVPESEGLRVSHRKALTITLIFFLCPYHTRTV-HLTIVWKVGLCK--DRLHKAL 287

Qy 289 KVTRPLASANSCLDPVLYLTGDKYRQLRQLC 343
Db 288 VITALANACPNPLYYFAGENFKDRLKSALKGHFQ 326

RESULT 12
US-10-930-055-6
i Sequence 6, Application US/10920055
i Publication No. US20060040329A1
i GENERAL INFORMATION:
i APPLICANT: Kelvin, David
i APPLICANT: Persad, David
i APPLICANT: Cameron, Mark J.
i TITLE OF INVENTION: CXCL10 - Based Diagnosis and Treatment of Respiratory Illnesses
i FILE REFERENCE: 85363-9
i CURRENT APPLICATION NUMBER: US/10/920, 055
i CURRENT FILING DATE: 2004-08-17
i NUMBER OF SEQ ID NOS: 8
i SOFTWARE: Patentin version 3.3
i SEQ ID NO: 6
i LENGTH: 368
i TYPE: PRT
i ORGANISM: Homo sapiens

Query Match Score 375; DB 6; Length 368;
• Best Local Similarity 30.6%; Pred. No. 5.9e-26;
• Matches 114; Conservative 57; Mismatches 155; Indels 46; Gaps 11;

Qy 6 SSSLRSLGLSPOPSSSEVELDCW----EDEDFPILLPSYAVFVPLGIGLNAPTLW 58
Db 17 AALLENFSSSYDGENESDSCTCTSPCPQDFSLNTRAFPLAISLLPLUGLNGAAVA 76

Qy 59 LFIFRFLRPWDATATMFHIALSDTIVLVLSPITLVYAHNNHWFGETEICKFVRFIFY 118
Db 77 VLLSRRTALSSSTDFLHLAVDTLNLTD--LWAVDAAVQWVFGSLCKVAGALENIN 134

Qy 119 LYCSVLFCLTCSVHRVLGICHPRLARWRGRPLAGLCLAVWVAGCIVPNLFFVTT 178
Db 135 FYAGALLACISFDRLNIVHTAQYRGRGPARYVTLCLAVWGCLFLFDFIFLSAH- 193

Qy 179 KGTTVLCHD----TTRPEEPDHTVHFSSAVMGLFG--VPCLVLTVCYCG-LMARBLRQ 230
Db 194 -----HDERLNATHCQYNEPQVGRALTVLQLVAGELPLLVMAYCYAHLLAVLV- 244

Qy 231 LPGSAGSSRLSLLTIAVLTVEFACFVYPFHITIYTLL-LEADCRLVNTVVVY 288
Db 245 ---SGQRQRRLRAMELUVVVVVVAPLICWTPXHLVVLDIMLGALARNGCRESDVAK 300

Qy 289 KVTRPLASANSCLDPVLYLTGDKYRQLRQLC 343
Db 301 SVTSGIGYMECILNLLYAEVGVKEFRERUMMLLRIGCPNQRGHQRPSSS----RRD 354

RESULT 13
US-11-017-058-2
i Sequence 2, Application US/11017058
i Publication No. US20060014243A1
i GENERAL INFORMATION:
i APPLICANT: Li, Yi
i TITLE OF INVENTION: Human G-Protein Chemokine Receptor HSATU68
i FILE REFERENCE: FP2-18C1
i CURRENT APPLICATION NUMBER: US/11/017, 058
i CURRENT FILING DATE: 2004-12-21
i PRIOR APPLICATION NUMBER: US 09/105, 518
i PRIOR FILING DATE: 1998-12-21
i PRIOR APPLICATION NUMBER: PCT/US96/00499
i PRIOR FILING DATE: 1996-01-11
i NUMBER OF SEQ ID NOS: 9

SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 415
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-017-058-2

Query Match Score 19.3%; Pred. No. 6 7e-26; Length 415;
Best Local Similarity 30.6%; Matches 114; Conservative 57; Mismatches 155; Indels 46; Gaps 11;

Qy 6 SSIURSLGSLSPGGSSEYELDCW-----FDEDFKEFLLPVSYAVVFGLNAPTLW 58
Db 64 AALENPSYSDYGENEDSCTTSPPCPQDFSLNSDFRFLPAVSLLLGJGUJNGAAVA 123
Qy 59 LTFRLRMPDATATYMFHIALSDTLYTSLPLTIYYAHNNWPFGTEICKEVRFLYW 118
Db 124 VLLSRRTALSSTDFFLILAVADTLLVLTLP-LWAVDAVONVFGSCLCKYAGALFN 181
Qy 119 LYCSVLFETCISYRYLGCIPHLRGRPLLAGLICLAWLIVAGGLVPNLFFTTSN 178
Db 182 FYAGALLACISFDRLINVTHATOLYRROPPARTVLTICLAWGLCLLEALPDEIFSAH- 240
Qy 179 KGTIVLCHD----TTRPEEFDHYVHESAVMGHLFG--VPCLUVYCG-LMARRIYQP 230
Db 241 -----DIERLNATHCQYNFPQGVRTAIVRLQVAGFLPLVMAYAHILLVY-- 291
Qy 231 LPGSAQSSPLRSLSRTIAVLTIVPAVCYFPFHITRITYYLARL-LEADCVRVINVVY 288
Db 292 ---SRGGQRLLRANBLVVVVVVAFAFCPTPYHLVVLVTDLMDGALANGRESRVDAK 347
Qy 289 KVTRPLASANSCDPVLVLTGDKYRQQ---LRQLCGGKPOPRTAASSLAALSLED 343
Db 348 SVTSGLGYRHCCUNPLLYAFVGKFRERMWMLLRLGCPNQRGLQRQSSS-----RFD 401
Qy 344 SSCRWAATPQDS 355
Db 402 SS--WSETSEAS 411

RESULT 14
US-11-261-135-2
; Sequence 2, Application US/11/261135
; Publication No. US2006004148A1
; GENERAL INFORMATION:
; APPLICANT: Allen, Keith D.
; TITLE OF INVENTION: TRANSGENIC MICE CONTAINING CHEMOKINE
; TITLE OF INVENTION: RECEPTOR 9A GENE DISRUPTIONS
; FILE REFERENCE: R-365
; CURRENT FILING DATE: 2005-10-27
; PRIOR FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: US 60/217,255
; PRIOR FILING DATE: 2000-07-10
; PRIOR FILING DATE: 2000-07-27
; PRIOR APPLICATION NUMBER: US 60/221,183
; NUMBER OF SEQ ID NOS: 4
; SEQ ID NO: 2
; LENGTH: 357
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Targeting vector

Qy 38 LPVSYAVVFVUIGLNAAPTILWFLIRPLRPDATAATYMFHIALSDTLYVLSLPTLYYYYAA 97
Db 39 LPPLTVLFLVGALESLVLVIVTCRVKMTDPLFLNIAIDLFLEVLP-TRVAILDA 96
Qy 98 HNHMPFGTEICKEVRFLYYNNLYCSVFLPLTICISYRYLGCIPHLRGRPL--AGLL 155
Db 97 ADQWKEQTFRMCKVNVNSMVKQNFYSCVTLIMCISVDRXIAAQAMRAHTWRKRLYSKMW 156

Qy 156 CLAVILVAGLIVPLNPFVFTSNKGTTVLCDHTTREBEEHYHFSAAVMGUL---FGV 211
Db 157 CFTIWVLAACIPELISQIKEESGIAIC---TMVTPSDESTKRSAVLTUFLKVIGFFL 213
Qy 212 PCLVLTVCYGLMARLQYQPLPGSAQSSRSRLSLTAVLTIVFAVCVVPFH---ITRTIY 268
Db 214 PFVVMACCYTIIHIIHQ---AKESSKXHAKLKTTVLTIVFVSOPPYNCILVQRTD 268
Qy 269 YLARLLEADCRVINVNTYNNVYKVTRPLASANSCDPVLVYLTGDKYRQL 317
Db 269 AYAMFI-SNCAVSTNIDICFOVQTIAFFHSCLNPVLYVFGVBRFRDL 316

RESULT 15
US-10-330-773-443
; Sequence 443, Application US/10330773
; Publication No. US/0060040262A1
; GENERAL INFORMATION:
; APPLICANT: David W. Morris B
; APPLICANT: Marc Malandro
; APPLICANT: David W. Morris B
; TITLE OF INVENTION: Novel Compositions and Methods in Cancer
; FILE REFERENCE: 52945200300
; CURRENT APPLICATION NUMBER: US/10/330,773
; CURRENT FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 981
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 443
; LENGTH: 380
; TYPE: PRT
; ORGANISM: Mus musculus
; US-10-330-773-443

Query Match Score 18.6%; Pred. No. 7.9e-25; DB 6; Length 380;
Best Local Similarity 27.9%; Mismatches 56;保守性 83; Indels 59; Gaps 10;
Matches 83; Conservative 56; Mismatches 100;

Qy 37 LLPSYAVVFVUIGLNAAPTILWFLIRPLRPDATAATYMFH-LALSDTLYVLSIPTLYYYY 94
Db 106 VTPBIYVLLFVVGPNVTVLKLSLRTP---SISLVFHTNLAIDLJFCVTLPKIAY 162
Qy 95 YAHHNHWPFGTECKFVRFPLFTNLYCSVFLTCISYRYLGCIPHLRGRPLLAGL 154
Db 163 HLNQMVWVEGEVNRVYVFKMYCAUILLCQMGINRYLAPHPFTYQKLPRSFSML 222
Qy 155 LCLAWWLVAGLIVPNLFFFVTTSNK---GTVLCHDFT---RPEEPDHVYFVSSAM 205
Db 223 MGRVWWVWFLYMP---FVILKCEYHLVSEITCVDVDAESPSSFRYYVSLAFF 279
Qy 206 GLISQVPLCLTYCGLMARRIGQPLPGSAQSSR-LRSLRTIAVLTIVFAVCVFPV-- 260
Db 280 GFL--IPFVLIIFCYTTLHKL---KSKRIVLGYIKAVLILVIFTICAPTN 329
Qy 261 -----FHRTIYIYLARLLEADCRVINVNTVYKVTRPLASANSCLDPVLYLL 308
Db 330 ILVIFHANYYENTDSLYM-----YUIALCGSLSNCLDPFXFV 370

Search completed: April 4, 2006, 20:29:49
Job time : 26 sec

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: April 4, 2006, 20:25:38 ; Search time 167 Seconds
(without alignments)
913,220 Million cell updates/sec

Title: US-10-811-198-2
Perfect score: 1944
Sequence: 1 MASTESSLRLSIGLSPGPGS.....CRVATPODSCSTPRADRL 365

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing First 45 summaries

Database : Published Applications AA_Main:
 1: /cgn2_5/_pcodata/1/_pubpaas/JS07_PUBCOMB.pep:
 2: /cgn2_6/_pcodata/1/_pubpaas/JS08_PUBCOMB.pep:
 3: /cgn2_6/_pcodata/1/_pubpaas/JS09_PUBCOMB.pep:
 4: /cgn2_6/_pcodata/1/_pubpaas/JS10_PUBCOMB.pep:
 5: /cgn2_6/_pcodata/1/_pubpaas/JS10B_PUBCOMB.pep:
 6: /cgn2_6/_pcodata/1/_pubpaas/JS11_PUBCOMB.pep:
 Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB ID	Description
1	1944	100.0	365	3	US-09-742-16	Sequence 16, Appl
2	1944	100.0	365	4	US-10-725-567A-332	Sequence 332, Appl
3	1944	100.0	365	4	US-10-753-685-2	Sequence 2, Appl
4	1944	100.0	365	5	US-10-811-198-2	Sequence 2, Appl
5	1944	100.0	365	5	US-10-811-192-2	Sequence 2, Appl
6	1940	99.8	365	3	US-09-077-113A-2	Sequence 2, Appl
7	1932	99.4	365	4	US-10-366-988-42	Sequence 42, Appl
8	1597	82.2	361	3	US-09-964-021B-15	Sequence 15, Appl
9	1597	82.2	361	4	US-10-010-568-9	Sequence 9, Appl
10	1597	82.2	361	4	US-10-268-332-15	Sequence 15, Appl
11	1597	82.2	361	4	US-10-375-157-9	Sequence 9, Appl
12	1597	82.2	361	4	US-10-072-012-521	Sequence 521, Appl
13	1597	82.2	361	4	US-10-775-665-15	Sequence 15, Appl
14	1127	58.0	374	3	US-09-745-842-15	Sequence 15, Appl
15	1127	58.0	374	4	US-10-010-568-11	Sequence 11, Appl
16	1127	58.0	374	4	US-10-375-157-11	Sequence 11, Appl
17	1127	58.0	374	4	US-10-072-012-518	Sequence 518, Appl
18	1007	51.8	537	4	US-10-311-956-4	Sequence 4, Appl
19	1007	51.8	537	4	US-10-010-568-12	Sequence 12, Appl
20	1007	51.8	537	4	US-10-375-157-12	Sequence 12, Appl
21	1007	51.8	537	4	US-10-055-569A-52	Sequence 52, Appl
22	1007	51.8	537	4	US-10-072-012-517	Sequence 517, Appl
23	965	49.6	377	3	US-09-745-842-17	Sequence 17, Appl
24	965	49.6	377	4	US-10-225-567A-217	Sequence 217, Appl
25	965	49.6	377	5	US-10-756-149-5688	Sequence 5688, Appl
26	955	49.1	374	4	US-10-242-499-3	Sequence 3, Appl
27	951	48.9	341	4	US-10-270-587-3	Sequence 3, Appl

ALIGNMENTS

RESULT 1
US-09-745-842-16
Sequence 16, Application US/09745842
Publication No. US2003017077A1
GENERAL INFORMATION:
 APPLICANT: Conley, Pamela B.
 APPLICANT: Jantzen, Hans-Michael
 APPLICANT: Ramakrishnan-DubBridge, Vanitha
 APPLICANT: Julius, David
 APPLICANT: Holopeter, Gunter
 APPLICANT: COR Therapeutics, Inc.
 TITLE OF INVENTION: P2Y2 Receptor
 CURRENT APPLICATION NUMBER: US/09/745,842
 CURRENT FILING DATE: 2000-12-26
 PRIOR APPLICATION NUMBER: US 60/171,622
 PRIOR FILING DATE: 1999-12-23
 NUMBER OF SEQ ID NOS: 21
 SOFTWARE: PatentIn Ver: 2.1
 SEQ ID NO 16
 LENGTH: 365
 TYPE: PPT
 ORGANISM: Homo sapiens
 FEATURE: OTHER INFORMATION: P2Y4 pyrimidinergic receptor
 US-09-745-842-16
 Query Match 100.0%; Score 1944; DB 3; Length 365;
 Best Local Similarity 100.0%; Prod. No. 1..3e-158;
 Matches 365; Conservative 0; Missmatches 0; Indels 0; Gaps 0;
 Qy 1 MASTESSLRLSIGLSPGGSSEVLDCWFDDEDPKILLPVSYAVFVGLGNAFTLWLF 60
 Db 1 MASTESSLRLSIGLSPGGSSEVLDCWFDDEDPKILLPVSYAVFVGLGNAFTLWLF 60
 Qy 61 IFRURPDATAATMFLHSLDTLYVSLPLTLIYYAHHWPFGTEICKFVRFLFYNNLY 120
 Db 61 IFRURPDATAATMFLHSLDTLYVSLPLTLIYYAHHWPFGTEICKFVRFLFYNNLY 120
 Qy 121 CSVFLFCISVARYLGICPLRLRGRPLLAGLCLAWLIVAGCLWPNLFFTTSNGK 180
 Db 121 CSVFLFCISVARYLGICPLRLRGRPLLAGLCLAWLIVAGCLWPNLFFTTSNGK 180
 Qy 181 TTVLCHDTRPPEEDHYFHPSAAMVGLFGVPCLVLTVCYGLMARRLYQPLPGSAQSSR 240
 Db 181 TTVLCHDTRPPEEDHYFHPSAAMVGLFGVPCLVLTVCYGLMARRLYQPLPGSAQSSR 240
 Qy 241 LRSPTIAVLTIVFAVCFVPPFHITRITXYLARLIEADCRVLNTVNYYKVTRPLASANSC 300
 Db 241 LRSPTIAVLTIVFAVCFVPPFHITRITXYLARLIEADCRVLNTVNYYKVTRPLASANSC 300

Qy 301 LDPVLYLTGDKYRQLRQLGGKEQPTTAASSLALVLSPEDSSCRWAATPQDSSCSTP 360
Db . 301 LDPVLYLTGDKYRQLRQLGGKEQPTTAASSLALVLSPEDSSCRWAATPQDSSCSTP 360
Qy 361 RADRL 365
Db 361 RADRL 365

RESULT 2
US-10-225-567A-332, Application US/10225567A
Sequence 332, Application US/10225567A
Publication No. US20030113798A1
GENERAL INFORMATION:
APPLICANT: Lifespan Biosciences
PRIORITY FILING DATE: 2001-12-19
NUMBER OF SEQ ID NOS: 2292
SOFTWARE: PatentIn version 3.1
SEQ ID NO 332
LENGTH: 365
TYPE: PRT
ORGANISM: Homo sapiens
TITLE OF INVENTION: ANTIgenic PEPTIDES AND ANTIBODIES FOR G PROTEIN-COUPLED RECEPTORS
FILE REFERENCE: 1520-4-4
CURRENT APPLICATION NUMBER: US/10/225,567A
CURRENT FILING DATE: 2001-12-19
PRIORITY FILING DATE: 2000-12-19
NUMBER OF SEQ ID NOS: 2292
SOFTWARE: PatentIn version 3.1
SEQ ID NO 332
LENGTH: 365
TYPE: PRT
ORGANISM: Homo sapiens
US-10-225-567A-332

Query Match 100.0%; Score 1944; DB 4; Length 365;
Best Local Similarity 100.0%; Pred. No. 1..3e-158;
Matches 365; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MASTESSLLRSLGSPGGSSEVLDCKFILLPVSYAVVFLVGLGNAPTLWLF 60
Db 1 MASTESSLLRSLGSPGGSSEVLDCKFILLPVSYAVVFLVGLGNAPTLWLF 60
Qy 61 IFLRLRPMDATYMFHIALSSTDLYTSLPLTLIYYAAHNHWPGTICKYVRFLYWNLY 120
Db 61 IFLRLRPMDATYMFHIALSSTDLYTSLPLTLIYYAAHNHWPGTICKYVRFLYWNLY 120
Qy 121 CSVLFITCISVRYLGICHLPLRLGRPRLAGLCLAVLVAGCLVLPNLFVFTSNKG 180
Db 121 CSVLFITCISVRYLGICHLPLRLGRPRLAGLCLAVLVAGCLVPNLFVFTSNKG 180
Qy 181 TTVLCHDTTRPREFDHYFHSSAVMGFLFGVBCLYLTCYGLMARRLYQPLPGSAQSSR 240
Db 181 TTVLCHDTTRPREFDHYFHSSAVMGFLFGVCLVLYCGLVPLAGLCLAVLVAGCLVPNLFVFTSNKG 240
Qy 241 LRSLRTAIVLVTLYFACVFPFHITRTYIYLARLLEADCRVNIIVVVYKTRPLASANS 300
Db 241 LRSLRTAIVLVTLYFACVFPFHITRTYIYLARLLEADCRVNIIVVVYKTRPLASANS 300
Qy 301 LDPLVLYLTGDKYRQLRQLCGGGKQPTTAASSLALVLSPEDSSCRWAATPQDSSCSTP 360
Db 301 LDPLVLYLTGDKYRQLRQLCGGGKQPTTAASSLALVLSPEDSSCRWAATPQDSSCSTP 360
Qy 361 RADRL 365
Db 361 RADRL 365

RESULT 3
US-10-753-695-2, Application US/10753695
Sequence 2, Application US/10753695
Publication No. US20040117566A1
GENERAL INFORMATION:
APPLICANT: Communi, Didier
APPLICANT: Boeynaems, Jean-Marie
APPLICANT: Pirotton, Sabine
APPLICANT: Parentier, Marc
TITLE OF INVENTION: P2Y4 Antibody and Methods of Use
FILE REFERENCE: 9409/2113B
CURRENT APPLICATION NUMBER: US/10/811,198
CURRENT FILING DATE: 2004-03-26
PRIOR APPLICATION NUMBER: 10/753,695
PRIOR FILING DATE: 2004-01-08
PRIOR APPLICATION NUMBER: 09/077,173
PRIOR FILING DATE: 1998-11-12
PRIOR APPLICATION NUMBER: PCT/BE96/00123
PRIOR FILING DATE: 1996-11-21
PRIOR APPLICATION NUMBER: EP 95870124.5

Qy 301 LDPVLYLITGDKYRQLRQLPQCGGKPKPRTAASSLALVSLPEDSSCRWAATPQDSSCSTP 360
 Db 297 LDPVLYLITGDKYRNQQLCROSSKPKRRTAASSLALVTLHEESISRWADTHQDSTSAY 356

Qy 361 RADRL 365
 Db 357 EGDRL 361

RESULT 9
 / Sequence 9, Application US/10010568
 / Publication No. US2003015759841
 / GENERAL INFORMATION:
 / APPLICANT: Bristol-Myers Squibb Company
 / TITLE OF INVENTION: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR, HGPRBMY23, EXPRESSED HI
 / FILE REFERENCE: D0042A CIP
 / CURRENT APPLICATION NUMBER: US/10/268,332
 / CURRENT FILING DATE: 2002-10-10
 / PRIORITY APPLICATION NUMBER: U.S. 60/235,713
 / PRIORITY FILING DATE: 2000-09-27
 / PRIORITY APPLICATION NUMBER: U.S. 60/261,783
 / PRIORITY FILING DATE: 2001-01-16
 / PRIORITY APPLICATION NUMBER: U.S. 60/305,085
 / PRIORITY FILING DATE: 2001-07-13
 / PRIORITY APPLICATION NUMBER: U.S. 60/313,171
 / PRIORITY FILING DATE: 2001-08-17
 / PRIORITY APPLICATION NUMBER: U.S. 09/964,821
 / PRIORITY FILING DATE: 2001-09-26
 / NUMBER OF SEQ ID NOS: 66
 / SOFTWARE: PatentIn version 3.1
 / SEQ ID NO 15

Query Match 82.2%; Score 1597; DB 4; Length 361;
 Best Local Similarity 82.7%; Pred. No. 8.1e-129;
 Matches 302; Conservative 20; Mismatches 39; Indels 4; Gaps 1;

Qy 1 MASTESSLRLSGLSPGPSSSEVELDCWFDEDFKEPLPVSYAVVFLGIGLNAPTLWLF 60
 Db 1 MTSABELLFTSLGPSPSGDG--DCRNEBEFKILLPNSYAVVFLGILNAPTLWLF 56

Qy 61 IFRLRPDATATMFMHIALSDTLYVSLPLIYYTAAHHNPFGTBICKFVRFLFYWNLY 120
 Db 57 LFRLRPDATATMFMHIALSDTLYVSLPLIYYTAAHNWPFGTBICKFVRFLFYWNLY 120

Qy 181 TTVLCDTTRPEEFDHYVFHSSAYMGLLPGVPCLVTLVCYGLMARRYQPLPGSAOSSR 240
 Db 177 TILCHDTTPEEFHYVFHSSAVNLFLGPFLLTVCYGLMARRYRPQGACOSSR 236

Qy 1 MASTESSLRLSGLSPGPSSSEVELDCWFDEDFKEPLPVSYAVVFLGIGLNAPTLWLF 60
 .Db 1 MTSAESELFTSLGPSPSGDG--DCRNEBEFKILLPNSYAVVFLGILNAPTLWLF 56

Qy 61 IFRLRPDATATMFMHIALSDTLYVSLPLIYYTAAHHNPFGTBICKFVRFLFYWNLY 120
 Db 57 LFRLRPDATATMFMHIALSDTLYVSLPLIYYTAAHNWPFGTBICKFVRFLFYWNLY 116

Qy 121 CSVLFITCISVRYLGICHPRLALWGRPLAGLCLAWLVAGLVLVPLNPFVTTSNKG 180
 Db 117 CSVLFITCISVRYLGICHPRLALWGRPLAGLCLAWLVAGLVLVPLNPFVTTNANG 176

Qy 181 TTVLCDTTRPEEFDHYVFHSSAVMGLLPGVPCLVTLVCYGLMARRYQPLPGSAOSSR 240
 Db 177 TILCHDTTPEEFHYVFHSSAVNLFLGPFLLTVCYGLMARRYRPQGACOSSR 236

Qy 241 LRSLSLTIAVVLTVFACVCPFHITTTIYARLLEADCRVNLNVVYKVTRPLASANSC 300
 Db 237 LRSLSLTIAVVLTVFACVCPFHITTTIYARLLEADCRVNLNVVYKVTRPLASANSC 300

Qy 121 CSVLFITCISVRYLGICHPRLALWGRPLAGLCLAWLVAGLVLVPLNPFVTTSNKG 180
 Db 117 CSVLFITCISVRYLGICHPRLALWGRPLAGLCLAWLVAGLVLVPLNPFVTTNANG 176

Qy 181 TTVLCDTTRPEEFDHYVFHSSAVMGLLPGVPCLVTLVCYGLMARRYQPLPGSAOSSR 240
 Db 177 TILCHDTTPEEFHYVFHSSAVNLFLGPFLLTVCYGLMARRYRPQGACOSSR 236

Qy 241 LRSLSLTIAVVLTVFACVCPFHITTTIYARLLEADCRVNLNVVYKVTRPLASANSC 300
 Db 237 LRSLSLTIAVVLTVFACVCPFHITTTIYARLLEADCRVNLNVVYKVTRPLASANSC 296

RESULT 11
 / Sequence 9, Application US/10375157
 / Publication No. US2003022458A1
 / GENERAL INFORMATION:
 / APPLICANT: Bristol-Myers Squibb Company
 / TITLE OF INVENTION: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR, HGPRBMY23, EXPRESSED HI
 / FILE REFERENCE: D0077A CIP
 / CURRENT APPLICATION NUMBER: US/10/375,157
 / CURRENT FILING DATE: 2003-02-26
 / PRIORITY APPLICATION NUMBER: US 60/251,926
 / PRIORITY FILING DATE: 2000-12-07
 / PRIORITY APPLICATION NUMBER: US 10/010,568
 / PRIORITY FILING DATE: 2001-12-07
 / PRIORITY APPLICATION NUMBER: US 60/269,795
 / PRIORITY FILING DATE: 2001-02-14
 / NUMBER OF SEQ ID NOS: 65
 / SOFTWARE: PatentIn version 3.2

RESULT 10
 US-10-268 332-15
 / Sequence 15, Application US/10268332
 / Publication No. US2003017578A1
 / GENERAL INFORMATION:
 / APPLICANT: Bristol-Myers Squibb Company
 / TITLE OF INVENTION: NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR, HGPRBMY3, EXPRESSED HIGH
 / TITLE OF INVENTION: IMMUNE- AND COLON- RELATED TISSUES

SEQ ID NO 9
; LENGTH: 361.
; TYPE: PRN
; ORGANISM: RATTUS NORVEGICUS
US-10-375-157-9

Query Match 82.2%; Score 1597; DB 49; Length 361;
Best Local Similarity 82.7%; Pred. No. 8.1e-129; Gaps 1;
Matches 302; Conservative 20; Mismatches 39; Indels 4;

Qy 1 MASTESSLRLSGLSPGPSSSEVLDCCNDFDEDPKFILLPVSTAVVFVGLGINAPTLWF 60
Db 1 MTSAESLILPTSLGPSPSSDG---DCRNEEFKILLMSAYVVFVGLALNAPTLWF 56

Qy 61 IFRLRPWDATATMFHLALSDTLVLSIPLTITYAAARNHWPPCTEICKFVRLFYNNLY 120
Db 57 LFRLRPWDATATMFHLALSDTLVLSIPLTLYAAARNHWPPCTGCKFVRLFYNNLY 116

Qy 121 CSVLFLLTCISVHRYLGICPBLRALKWGRPLAGLCLAWLWVAGLCLVPLNLFVTTSAKG 180
Db 117 CSVFLTCISVHRLGICPBLRALKWGRPLAGLCLAWLWVAGLCLVPLNLFVTTSAKG 176

Qy 181 TTVLCHDTTRPEEDHYYHVFSSAYVGLLFCYCPCLTYCYGMARRLYOPLPGSAQSSR 240
Qy 177 TTVLCHDTTRPEEDHYYHVFSSAYVNLFLGPFLTLYCYGMARRLYOPLPGAGQSSR 236

Qy 241 LRSERTIAVLTIVAVCFPFHITRTIYIYLARLLEADCRVNTINVVVYKVTRPLASANSC 300
Db 237 LRSERTIAVLTIVAVCFPFHITRTIYIYLARLLEADCRVNTINVVVYKVTRPLASANSC 296

Qy 301 LDPIVLYLRLGDKYRQLRDLGGKRPQPTAASSLALVSLPEDSSCRWATPDQSSCSTP 360
Db 297 LDPIVLYLRLGDKYRQLRDLGGKRPQPTAASSLALVSLPEDSSCRWATPDQSSCSTP 356

Qy 361 RADRL 365
Db 357 EGDRL 361

RESULT 12
US-10-072-012-521
Sequence 521, Application US/10072012
Publication No. US20040033493A1
GENERAL INFORMATION:
APPLICANT: Tchernev, Velizar
APPLICANT: Spytek, Kimberly
APPLICANT: Zerhusen, Bryan
APPLICANT: Paturajan, Meera
APPLICANT: Shmikte, Richard
APPLICANT: Li, Li
APPLICANT: Gangoli, Esha
APPLICANT: Padigaru, Muralidhara
APPLICANT: Anderson, David W.
APPLICANT: Rastelli, Luca
APPLICANT: Miller, Charles E.
APPLICANT: Gerlach, Valerie
APPLICANT: Taupier Jr, Raymond J.
APPLICANT: Gusev, Vladimir Y.
APPLICANT: Colman, Steven D.
APPLICANT: Wolenc, Adam R.
APPLICANT: Furrak, Katarzyna
APPLICANT: Gross, William M.
APPLICANT: Alsobrook II, John P.
APPLICANT: Lepley, Denise M.
APPLICANT: Rieger, Daniel K.
APPLICANT: Burgess, Catherine E.
TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same

FILE REFERENCE: 21402-258
CURRENT APPLICATION NUMBER: US/10/072,012
CURRENT FILING DATE: 2002-01-31
PRIOR APPLICATION NUMBER: 60/265,102
PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: 60/265,514
PRIOR FILING DATE: 2001-01-31
PRIOR APPLICATION NUMBER: 60/265,517
PRIOR FILING DATE: 2001-01-31
PRIOR APPLICATION NUMBER: 60/265,412
PRIOR FILING DATE: 2001-01-31
PRIOR APPLICATION NUMBER: 60/265,395
PRIOR FILING DATE: 2001-01-31
PRIOR APPLICATION NUMBER: 60/266,406
PRIOR FILING DATE: 2001-02-02
PRIOR APPLICATION NUMBER: 60/266,767
PRIOR FILING DATE: 2001-02-05
PRIOR APPLICATION NUMBER: 60/267,057
PRIOR FILING DATE: 2001-02-07
PRIOR APPLICATION NUMBER: 60/266,975
PRIOR FILING DATE: 2001-02-07
PRIOR APPLICATION NUMBER: 60/267,459
PRIOR FILING DATE: 2001-02-08
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 1391
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 521
LENGTH: 361
TYPE: PRN
ORGANISM: Rattus norvegicus
US-10-072-012-521

Query Match 82.2%; Score 1597; DB 49; Length 361;
Best Local Similarity 82.7%; Pred. No. 8.1e-129; Gaps 1;
Matches 302; Conservative 20; Mismatches 39; Indels 4;

Qy 1 MASTESSLRLSGLSPGPSSSEVLDCCNDFDEDPKFILLPVSTAVVFVGLGINAPTLWF 60
Db 1 MTSAESLILPTSLGPSPSSDG---DCRNEEFKILLMSAYVVFVGLALNAPTLWF 56

Qy 61 IFRLRPWDATATMFHLALSDTLVLSIPLTITYAAARNHWPPCTEICKFVRLFYNNLY 120
Db 117 CSVFLTCISVHRLGICPBLRALKWGRPLAGLCLAWLWVAGLCLVPLNLFVTTSAKG 176

Qy 121 CSVFLTCISVHRYLGICPBLRALKWGRPLAGLCLAWLWVAGLCLVPLNLFVTTSAKG 180
Db 1 MTSAESLILPTSLGPSPSSDG---DCRNEEFKILLMSAYVVFVGLALNAPTLWF 56

Qy 1 MASTESSLRLSGLSPGPSSSEVLDCCNDFDEDPKFILLPVSTAVVFVGLGINAPTLWF 60
Db 1 MTSAESLILPTSLGPSPSSDG---DCRNEEFKILLMSAYVVFVGLALNAPTLWF 56

Qy 61 IFRLRPWDATATMFHLALSDTLVLSIPLTITYAAARNHWPPCTEICKFVRLFYNNLY 120
Db 57 LFRLRPWDATATMFHLALSDTLVLSIPLTLYAAARNHWPPCTGCKFVRLFYNNLY 116

Qy 121 CSVFLTCISVHRYLGICPBLRALKWGRPLAGLCLAWLWVAGLCLVPLNLFVTTSAKG 180
Db 117 CSVFLTCISVHRLGICPBLRALKWGRPLAGLCLAWLWVAGLCLVPLNLFVTTSAKG 176

Qy 181 TTVLCHDTTRPEEDHYYHVFSSAYVGLLFCYCPCLTYCYGMARRLYOPLPGSAQSSR 240
Db 177 TTVLCHDTTRPEEDHYYHVFSSAYVNLFLGPFLTLYCYGMARRLYOPLPGAGQSSR 236

Qy 241 LRSERTIAVLTIVAVCFPFHITRTIYIYLARLLEADCRVNTINVVVYKVTRPLASANSC 300
Db 237 LRSERTIAVLTIVAVCFPFHITRTIYIYLARLLEADCRVNTINVVVYKVTRPLASANSC 296

Qy 301 LDPIVLYLRLGDKYRQLRDLGGKRPQPTAASSLALVSLPEDSSCRWATPDQSSCSTP 360
Db 301 LDPIVLYLRLGDKYRQLRDLGGKRPQPTAASSLALVSLPEDSSCRWATPDQSSCSTP 360

Qy 361 RADRL 365
Db 357 EGDRL 361

RESULT 13
US-10-775-965-15
Sequence 15, Application US/10775965
Publication No. US2004020908A1
GENERAL INFORMATION:
APPLICANT: Bristol-Myers Squibb Company
APPLICANT: Kornacker, Michael
TITLE OF INVENTION: MODULATORS OF HUMAN G-PROTEIN COUPLED RECEPTORS
FILE REFERENCE: D0286 NP
CURRENT APPLICATION NUMBER: US/10/775,965
CURRENT FILING DATE: 2004-02-10
PRIOR APPLICATION NUMBER: U.S. 60/446,655
PRIOR FILING DATE: 2003-02-11

NUMBER OF SEQ_ID NOS: 112
; SOFTWARE: PatentIn version 3.2
; SEQ_ID NO 15
; LENGTH: 361
; TYPE: PRT
; ORGANISM: rat
US-10-775-965-15

Query Match 82.2%; Score 1597; DB 4; Length 361;
Best Local Similarity 82.7%; Pred. No. 8.1e-129;
Matches 302; Conservative 20; Mismatches 39; Indels 4; Gaps 1;

Qy 1 MASTESSLLRSGLSGPSSBEVLDLWFDFDFKFLLP/SYAVVFVLGIGLNAPTLWIF 60
Db 1 MTSAAELLPLTSLGPSSGDG---DCRFNEEKFILLPSVAVVFVLGALNAPTLWIF 56

Qy 61 IFRFLRWDATATMFHIALSDPTLYLSPYLIIYYAHHNWPFGTEICKTYRELFYWWYI 120
Db 57 LFLRLRWDATATMFHIALSDPTLYLSPYLIIYYAHHNWPFGTGLCKEVRELFYWWYI 116

Qy 121 CSVLFITCISYTHRYLGICPIRALWKGRPLAGLCLAWLVAGCLVPNLFFTTSNKG 180
Db 117 CSVLFITCISYTHRYLGICPIRALWKGRPLAGLCLAWLVAGCLVPNLFFTTTNANG 176

Qy 181 TTVLCHDTTRPEEFDHYVHFSSAVMCLLFGVPCLYTLCVYGLMARRYQPLGSAQSSR 240
Db 177 TTILCHDTTRPEEFDHYVHFSSAVMCLLFGVPCLYTLCVYGLMARRYQPLGAGQSSR 236

Qy 241 LRSRRTIAVVLTVFAVCFVDPFHITRITYLARLLADCRUNIVVVYKTRPLASANC 300
Db 237 LRSRRTIAVVLTVFAVCFVDPFHITRITYLARLLQADCHYUNIVVVYKTRPLASANC 296

Qy 301 LDPVLYLTTGDKYRQLRQCGGKRPQTAASSLVSIDEFSSCRWATPQDSSCSCP 360
Db 297 LDPVLYLFTGDKYRNQQLQCRGSKPKPMASSALVTHEESTSRWADTHQDSTFSAY 356

Qy 361 RADRL 365
Db 357 EGDRL 361

RESULT 14
US-09-745-842-15
; Sequence 15. Application US/09745842
; PUBLICATION NO. US200301017077A1
; GENERAL INFORMATION:
; APPLICANT: Conley, Pamela B.
; APPLICANT: Jantzen, Hans-Michael
; APPLICANT: Ramakrishnan-DuBridge, Vanitha
; APPLICANT: Julius, David
; APPLICANT: Holloteter, Gunter
; APPLICANT: COR Therapeutics, Inc.
; TITLE OF INVENTION: PY12 Receptor
; FILE REFERENCE: 44415-5053-US
; CURRENT APPLICATION NUMBER: US/09/745,842
; CURRENT FILING DATE: 2000-12-26
; PRIOR APPLICATION NUMBER: US 60/171,622
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.1
; SEQ_ID NO 15
; LENGTH: 374
; OTHER INFORMATION: Turkey P2Y nucleotide receptor; tpynovel

Query Match 58.0%; Score 1127.5; DB 3; Length 374;
Best Local Similarity 59.3%; Pred. No. 1.8e-88;
Matches 208; Conservative 56; Mismatches 70; Indels 17; Gaps 4;

Qy 119 LYCSVLFITCISYTHRYLGICPIRALWKGRPLAGLCLAWLVAGCLVPNLFFTTSN 178
Db 125 LYSSILFLTCISYTHRYMGICPDRSLKVTKTKEARLICGVWLVTTICLIPNLFFTTSS 184

Qy 179 KGTTVLCIDTTRPEEFDHYVHFSSAVMCLLFGVPCLYTLCVYGLMARRYQ---PLGSA 235
Db 185 KDNSTLCHDTTRPEEFDHYVHFSSIMALLFGVPCLYTLCVYCLMAKLCKRSFPSPSR 244

Qy 236 QSSSRRLSRLRTIAVVLTVFAVCFVDPFHITRITYLARLLADCRVNLIVVVYKTRPLA 295
Db 245 VPSTYKRSKTMIVLTVACFVDPFHITRITYLARLLADCRVNLININFTYKTRPLA 304

Qy 245 SANSCLDPVLYLTTGDKYRQLRQCGGKRPQPTAASS-LALVSLPEDSS 345
Db 305 SINSCLDPVLYFNGDKYRQLRER--GAAQRPRPVPFTSLLALVSPVSDSS 352

RESULT 15
US-10-010-568-11
; Sequence 11. Application US/10010568
; Publication No. US20030157598A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR, HGPRBMY23, EXPRESSION
; FILE REFERENCE: D0077 NP
; CURRENT APPLICATION NUMBER: US/10/010,568
; CURRENT FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: US 60/251,926
; PRIOR FILING DATE: 2000-12-07
; PRIOR APPLICATION NUMBER: US 60/269,795
; PRIOR FILING DATE: 2001-02-14
; NUMBER OF SEQ ID NOS: 55
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 11
; LENGTH: 374
; TYPE: PRT
; ORGANISM: MELEAGRIS GALLOPAVO
US-10-010-568-11

Query Match 58.0%; Score 1127.5; DB 4; Length 374;
Best Local Similarity 59.3%; Pred. No. 1.8e-88;
Matches 208; Conservative 56; Mismatches 70; Indels 17; Gaps 4;

Qy 9 LRSLGILSP-----GPGSSEVELDCWFEDDFKTFILLPSVAVVFVGLGNAPTLW 58
Db 5 VRMFSLAPTPPTPWNLSGNTTAAEAFCVNFBKFILLPSVAVVFVGLGNAPTLW 64

Qy 59 LFIFPLRWDATATMFHIALSDPTLYLSPYLIIYYAHHNWPFGTEICKPYRFLFTN 118
Db 65 IPYSRMRPNWATATMFHIALSDPTLYLSPYLIIYYAHHNWPFGKVECKPYRFLFTAN 124

Qy 119 LYCSVLFITCISYTHRYLGICPIRALWKGRPLAGLCLAWLVAGCLVPNLFFTTSN 178
Db 125 LYSSILFLTCISYTHRYMGICPDRSLKVTKTKEARLICGVWLVTTICLIPNLFFTTSS 184

Qy 179 KGTTVLCIDTTRPEEFDHYVHFSSAVMCLLFGVPCLYTLCVYGLMARRYQ---PLGSA 235
Db 185 KDNSTLCHDTTRPEEFDHYVHFSSIMALLFGVPCLYTLCVYCLMAKLCKRSFPSPSR 244

Qy 236 QSSSRRLSRLRTIAVVLTVFAVCFVDPFHITRITYLARLLADCRVNLIVVVYKTRPLA 295
Db 245 VPSTYKRSKTMIVLTVACFVDPFHITRITYLARLLADCRVNLININFTYKTRPLA 304

Qy 296 SANSCLDPVLYLTTGDKYRQLRQCGGKRPQPTAASS-LALVSLPEDSS 345

Db 305 SINSCLDPPLYFMAGDKYRGRLLR --GAPQRPRPVPTSSLALVSPSVDS 352

Search completed: April 4, 2006, 20:29:19
Job time : 168 secs

Copyright (c) 1993 - 2006 Biocceleration Ltd.	GenCore version 5.1.7	ADO29596 Human GPC
OM protein - protein search, using sw model		Adp49189 Human P2Y
Run on: April 4, 2006, 20:06:42 ; Search time 189 Seconds (without alignments) 848.536 Million cell updates/sec		Aae20604 Mus muscu
Title: US-10-811-198-2		Ade29597 Mouse GPC
Perfect score: 1944		Abu63310 Mouse P u
Sequence: 1 MASTESSLLRLSGLSPGPGS.....CRWAATPQDSSCSTPPADRL 365		Ade62164 Rat Prote
Scoring-table: BLOSUM62		Adr89633 Rat P2U
Gapext 0.5		Aar72457 Human P2O
Searched: 243136 seqs, 439378781 residues		Ado30396 Mouse GPC
Total number of hits satisfying chosen parameters:	2443163	Aae04389 Human P2-
Minimum DB seq length: 0		Abp54315 Human P2Y
Maximum DB seq length: 2000000000		Aau0983 Purinergi
Post-processing: Maximum Match 0*		Aau10984 Purinergi
Listing first 45 summaries		Abp81867 Human pur
Database : A_Geneseq_21:*		Add46171 Human Pro
1: geneseqP1980s:*		Adf42110 Human P2R
2: geneseqP1990s:*		Aee04389 Human P2-
3: geneseqP2000s:*		Abp54316 Human P2Y
4: geneseqP2001s:*		Aau10983 Purinergi
5: geneseqP2002s:*		Aau10984 Purinergi
6: geneseqP2003as:*		Aab89633 Rat P2U
7: geneseqP2003bs:*		Aad62164 Rat Prote
8: geneseqP2004s:*		Adr89633 Rat P2U
9: geneseqP2005s:*		Aar72457 Human P2O
Pred. No. is the number of results Predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Abp81867 Human pur
		Add46171 Human Pro
		Adf42110 Human P2R
		Aee04389 Human P2-
		Abp54316 Human P2Y
		Aau10983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Abp81867 Human pur
		Add46171 Human Pro
		Adf42110 Human P2R
		Aee04389 Human P2-
		Abp54316 Human P2Y
		Aau10983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Abp81867 Human pur
		Add46171 Human Pro
		Adf42110 Human P2R
		Aee04389 Human P2-
		Abp54316 Human P2Y
		Aau10983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr89633 Rat P2U
		Aar72457 Human P2O
		Ado30396 Mouse GPC
		Aae04389 Human P2-
		Abp54315 Human P2Y
		Aau0983 Purinergi
		Aau10984 Purinergi
		Aab89633 Rat P2U
		Aad62164 Rat Prote
		Adr

FT	Modified-site	345 /note= "potential protein kinase C (PKC) phosphorylation site"	ID XX	AAE04391 standard; protein; 365 AA.
FT	Modified-site	359 /note= "potential protein kinase C (PKC) phosphorylation site"	AC XX	AAE04391;
FT			DT XX	04-SEP-2001 (first entry)
FT			DE XX	Human P2Y4 pyrimidinergic receptor.
XX	WO9719170-A1.		XX	Human; P2-purinergic receptor; P2Y1; cardiotonic; vasodilator; thrombolytic; cerebroprotective; gynaecological; ADP; adenosine 5'-diphosphate; angina; myocardial infarction; ischaemic attack; preclampsia; bleeding disorder; carotid endarterectomy; vascular graft surgery; brain disorder; migraine; vascular injury; schizophrenia; eating disorder; depression; angioplasty; peripheral vascular disease; platelet aggregation; restenotic; embolism; thrombocytopanic purpura; stroke; Pertussis toxin-sensitive G protein; Gi; disseminated intravascular coagulation; P2Y4 pyrimidinergic receptor; thrombosis.
XX	29-MAY-1997.		KW XX	KW
XX	21-NOV-1996;	96WO-BE000123.	KW XX	KW
PF	21-NOV-1995;	95EP-00870124.	KW XX	KW
PR	(EURO-) EUROSCREEN SA.		KW XX	KW
XX	PI Communi D, Pirotton S, Parmentier M, Boeynaems J;		KW XX	KW
PI	XX	Homo sapiens.	OS XX	OS
XX	WPI: 1997-402177/37.		XX	WO200146454-A1.
DR	N-PSDB; AAT7421.		XX	28-JUN-2001.
XX	Receptor having preference for pyrimidine over purine nucleotide(s) - especially uridine triphosphate, agonist and antagonists of which are useful in treatment of cystic fibrosis.		PD XX	26-DEC-2000; 2000WO-US034998.
PT	¶XX		PR XX	23-DEC-1999; 99US-01716222.
PS	Claim 1; Fig 1; 56pp; English.		XX	(CORT-) COR THERAPEUTICS INC.
XX	This sequence represents a novel human P2 receptor, P2Y4, which has a preference for pyrimidine binding, especially uridine triphosphate. This receptor could be used to screen for novel drugs which specifically bind to it. Transgenic animals could be used to determine the physiological effects of expressing varying levels of the receptor or to identify novel agonists or antagonists. The agonists and antagonists of human P2Y4 may be used, e.g., in treatment of cystic fibrosis.		PA XX	PA.
CC	Sequence 365 AA;		PI XX	Conley PB, Jantzen H, Ramakrishnan-Dubridge V, Julius DJ; Hollopeter G;
CC	Query Match 100.0%; Score 1944; DB 2; Length 365;		PI XX	WPI: 2001-418082/44.
CC	Best Local Similarity 100.0%; Pred. No. 1-1e-203; Mismatches 0; Indels 0; Gaps 0;		DR XX	WPI: 2001-418082/44.
Qy	1 MASTESSLLRSLGLSPGGSSEVELCWFDDEFKFLPVSAYYEVGLGLNAPTLWLF 60		XX	Novel isolated ADP receptor, termed P2Y12 receptor, useful for identifying binding partners and for diagnostic applications.
Db	1 MASTESSLLRSLGLSPGGSSEVELCWFDDEFKFLPVSAYWVLGLGNATLWLF 60		XX	Disclosure; Page 97-98; 108pp; English.
Qy	1 IFRLRPMDATAATMFLIALSDPLIVSLSPLTLLIYIYYAHNNHPPGTEICKYFRLFYWNLY 120		XX	The invention relates to ADP (adenosine 5'-diphosphate) receptor, termed P2Y12 receptor and its corresponding cDNA molecule. P2Y12 receptor is the subtype of P2-purinergic receptor. The P2Y12 receptor is expressed selectively in the platelets and brain, and couples to a pertussis toxin-sensitive G protein (Gi). P2Y12 receptor is a G protein-coupled receptor that responds to ADP. The invention also relates to a method for identifying an agent which is useful for modulating acute myocardial infarction, unstable angina, chronic stable angina, transient ischaemic attacks, strokes, peripheral vascular disease, preeclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation, thrombotic and restenotic complications following angioplasty, carotid endarterectomy, post CABG (coronary artery bypass graft) surgery, vascular graft surgery, stent placement or insertion of endovascular devices and prostheses.
Db	1 IFRLRPMDATAATMFLIALSDPLIVSLSPLTLLIYIYYAHNNHPPGTEICKYFRLFYWNLY 120		CC	P2Y12 receptor is useful for identifying binding partners and for diagnostic applications. P2Y12 receptor provides targets for screening synthetic small molecules and combinatorial or naturally occurring compound libraries to regulate platelet aggregation, vascular injury, or disease as well as schizophrenia, eating disorders, depression, migraine and other brain disorders. The present sequence is human P2Y4 pyrimidinergic receptor related to the invention
Qy	121 CSVLFCTISVERYLGIChPILARLNRPRLAQVNLFFVTSNKG 180		CC	Sequence 365 AA;
Db	121 CSVLFCTISVERYLGIChPILARLNRPRLAQVNLFFVTSNKG 180		XX	Query Match 100.0%; Score 1944; DB 4; Length 365;
Qy	181 TTVLCHDTRPPEFDAYTHPSSAVMGILFGVPCLVLYCYGLMARRLYQPLPSAQSSR 240		CC	Best Local Similarity 100.0%; Pred. No. 1.1e-203; Mismatches 0; Indels 0; Gaps 0;
Db	181 TTVLCHDTRPPEFDAYTHPSSAVMGILFGVPCLVLYCYGLMARRLYQPLPSAQSSR 240		Db	1 MASTESSLLRSLGLSPGGSSEVELCWFDDEFKFLPVSAYWVLGLGNAPTLWLF 60
Qy	241 LRSLRRTIAVVLTVFAVCVPPFHITRITYLARLEADCRVNIVNVVYKTRPLASANSC 300		Qy	1 MASTESSLLRSLGLSPGGSSEVELCWFDDEFKFLPVSAYWVLGLGNAPTLWLF 60
Db	241 LRSLRRTIAVVLTVFAVCVPPFHITRITYLARLEADCRVNIVNVVYKTRPLASANSC 300		Db	1 MASTESSLLRSLGLSPGGSSEVELCWFDDEFKFLPVSAYWVLGLGNAPTLWLF 60
Qy	301 LDGVLYLTGDKYRQLRQLCGGKPKORTAASSLALVSPLPDSSCRWAATPQDSSCTP 360		Qy	61 IFRLRPMDATAATMFLIALSDPLIVSLSPLTLLIYIYYAHNNHPPGTEICKYFRLFYWNLY 120
Db	301 LDGVLYLTGDKYRQLRQLCGGKPKORTAASSLALVSPLPDSSCRWAATPQDSSCTP 360		AAE04391	
Qy	361 RADRL 365			
Db	361 RADRL 365			

kidney disorder; liver disorder; lung disorder; breast disorder;
 ovarian disorder; uterus disorder; prostate disorder; testis disorder;
 skin disorder; stomach disorder; pancreatic disorder; spleen disorder;
 thymus disorder; thyroid disorder; anti-parkinsonian; antimanic;
 cytostatic; anti-inflammatory; vasotropin; antianginal; antiarhythmic;
 CNS; central nervous system; respiratory; antibacterial; antidiabetic;
 virucotic; hepatotropic; antidiarrhoeic; antianemic; antiseborrheic;
 dermatological; antivulcer; antithyroid; antiallergic; anorectic;
 KW immunosuppressive; nephrotoxic; gene therapy; GPCR modulator; human;
 XX receptor.
 XX Homo sapiens.
 PN WO2004040000-A2.
 XX PD 13-MAY-2004.
 XX PF 09-SEP-2003; 2003WO-US028226.
 XX PR 09-SEP-2002; 2002US-0409303P.
 PR 09-APR-2003; 2003US-0461329P.
 PA (PRIM-) PRIMAL INC.
 XX Gaitanaris GA, Bergmann JB, Gragerov A, Hohmann J, Li F;
 Madisen L, Mcilwain KL, Pavlova MN, Vassilatis D, Zeng H;
 PI DR; 2004-390329/36.
 DR N-PSDB; ADP030018.
 XX Novel mammalian G protein coupled receptors, useful for identifying
 PT compounds that modulates diagnosing and treating disease condition
 PT associated with GPCR dysfunction e.g. autoimmune diseases, angina
 pectoris, Parkinson's disease.
 XX Claim 151; SEQ ID NO 700; 542pp; English.
 PS DR; 2004-390329/36.
 DR N-PSDB; ADP030018.
 XX The invention relates to human and mouse G protein-coupled receptors
 CC (GPCRs) and nucleic acids encoding them. The invention also relates to
 CC sequences at least 90% identical to the GPCR proteins and nucleic acids
 CC of the invention; methods of treating, preventing or diagnosing diseases
 CC associated with GPCRs of the invention; methods of screening for
 CC compounds useful in the treatment of GPCR-related diseases; a transgenic
 CC mouse comprising a GPCR gene of the invention; a mouse comprising a
 CC mutation in a GPCR transgene or in an endogenous GPCR gene; cells derived
 CC from the transgenic mice; kits comprising several mice, each of which has
 CC a mutation in a different GPCR gene of the invention; and kits comprising
 CC probes which hybridise to GPCR polynucleotides of the invention. The
 CC invention further discloses variants of the GPCR polypeptides and vectors
 CC comprising a GPCR nucleic acid. The GPCR nucleic acids and proteins may
 CC be used in the diagnosis, treatment or prevention of a wide variety of
 CC diseases including neurological disorders (e.g., Alzheimer's disease,
 CC depression, diabetic neuropathy, Parkinson's disease or schizophrenia);
 CC disorders of the adrenal gland; disorders of the colon or intestine
 CC (e.g., Crohn's disease, diarrhoea, food poisoning or irritable bowel
 CC syndrome); cardiovascular disorders (e.g., angina, cardiac arrhythmia or
 CC myocardial infarction); muscular disorders (e.g., bldod disorders or
 CC anaemia or leukaemia); immune disorders (e.g., autoimmune disorders or
 CC AIDS); bone and joint disorders (e.g., osteoarthritis, rheumatoid
 CC arthritis, gout or osteoporosis); metabolic or nutritive disorders (e.g.,
 CC obesity, enzyme deficiency related diseases or vitamin deficiency-related
 CC diseases); and disorders of the kidney, liver, lung, breast, ovary,
 CC uterus, prostate, testis, skin, stomach, pancreas, thymus and
 CC thyroid (e.g., cancers). The present sequence represents a GPCR of the
 CC invention. Note: The full sequence data for this patent did not form part
 CC of the printed specification; those sequences not shown were obtained in
 CC electronic format directly from WIPO at
 CC ftp://ipo.int/pub/published_pct_sequences.
 XX Sequence 365 AA;
 PS Best Local Similarity 100.0%; Score 1944; DB 8; Length 365;
 Pred. No. 1.e-203;

Matches 365; Conservative 0; Mismatches 0; Indexes 0; Gaps 0;
 Qy 1 MASTESSLRLSGLSPGSSSEVLDCCWFDDEDKFILLPVSYAVTFVGLGINAPNTLWF 60
 Db 1 MASTESSLRLSGLSPGSSSEVLDCCWFDDEDKFILLPVSYAVTFVGLGINAPNTLWF 60
 Qy 61 IFRLRPWDTATMNFHLASDFTLVSLPLTLYAARHNPFCETICKFVRFLFYFWNLY 120
 Db 61 IFRLRPWDTATMNFHLASDFTLVSLPLTLYAARHNPFCETICKFVRFLFYFWNLY 120
 Qy 121 CSVLFLTCISVHRVYLGICHPLRLAFLCLAWLWVAGCLVNLFFVTSNKG 180
 Db 121 CSVLFLTCISVHRVYLGICHPLRLAFLCLAWLWVAGCLVNLFFVTSNKG 180
 Qy 181 TTVLCHDTRPEEDEWVFESSAALGILLCQVPCUFLVCYGLMAPRLYQPLPGSAQSSSR 240
 Db 181 TTVLCHDTRPEEDEWVFESSAALGILLCQVPCUFLVCYGLMAPRLYQPLPGSAQSSSR 240
 Qy 241 LRSIITIAVVLTVPAVCYFBHITRITYYLARLLLEADERVNIINVVYKTRPLSANS 300
 Db 241 LRSIITIAVVLTVPAVCYFBHITRITYYLARLLLEADERVNIINVVYKTRPLSANS 300
 Qy 301 LDPTVYLLTDKTRQLRQLCGGGPQPRTAAASSIALVSLPEDSSCRWAATPQDSSCSTP 360
 Db 301 LDPTVYLLTDKTRQLRQLCGGGPQPRTAAASSIALVSLPEDSSCRWAATPQDSSCSTP 360

RESULT 5
 ADP49193 standard; protein: 365 AA.
 XX ADP49193;
 XX DT 26-AUG-2004 (first entry)
 AC ADP49193;
 XX DE Human P2Y4 purinergic receptor protein sequence for odour modulation.
 XX XX odour sensitivity; P2X purinergic receptor; P2Y purinergic receptor;
 KW signal transduction pathway; olfactory signalling; micro-array.
 XX Homo Sapiens.
 XX PN WO2004047749-A2.
 XX PR 21-NOV-2003; 2003WO-US037389.
 XX PD 10-JUN-2004.
 XX PR 21-NOV-2002; 2002US-0428140P.
 XX PA (UTAH) UNTV UTAH RES FOUND.
 XX PI Lucero M, Hegg C;
 XX DR WPI; 2004-460642/43.
 XX PS Modulating odor sensitivity in a subject, comprises administering a
 CC composition comprising an agonist or antagonist of P2X or P2Y purinergic
 PR receptor to the subject.
 XX Disclosure; SEQ ID NO 22; 108pp; English.
 XX The invention relates to a method of modulating (M1) odour sensitivity in
 CC a subject, by administering a composition which is an agonist or
 CC antagonist of a P2X or P2Y purinergic receptor. (M1) is useful for
 CC modulating odour sensitivity in a subject (claimed). The compositions
 CC used for modulating odour sensitivity in a subject are useful for
 CC studying the signal transduction pathways related to olfactory signaling.
 CC The compositions are also useful as reagents in micro-arrays or as

CC reagents to probe or analyze existing micro-arrays. This sequence
 CC corresponds to the human P2Y4 protein sequence.
 SQ Sequence 365 AA;

Query Match 100.0%; Score 1944; DB 8; Length 365;
 Best Local Similarity 100.0%; Pred. No. 1.1e-203;
 Matches 365; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MASTESSILRSLGSPGGSESSEYLDWFDEDFKFLIPVGLGNAPTLWLF 60
 Db 1 MASTESSILRSLGSPGGSESSEYLDWFDEDFKFLIPVGLGNAPTLWLF 60
 Qy 61 IFRLRPMDATATYMFHLSDTLVLISPLTLYYYAAAHNNHPFGTECKFVRFLFTWNL 120
 Db 61 IFRLRPMDATATYMFHLSDTLVLISPLTLYYYAAAHNNHPFGTECKFVRFLFTWNL 120
 Qy 121 CSVLFCLTCISVRYLGICHLPLRGRPRLLGICLAVMLVAGCLVPNLFFVTSNKG 180
 Db 121 CSVLFCLTCISVRYLGICHLPLRGRPRLLGICLAVMLVAGCLVPNLFFVTSNKG 180
 Qy 181 TTVLCHDTRPPEFDHYFHSSAVMGLIIFGVPCLVLYCIGLMLRRLYQPLPGSAOSSR 240
 Db 181 TTVLCHDTRPPEFDHYFHSSAVMGLIIFGVPCLVLYCIGLMLRRLYQPLPGSAOSSR 240
 Qy 241 LSLRLTIAVVLTVFAVCFVPFHITRTRYYLARLLEADCRVNIVVVYKVTRPLASNSC 300
 Db 241 LSLRLTIAVVLTVFAVCFVPFHITRTRYYLARLLEADCRVNIVVVYKVTRPLASNSC 300
 Qy 301 LDPPVLYLTGDKYRQLRQLCGGKEQPTTAASSLALSPBDSSCRWAATPQDSSCSTP 360
 Db 301 LDPPVLYLTGDKYRQLRQLCGGKEQPTTAASSLALSPBDSSCRWAATPQDSSCSTP 360

Qy 361 RADRL 365
 Db 361 RADRL 365

RESULT 6

ADE40463 standard; protein; 365 AA.

AC ADE40463;

DT 29-JAN-2004 (first entry)

XX Human pyrimidinergic GPCR P2Y4 (gene ID 326) protein.

KW AIDS; acquired immunodeficiency syndrome; human immunodeficiency virus;
 KW HIV-related disorder; differential expression; drug screening;
 KW viral replication modulation; diagnosis; prognosis; predisposition;
 KW anti-HIV; gene therapy; antisense therapy; human;
 KW pyrimidinergic GPCR P2Y4; receptor.
 XX Homo sapiens.

PN WO2003070883-A2.

XX PD 28-AUG-2003.

XX PF 13-FEB-2003; 2003WO-US004246.

XX PR 15-FEB-2002; 2002US-0357391P.

PR 13-MAY-2002; 2002US-0380249P.

PR 25-JUN-2002; 2002US-0391306P.

PR 27-AUG-2002; 2002US-0406297P.

PR 19-SEP-2002; 2002US-0412007P.

PR 10-OCT-2002; 2002US-0417508P.

PR 10-DEC-2002; 2002US-0432318P.

XX PA (MILL-) MILLENNIUM PHARM INC.

PI Powell DM, Weich NS;

XX WPI; 2003-671808/63.
 DR N-PSpp; ADB40462.

XX PT Identifying a compound capable of diagnosing, preventing or treating AIDS or an HIV-related disorder comprises assaying the ability of the compound to modulate e.g. 1481 or 1553 nucleic acid expression or polypeptide activity.

XX PS Claim 1; SEQ ID NO 42; 167pp; English.

XX The invention relates to a method of identifying a compound useful in the treatment of AIDS (acquired immunodeficiency syndrome) or an HIV (human immunodeficiency virus)-related disorder. The invention involves assaying the ability of a test compound to modulate the activity or expression of these proteins and nucleic acids encoding them (ADE40422-ADBE0473) are differentially expressed in tissues relating to AIDS or an HIV-related disorder compared to their expression in normal tissues. The invention also relates to the use of the compounds identified to modulate viral replication in a cell and to treat a patient with AIDS or an HIV-related disorder. The invention further discloses methods for the diagnostic evaluation and prognosis of various HIV-related disorders, and for the identification of individuals exhibiting a predisposition to such conditions. The modulatory compounds identified using the method of the invention may be small organic molecules, peptides, antibodies or antisense nucleic acid molecules. The methods of the invention are useful in diagnosing, preventing or treating AIDS or HIV-related disorders. The present sequence represents a human protein which is differentially expressed in AIDS or HIV-related disorders.

XX Sequence 365 AA;

XX Query Match 99.4%; Score 1932; DB 7; Length 365;

XX Best Local Similarity 99.2%; Pred. No. 2.3e-202;

XX Matches 362; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

XX 1 MASTESSILRSLGSPGGSESSEYLDWFDEDFKFLIPVGLGNAPTLWLF 60

XX 1 MASTESSILRSLGSPGGSESSEYLDWFDEDFKFLIPVGLGNAPTLWLF 60

XX 61 IFRLRPMDATATYMFHLSDTLVLISPLTLYYYAAAHNNHPFGTECKFVRFLFTWNL 120

XX 61 IFRLRPMDATATYMFHLSDTLVLISPLTLYYYAAAHNNHPFGTECKFVRFLFTWNL 120

XX 121 CSVLFCLTCISVRYLGICHLPLRGRPRLLGICLAVMLVAGCLVPNLFFVTSNKG 180

XX 121 CSVLFCLTCISVRYLGICHLPLRGRPRLLGICLAVMLVAGCLVPNLFFVTSNKG 180

XX 181 TTVLCHDTRPPEFDHYFHSSAVMGLIIFGVPCLVLYCIGLMLRRLYQPLPGSAOSSR 240

XX 181 TTVLCHDTRPPEFDHYFHSSAVMGLIIFGVPCLVLYCIGLMLRRLYQPLPGSAOSSR 240

XX 241 LSLRLTIAVVLTVFAVCFVPFHITRTRYYLARLLEADCRVNIVVVYKVTRPLASNSC 300

XX 241 LSLRLTIAVVLTVFAVCFVPFHITRTRYYLARLLEADCRVNIVVVYKVTRPLASNSC 300

XX 301 LDPPVLYLTGDKYRQLRQLCGGKEQPTTAASSLALSPBDSSCRWAATPQDSSCSTP 360

XX 301 LDPPVLYLTGDKYRQLRQLCGGKEQPTTAASSLALSPBDSSCRWAATPQDSSCSTP 360

XX Qy 361 RADRL 365
 XX Db 361 RADRL 365

XX 1 MASTESSILRSLGSPGGSESSEYLDWFDEDFKFLIPVGLGNAPTLWLF 60

XX 1 MASTESSILRSLGSPGGSESSEYLDWFDEDFKFLIPVGLGNAPTLWLF 60

XX 61 IFRLRPMDATATYMFHLSDTLVLISPLTLYYYAAAHNNHPFGTECKFVRFLFTWNL 120

XX 61 IFRLRPMDATATYMFHLSDTLVLISPLTLYYYAAAHNNHPFGTECKFVRFLFTWNL 120

XX 121 CSVLFCLTCISVRYLGICHLPLRGRPRLLGICLAVMLVAGCLVPNLFFVTSNKG 180

XX 121 CSVLFCLTCISVRYLGICHLPLRGRPRLLGICLAVMLVAGCLVPNLFFVTSNKG 180

XX 181 TTVLCHDTRPPEFDHYFHSSAVMGLIIFGVPCLVLYCIGLMLRRLYQPLPGSAOSSR 240

XX 181 TTVLCHDTRPPEFDHYFHSSAVMGLIIFGVPCLVLYCIGLMLRRLYQPLPGSAOSSR 240

XX 241 LRSRLTIAVVLTVFAVCFVPFHITRTRYYLARLLEADCRVNIVVVYKVTRPLASNSC 300

XX 241 LRSRLTIAVVLTVFAVCFVPFHITRTRYYLARLLEADCRVNIVVVYKVTRPLASNSC 300

XX 301 LDPPVLYLTGDKYRQLRQLCGGKEQPTTAASSLALSPBDSSCRWAATPQDSSCSTP 360

XX 301 LDPPVLYLTGDKYRQLRQLCGGKEQPTTAASSLALSPBDSSCRWAATPQDSSCSTP 360

XX Qy 361 RADRL 365
 XX Db 361 RADRL 365

RESULT 7
 ADR89630
 ID ADR89630;
 AC ADR89630;
 DT 02-DEC-2004 (first entry)

DE	Human uridine nucleotide receptor.	Db	312 RADRL 316
XX	HGPRTM23; G-protein coupled receptor; receptor; human;	RESULT 8	
RW	uridine nucleotide receptor.	AD116985	standard; protein; 361 AA.
XX	Homo sapiens.	ID	AD116985
OS	WO2004076636-A2.	AC	AD116985;
XX	PD 10-SEP-2004.	XX	XX
XX	PP 26-FEB-2004; 2004WO-US005535.	DT	15-APR-2004 (first entry)
XX	PR 26-FEB-2003; 2003US-00375157.	XX	Rat NOVX protein homologue SeqID 521.
PA	(BRIM) BRISTOL-MYERS SQUIBB CO.	XX	
XX	Barber LE, Cacace A, Feder JN, Nelson TC, Ramanathan CS;	XX	rat; NOVX; cardiomyopathy; atherosclerosis; cancer; diabetes;
P1	Ryseck R, Neubauer MG, Kornacker MG;	XX	inflammation; autoimmune disorder; allergy; blood disorder;
XX	DR; WPI: 2004-653403/63.	XX	acquired immunodeficiency syndrome; AIDS; obesity; asthma;
DR	SWISSPROT; P51582.	XX	immunoglobulin (Ig)A nephropathy; cirrhosis; arthritis;
XX	PT New nucleic acid molecules encoding HGPRTM23 polypeptides of the G-	XX	Alzheimer's disease; infection; str.
PT	protein coupled receptor superfamily, useful for diagnosing, treating, or	XX	
PT	ameliorating pulmonary, renal, or proliferative disorders, e.g. cancer.	XX	Rattus norvegicus.
PR	■ Disclosure: SEQ ID NO 10; 370pp; English.	XX	OS
PS	XX	XX	XX
XX	The present sequence is that of human uridine nucleotide receptor. The	XX	PR 31-JAN-2001; 2001US-0265305P.
CC	sequence shows 32% identity and 40% similarity to the protein sequence	XX	PR 31-JAN-2001; 2001US-0265412P.
CC	of novel human G-protein coupled receptor HGPRTM23. The	XX	PR 31-JAN-2001; 2001US-0265514P.
CC	invention provides HGPRTM23 polypeptides and polynucleotides, vectors,	XX	PR 31-JAN-2001; 2001US-0265517P.
CC	host cells, antibodies, and recombinant and synthetic methods for	XX	PR 02-FEB-2001; 2001US-0266406P.
CC	producing the polypeptides. Methods are provided for identifying agonists	XX	PR 05-FEB-2001; 2001US-0266767P.
CC	and antagonists of HGPRTM23. The polypeptides, polynucleotides,	XX	PR 07-FEB-2001; 2001US-0266915P.
CC	modulators and methods are useful for diagnosing, treating or	XX	PR 07-FEB-2001; 2001US-0267077P.
CC	ameliorating a disease or disorder related to HGPRTM23, particularly	XX	PR 08-FEB-2001; 2001US-0267459P.
CC	renal diseases and/or disorders, colon cancer, and	XX	PR 09-FEB-2001; 2001US-0267833P.
CC	breast cancer, and	XX	PR 15-FEB-2001; 2001US-0268974P.
CC	diseases and disorders related to aberrant NFKappaB modulation.	XX	PR 26-FEB-2001; 2001US-0271664P.
XX	Sequence 316 AA;	XX	PR 27-FEB-2001; 2001US-0271839P.
SQ	Query Match 85.1%; Score 1653.5; DB 8; Length 316;	XX	PR 02-MAR-2001; 2001US-0272788P.
Best Local Similarity 86.6%; Pred. No. 6e-172; Mismatches 0; Indels 49; Gaps 1;	XX	PR 02-MAR-2001; 2001US-0273046P.	
Matches 316; Conservative 0; Mismatches 0;	XX	PR 02-MAR-2001; 2001US-0275925P.	
Qy 1 MASTESSLRLSISLGSPGSSSEVLDCTWDEDFFKILLPVSYAVVFVIGLNAPTLWLF 60	XX	PR 14-MAR-2001; 2001US-0275947P.	
Db 1 MASTESSLRLSISLGSPGSSSEVLDCTWDEDFFKILLPVSYAVVFVIGLNAPTLWLF 60	XX	PR 14-MAR-2001; 2001US-0275950P.	
Qy 35 -----YVLSPLTLLYYAAAHNPFPGEIEKFKVRLFLFYNNLY 71	XX	PR 14-MAR-2001; 2001US-0275959P.	
Db 35 -----YVLSPLTLLYYAAAHNPFPGEIEKFKVRLFLFYNNLY 71	XX	PR 15-MAR-2001; 2001US-0276449P.	
Qy 121 CSVLFLLTCTSVHRYLGICHPFLPLRGRPLAGLCLAWLVAAGCIVPNLFFTTTSNKG 180	XX	PR 15-MAR-2001; 2001US-0276450P.	
Db 72 CSVLFLLTCTSVHRYLGICHPFLPLRGRPLAGLCLAWLVAAGCIVPNLFFTTTSNKG 131	XX	PR 16-MAR-2001; 2001US-0276397P.	
Qy 181 TTVLCHDTRPPEEDHYFESSAVMGLFGVPCLVLYCYGMARRLYQPLPSAQSSR 240	XX	PR 16-MAR-2001; 2001US-0276768P.	
Db 132 TTVLCHDTRPPEEDHYFESSAVMGLFGVPCLVLYCYGMARRLYQPLPSAQSSR 191	XX	PR 20-MAR-2001; 2001US-0278650P.	
Qy 241 LRSLRITIAVLTIVPFCVYFPHTRITYYLARLLEADERVLNVYKVTRPLASANSC 300	XX	PR 20-MAR-2001; 2001US-0282929P.	
Db 192 LRSLRITIAVLTIVPFCVYFPHTRITYYLARLLEADERVLNVYKVTRPLASANSC 251	XX	PR 21-MAR-2001; 2001US-0283033P.	
Qy 301 LDPPVLYLJNGDKYRQLRQLGGKKPKPRTAAASSLLAISLPEDSSCRWAATPODSSCTP 360	XX	PR 23-APR-2001; 2001US-0285133P.	
Db 252 LDPPVLYLJNGDKYRQLRQLGGKKPKPRTAAASSLLAISLPEDSSCRWAATPODSSCTP 311	XX	PR 18-JUN-2001; 2001US-0296959P.	
Qy 361 RADRL 365	XX	PR 19-JUN-2001; 2001US-0299324P.	
Db		PR 13-AUG-2001; 2001US-0312030P.	
Qy		PR 16-AUG-2001; 2001US-0312889P.	
Db		PR 16-AUG-2001; 2001US-0312908P.	
Qy		PR 21-AUG-2001; 2001US-0313339P.	
Db		PR 28-AUG-2001; 2001US-0315470P.	

PR	31-AUG-2001;	2001US-0316447P.	Qy	241	I R S L R T I A V Y L T V F A V C P V P H I T T I Y L Y L A R L L B A D C R V I N V Y V K T R P L A S A N S C 300
PR	07-SEP-2001;	2001US-0318115P.	Db	237	I R S L R T I A V Y L T V F A V C P V P H I T T I Y Q A R L L Q A D C H V I N V V Y K T R P L A S A N S C 296
PR	07-SEP-2001;	2001US-0318119P.			
PR	12-SEP-2001;	2001US-0318740P.			
PR	19-SEP-2001;	2001US-0323379P.	Qy	301	L D P V I Y L I T S D K Y R Q L R Q L G G G K P O R T A A S S I L A V S L P E D S C R W A T P Q D S C S T P 360
PR	18-OCT-2001;	2001US-0330245P.	Db	297	L D P V I Y L I T S D K Y R Q L R Q L Q Q L C R G S K P R T A A S S I L A V T H E E S I S R W A D T H Q D S T F S A Y 356
PR	18-OCT-2001;	2001US-0330308P.			
PR	14-NOV-2001;	2001US-0333270P.			
XX			Qy	361	R A D R L 365
PA	(CURA-)	CURAGEN CORP.	Db	357	E G D R L 361
XX					
PI	Tcherniev VT,	Spytek KA,	Zerhusen BD,	Patturajan M,	Shimkets RA;
PI	Li L,	Gangolli BA,	Padigaru M,	Anderson DW,	Rastelli L,
PI	Gerlach VL,	Tauiper RJ,	Gusev VY,	Coiman SP,	Miller CB;
PI	Purtak K,	Grosse WM,	Alsbrook JP,	Wolenc AR,	Pena CEA;
XX					
DR					
PT	New NOXV polypeptides and nucleic acids, useful for preventing or				
PT	treating NOXV-associated disorders, e.g. cancer, cardiomopathy,				
PT	atherosclerosis, or diabetes, and in chromosome mapping, tissue typing or				
PT	pharmacogenomics.				
XX					
PS	Disclosure: SEQ ID NO 521; 1498pp; English.				
XX	This invention relates to a novel nucleic acids, and encoded polypeptides				
CC	thereof, which have properties related to the stimulation of biochemical				
CC	or physiological responses in a cell, tissue, organ or organism.				
CC	Specifically, it refers to the use of biologically active fragments for				
CC	diagnostic and prognostic assays and furthermore in the treatment of				
CC	diverse pathological conditions. The present invention describes novel				
CC	human and murine NOXV proteins, as well as methods to modulate their				
CC	expression using antisense oligos, ribozymes and peptide nucleic acids.				
CC	The NOXV polypeptides, polymucleotides and antibodies are useful in				
CC	treating or preventing NOXV-associated disorders, e.g. cariomypathy,				
CC	atherosclerosis, cancer and diabetes. Furthermore, they may be used in				
CC	treating or preventing diseases such as inflammation, autoimmune				
CC	disorders, allergies, blood disorders, acquired immunodeficiency syndrome				
CC	(AIDS), obesity, asthma, immunoglobulin (Ig)A nephropathy, cirrhosis,				
CC	arthritis, Alzheimer's disease, infections, stroke, muscular dystrophy				
CC	cytotoxic, cardiotonic, antiinflammatory, immunosuppressive, antiallergic,				
CC	haemostatic, anti-HIV, antidiabetic, antiarteriosclerotic, anorectic,				
CC	antiasthmatic, nephrotropic, antiarthritic, hepatotropic,				
CC	neuroprotective, nootropic, antibiotic, antiparasitic,				
CC	relaxant and anticonvulsant. In addition, they are useful in screening				
CC	assays to identify small molecules that modulate or inhibit, for example,				
CC	neurogenesis, wound healing and angiogenesis. The nucleic acids are also				
CC	used as in chromosome mapping, tissue typing, preventive medicine and				
CC	pharmacogenomics. This polypeptide is a homologue of a human NOXV protein				
CC	of the invention.				
XX					
SQ	Sequence 361 AA;				
	Query Match 82.2%; Score 1597; DB 5; Length 361;				
	Best Local Similarity 82.7%; Pred. No. 1.1e-165;				
	Matches 302; Conservative 20; Mismatches 39; Indels 4; Gaps 1;				
Qy	1 M A S T E S S L R S G L S P G P G S S E V E L D C W F D D E K F T I L L P Y S A Y V F V L G L N A P T L W L F 60				
Db	1 M T S A B S S L F T S L G P S S G D G - - - D C R F N B E B K F T I L L P M S A Y V F V L G L N A P T L W L F 56				
Qy	61 I F R I R P D A T A T Y M F H L A S D T L Y V S P I L Y Y K A H M A P F E T C K V R E F Y M N Y 120				
Db	57 I F R I R P D A T A T Y M F H L A S D T L Y V S P I L Y Y K A H M A P F E T C K V R E F Y M N Y 116				
Qy	121 C S V L F T C I S Y R Y L G C P R A L R G R P R A L G I L C L A V W L V A G C L P V N L F F T T S N R G 180				
Db	117 C S V L F T C I S Y R Y L G C P R A L R G R P R A L G I L C L A V W L V A G C L P V N L F F T T S N R G 176				
Qy	181 T T V L C H D T R P E E F D Y V H V F S S A V M G I L F G Y P C L Y T V C Y G L M A R R L Y Q P L P G S A Q S S R 240				
Db	177 T T V L C H D T L P E E F D Y V Y F S S A V M T F G L P L I T V C Y G L M A R R L Y Q P L P G S A Q S S R 236				

BS Disclosure; SEQ ID NO 15; 90pp; English.

XX The present invention relates to human G-protein coupled receptors encoding such receptors. The invention is useful for preventing, treating and/or ameliorating an immune disorder, proliferative disorder of the immune system, proliferative disorder of the haematopoietic system, proliferative disorder of B-cells, proliferative disorder of T-cells, proliferative disorder of lymph nodes, proliferative disorder of the kidney, breast cancer, proliferative disorder of the ovary, ovarian cancer, proliferative disorder of the uterus, uterine cancer, proliferative disorder of the skin, melanoma, cervical cancer, proliferative disorder of the colon, colon cancer, multiple myeloma, immune deficiencies, B-cell neoplasms, T-cell neoplasms, Hodgkin's disease, lymphoma, follicular lymphoma, splenic marginal zone lymphoma, nodal marginal zone lymphoma, mantle cell lymphoma, hairy cell leukaemia, prolymphocytic leukaemia (B cell or T cell), lymphoplasmacytic lymphoma, Sezary syndrome, smouldering adult T cell leukaemia/lymphoma, Burkitt's lymphoma, post-organ transplant lymphoma, Castlemann's disease, Rosai-Dorfman's disease, lymphomatoid papulosis, non-Hodgkin's lymphoma, increased susceptibility to EBV infection, increased susceptibility to HIV infection, increased susceptibility to H. pylori infections, autoimmune disorders, Sjogren's syndrome. The invention is also useful in gene therapy. The present sequence is rat orphan GPCR protein.

XX

SQ Sequence 361 AA;

Query Match 82.2%; Score 1597; DB 7; Length 361;

Best Local Similarity 82.7%; Pred. No. 1.1e-155; Matches 302; Conservative 20; Mismatches 39; Indels 4; Gaps 1;

Db 1 MASTESTLRSLGSLSPGGGSSEVLDCPFILLPSVAVVFTVLGIGLNAPTLWLF 60

Db 1 MTSAAESELFLTSGPSPSSGDD--DCRPNEERPKFILLPMSVAVVFTVLGALNAPTLWLF 56

Qy 61 IFLRLRPWDTATIMFHLLSDTLYLVSPTPLIYYAARHNNHWPGTEICKFVRFLFTWNL 120

Db 57 LFLRLRPWDTATIMFHLLSDTLYLVSPTPLIYYAARHNNWPGTGLCKFVRFLFTWNL 116

Qy 121 CSVLFITCISVRYLGLCHPLRALKGPRLAGLCLLAVALVYAGCLVPLNFFVTTSNKG 180

Db 117 CSVLFITCISVRYLGLCHPLRALKGPRLAGLCLLAVALVYAGCLVPLNFFVTTNKG 176

Qy 181 TRVFLCHDTRPEEDHYTHFSSAVMGLLFGVPVLTVLGIGMARRIQQLPGSAQSSR 240

Db 177 TTICLCHDTLPEEDHYTPSSAVMVLGLPLITLVCGLMARRIRPLPGAGQSSR 236

Qy 241 LRSLSRTIAVLTIVFAVCVPFHTRTITYLARLEADCRVLTIVNVYKTRPLASNSC 300

Db 237 LRSLSRTIAVLTIVFAVCVPFHTRTITYQARLQADHVLIVNVYKTRPLASNSC 296

Qy 301 LDPTVLYLTGDKYRROLEQLGGKKPQPTTAASSLAVLSPDSSCWAATPDSSCSTP 360

Db 297 LDPTVLYLTGDKYRNQOLCRESKPKRTAASSLAVLHEBESISRWDTHQDSFTSAY 356

Qy 361 RADRL 365

Db 357 EGDRL 361

XX cytostatic; anti-HIV; analgesic; anabolic; antiasthma; antiparkinsonian; KW hypotensive; osteopathic; anti-ulcer; KW antiallergic; neuroleptic; cardiovascular; neoplastic disease; cancer; CC tumour; HIV infection; pain; anorexia; intestinal bowel disorder; KW hypertension; asthma; Parkinson's disease; acute heart failure; hypotension; KW myocardial infarction; urinary retention; osteoporosis; angina pectoris; KW psychiatric disorder; ulcer; allergy; benign prostatic hypertrophy; KW cardiovascular disorder; immune disorder; metabolic disorder; KW cardiovascular disorder; neurological disorder; G-protein coupled receptor; HGPRBMY3; rat; orphan GPCR. XX Rattus sp. OS XX XX US2003186360-A1. XX PD 02-OCT-2003. XX PP 26-SEP-2001; 2001US-00954821. XX PR 27-SEP-2000; 2000US-0235713P. PR 16-JAN-2001; 2001US-0261783P. PR 13-JUL-2001; 2001US-030085P. PR 17-AUG-2001; 2001US-0313171P. XX PA (FEDE/) FEDER J N. PA (MINT/) MINTIER G. PA (RAMA/) RAMANATHAN C S. PA (HAWK/) HAWKEN D R. PA (CACAV/) CACACE A. PA (BARB/) BARBER L. PA (KORN/) KORNACKER M G. XX PI Feder JN, Mintier G, Ramanathan CS, Hawken DR, Cacace A; PI Barber L, Kornacker MG; PI DR WPI; 2004-041196/04. XX PT New isolated nucleic acid molecule for treating or preventing, e.g. pain, anoxia, intestinal bowel disorders, bulimia, asthma, or Parkinson's disease. XX PS Disclosure; SEQ ID NO 15; 77bp; English.

XX The invention describes an isolated nucleic acid molecule with cytostatic, anti-HIV, analgesic, anabolic, antiasthma, antiparkinsonian, hypotensive, osteopathic, anti-ulcer, antiallergic, neuroleptic, cardiovascular properties. The invention is used for preventing, treating, or ameliorating a medical condition, e.g. pathological condition. It is used for, e.g. neoplastic diseases such as cancers and tumours, HTV infections, pain, anoxia, intestinal bowel disorders, bulimia, asthma, Parkinson's disease, acute heart failure, hypertension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, ulcers, allergies, benign prostatic hypertrophy, psychotic, immune, metabolic, cardiovascular and neurological disorders. The invention does not hybridise under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues. This is the amino acid sequence of a receptor used in a n alignment with the novel human G-protein coupled receptor HGPRBMY3 of the invention.

XX SQ Sequence 361 AA;

Query Match 82.2%; Score 1597; DB 8; Length 361; Best Local Similarity 82.7%; Pred. No. 1.1e-165; Matches 302; Conservative 20; Mismatches 39; Indels 4; Gaps 1;

Qy 1 MASTESSLRLSIGLSPGPSSSEVELDQFDKPFILLPSVAVVFTVLGIGLNAPTLWLF 60

Db 1 MTSAAESELFLTSGPSPSSGDD--DCRPNEERPKFILLPMSVAVVFTVLGALNAPTLWLF 56

Qy 61 LDPTVLYLTGDKYRNQOLCRESKPKRTAASSLAVLHEBESISRWDTHQDSFTSAY 356

Db 297 LDPTVLYLTGDKYRNQOLCRESKPKRTAASSLAVLHEBESISRWDTHQDSFTSAY 356

Qy 361 RADRL 365

Db 357 EGDRL 361

RESULT 10
ID ADFF91782 Standard; protein: 361 AA.
XX AC ADFF91782;
XX DT 26-FEB-2004 (First entry)
XX DE Rat orphan GPCR.

57 LFLRLPRNDATATYMPHLLSDTLYLVSPLTVYYAARRNNHWPFGTGLICKFVRLFLFTWNL 116
 Qy 121 CSYLFICISVRYLGICHEPILALRWGRPRILAGILCLAVMLIVAGCLVPLNLFVFTTSNKG 180
 Qy 117 CSVLFICISVRYLGICHEPILALRWGRPRIAGILCLAVMLIVAGCLVPLNLFVFTTSNKG 176
 Db 181 TTVLCHDPTTRBEPFDHYTHFSSAVMGLLFCYPCLVLYCYGLMARLYQPLPGSAOSSR 240
 Db 177 TTVLCHDPTTRBEPFDHYTHFSSAVMGLLFCYPCLVLYCYGLMARLYRPLPGASOSSR 236
 Qy 241 LSLRLTIAVVLTVFAVCVPFHTRTIYLARLEADCRVINTVNYYKVTRPLASNSC 300
 Db 237 LSLRLTIAVVLTVFAVCVPFHTRTIYLARLEADCRVINTVNYYKVTRPLASNSC 296
 Qy 301 LDPEVLYLUTGDKYRROLQCGGKPOORTAASSLALVSLPDDSSCRWAATPQDSSCSTP 360
 Db 297 LDPEVLYLUTGDKYRNLQQLCRGSKPKRTAASSLALVLTHEESISRWAUTHQDSTSFSAY 356
 Qy 361 RADRL 365
 Db 357 EGDRL 361

RESULT 11
 ID ADR89629 standard; protein; 361 AA.
 XX ADR89629;
 DT 02-DEC-2004. (first entry)
 DE Rat G-protein coupled receptor.
 XX HGPRBMY23; G-protein coupled receptor; receptor; rat.
 KW Rattus sp.
 OS WO2004076636-A2.
 *XX PD 10-SEP-2004.
 XX PF 26-FEB-2004; 2004WO-US005535.
 XX PR 26-FEB-2003; 2003US-00375157.
 XX (BRIM) BRISTOL-MYERS SQUIBB CO.
 Barber LE, Cacace A, Feder JN, Nelson TC, Ramanathan CS;
 PI Ryseck R, Neubauer MG, Kornacker MG;
 XX WPI: 2004-653403/63.
 DR SWISSPROT; 035611.
 XX New nucleic acid molecules encoding HGPRBMY23 polypeptides of the G-protein coupled receptor superfamily, useful for diagnosing, treating, or ameliorating pulmonary, renal, or proliferative disorders, e.g. cancer.

Disclosure; SEQ ID NO 9; 370pp; English.

XX The present sequence is that of a rat G-protein coupled receptor that shows 31% identity and 41% similarity to the protein sequence ADR89622 of novel human G-protein coupled receptor HGPRMY23. The invention provides HGPRBMY23 polypeptides and polynucleotides, vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides. Methods are provided for identifying agonists and antagonists of HGPRBMY23. The polypeptides, polynucleotides, modulators and methods are useful for diagnosing, treating or ameliorating a disease or disorder related to HGPRBMY23, particularly renal diseases and/or disorders, colon cancer, breast cancer, and diseases and disorders related to aberrant NFKappaB modulation.

CC Sequence 361 AA;

Query Match Similarity 82.2%; Score 1597; DB 8; Length 361;
 Best Local Similarity 82.7%; Pred. No. 1.1e-165;
 Matchers 302; Conservative 20; Mismatches 39; Indels 4; Gaps 1;

Qy 1 MASTESSLLRSLSLSPGPSSSEVRLDCWPEDEDFKPLLPVSAYVFLGLINAPTLWLF 60
 Db 1 MTSABSLLFTSLGPSSSGD---DCRPNBPKFILLPMSAYVFLGLINAPTLWLF 56
 Qy 61 IFLPLRWDATATYMPHLLSDTLYLVSPLTVYYAARRNNPFGTGLICKFVRLFLFTWNL 120
 Db 57 LFRLRWDATATYMPHLLSDTLYLVSPLTVYYAARRNNPFGTGLICKFVRLFLFTWNL 116
 Qy 121 CSVLFLTCISVRYLGICHPRLRKGRLPLAGLICLAVLVLVAGCLVPLNLFVFTTSNKG 180
 Db 117 CSVLFLTCISVRYLGICHPRLRKGRLPLAGLICLAVLVLVAGCLVPLNLFVFTTSNKG 176
 Qy 181 TTVLCHDTRPEEPFHYVFHSSAVNGLLFGVPCLVLYCYGLMARLYQPLPGSAQSSR 240
 Db 177 TTVLCHDTRPEEPFHYVFHSSAVNGLLFGVPCLVLYCYGLMARLYRPLPGACGSSR 236
 Qy 241 LRSLTIAVVLTVFAVCVPFHTRTIYLARLEADCRVINTVNYYKVTRPLASNSC 300
 Db 237 LRSLTIAVVLTVFAVCVPFHTRTIYLARLEADCRVINTVNYYKVTRPLASNSC 296
 Qy 301 LDPPVYLLUTGDKYRROLQCGGKPOORTAASSLALVSLPDDSSCRWAATPQDSSCSTP 360
 Db 297 LDPPVYLLUTGDKYRNLQQLCRGSKPKRTAASSLALVLTHEESISRWAUTHQDSTSFSAY 356
 Qy 361 RADRL 365
 Db 357 EGDRL 361

RESULT 12
 ID ADS84264 standard; protein; 361 AA.
 XX ADS84264;
 AC ADS84264;
 XX DT 13-JAN-2005 (first entry)
 DB Rat G protein-coupled receptor 035811.
 XX KW Rat; receptor; G protein-coupled receptor; GPCR; HGPRBMY3; HGPRBMY11; HGPRBMY23; GPCR; PY10; proliferative disorder; immunological disorder; KW immunodeficiency disease; immune reaction; transplanted rejection; KW autoimmunity; infection; hypersensitivity; cancer; neurological disorder; KW dyskinesia; infection; arthritis; rheumatoid arthritis; asthma; leukaemia; granulomatous disease; inflammatory bowel disease; sepsis; KW allergy; acne; neutropenia; psoriasis; AIDS.
 XX OS Rattus sp.
 XX PN US2004209808-A1.
 XX PR 21-OCT-2004.
 XX P1 10-FEB-2004; 2004US-00775965.
 XX PR 11-FEB-2003; 2003US-0446655P.
 XX PA (KORN/) KORNACKER M G.
 XX P1 Kornacker MG;
 XX DR 2004-747284/73.
 XX PT New isolated peptide, useful for treating e.g., immunodeficiency diseases, immune reactions to transplanted organs and tissues, or proliferative disorders (e.g., cancer).
 PT
 PT
 PT
 PT
 SQ Example 1; SEQ ID NO 15; 113pp; English.

The invention relates an isolated peptide which binds to the human G protein-coupled receptor (GPCR) HGPBMY23 or to HGPBMY11, HGPBMY23 or GPCR P2Y10. Also included are an isolated nucleic acid encoding the peptides, a vector comprising the nucleic acid, a host cell comprising the vector (where the host cell is selected from bacterial, yeast, insect, mammalian, and plant cells), a primer or probe designed against the nucleic acid, a polypeptide complex (comprising a P2Y-type G-protein coupled receptor, and a peptide comprising an amino acid sequence above, or a polypeptide complex comprising a G-protein coupled receptor selected from P2Y10, human G-protein coupled receptor (HGPR) BM3, HGPBMY11, and HGPBMY23, and a peptide comprising the amino acid sequence above), an antibody that binds to the peptide, a peptide library generated from the nucleic acid molecules, identifying a binding agent for a P2Y-type G-protein coupled receptor (or G-protein coupled receptor selected from P2Y10, HGPBMY11, and HGPBMY23), identifying a P2Y-type G-protein coupled receptor, identifying a binding agent for a P2Y-type G-protein coupled receptor, a kit for detecting a P2Y-type G-protein coupled receptor (comprising the binding peptide or the antibody and one or more reagents for detecting binding of the receptor and the peptide or antibody), diagnosing a proliferative disorder and a pharmaceutical composition (comprising the nucleic acid molecule, the isolated vector, the peptide or the antibody, and a carrier, excipient, or diluent). The pharmaceutical composition is useful for treating a proliferative disorder. The peptides are useful as diagnostic, prophylactic, and therapeutic agents for immunological disorders, immunodeficiency diseases, immune reactions to transplanted organs and tissues, autoimmune disorders, hypersensitivity, cancer, neurological disorders, dyskinesias, and infection susceptibility, arthritis, rheumatoid arthritis, asthma, leukaemia, granulomatous disease, inflammatory bowel disease, sepsis, allergies, acne, neutropenia, psoriasis, AIDS and many more diseases and disorders given in the specification. The present sequence represents a GPCR homologous to HGPBMY3.

Sequence 361 AA;

Query Match Score 1597; DB 8; Length 361;
Best Local Similarity 82.7%; Pred. No. 1..le-165; 20; Mismatches 39; Indels 4; Gaps 1;

Matches 302; Conservative 39;

Query 1 MASTESSPLRSLSGLSPGPGSSEVLDGMFDEDKFKFLILLPVSAYVFTYVGLGNAPTLWLF 60

DB 1 MTAESLTLTSLGSPSSSDG---DCEFNEEFKFLILPMSTAVVFTYVGLGNAPTLWLF 56

Query 61 IFLRLRPWDATATMFMHLLSDTLVYLSPFLIVYYAAHNHWPGTE1CKFVRFLYWNLY 120

DB 57 LFLRLRPWDATATMFMHLLSDTLVYLSPFLIVYYAAHNHWPGTGKLUCKFVRFLYWNLY 116

Query 121 CSVFLTLCISVHRYLGICHPRLARLGPRPLAGLCLVQWLVYAGCLVPLFYTISMKG 180

DB 117 CSVFLTLCISVHRYLGICHPRLAIRWGPRFAISLCLGWLVTAGCLVPLFFVTTNANG 176

Query 181 TTIVLCHDPTTRPEEFDHYTHFSSAVMGLFGVPCLVLYCYGMARRLYQPLPGSAQSSSR 240

DB 177 TTIVLCHDPTTRPEEFDHYTSSAVMVLGLPFLITLYCYGMARRLRPLPAQGQSSSR 236

Query 241 LRSIERTIAVTVTPAVCFYPFHTRTITYLARLEADCRVLTNYVVKTRPLASANSC 300

DB 237 LRSIERTIAVTVTPAVCFYPFHTRTITYQARLQADCHVNLNVVVKTRPLASANSC 296

Query 301 LDPPVLYLTSQDVKYRQLRQCGGGKQPQRTAASSLALVSLPEDSSCRVAATPQDSCTP 360

DB 297 LDPPVLYLTFGDTRNQLQQLJRGSKPKRTAASSLALVSLPEDSSCRVAATPQDSCTP 356

Query 361 RADRU 365

DB 357 EGDRL 361

XX AC ADO29599;

XX DT 29-JUL-2004 (first entry)

XX DB Mouse GPCR P2Y4, SEQ ID NO: 701.

XX G protein-coupled receptor; GPCR; drug screening; diagnosis;

XX KW transgenic mouse; neurological disorder; adrenal gland disorder;

XX KW colon disorder; intestinal disorder; cardiovascular disorder;

XX KW muscular disorder; blood disorder; immune disorder; bone disorder;

XX KW joint disorder; metabolic disorder; nutritive disorder; cancer;

XX KW kidney disorder; liver disorder; lung disorder; breast disorder;

XX KW ovary disorder; uterus disorder; prostate disorder; testis disorder;

XX KW skin disorder; stomach disorder; pancreas disorder; spleen disorder;

XX KW thymus disorder; thyroid disorder; anti-parkinsonian; antimanic;

XX KW cytostatic; anti-inflammatory; vasoconstrictor; antiarrhythmic;

XX CNS; central nervous system; respiratory; anti-diarrhoeic; antidiabetic;

XX viricide; hepatotropic; antibacterial; antiaemic; antiseborrhoeic;

XX dermatological; antiulcer; antithyroid; anorectic;

XX immunosuppressive; nephrotropic; gene therapy; GPCR modulator; mouse;

XX murine; receptor.

XX Mus musculus.

XX OS WO2004040000-A2.

XX PN WO2004040000-A2.

XX PD 13-MAY-2004.

XX PP 09-SEP-2003; 2003WO-US028226.

XX PR 09-SEP-2002; 2002US-0409303P.

XX PR 09-APR-2003; 2003US-0461329P.

XX PA (PRIM-) PRIMAL INC.

XX PI Gaitanaris GA, Bergmann JE, Gragerov A, Hohmann J, Li F;

PI Madisen L, McIlwain KL, Pavlova MN, Vassilatis D, Zeng H;

XX WPI; 2004-390329/36.

XX N-PSDB; ADO30308.

XX Novel mammalian G protein coupled receptors, useful for identifying compounds that modulates diagnosing and treating disease conditions associated with GPCR dysfunctions e.g. autoimmune diseases, pectoritis, Parkinson's disease.

XX Claim 151, SEQ ID NO 701; 542DP; English.

XX The invention relates to human and mouse G protein-coupled receptors (GPCRs) and nucleic acids encoding them. The invention also relates to PT sequences at least 90% identical to the GPCR proteins and nucleic acids PT of the invention; methods of treating, preventing or diagnosing diseases PT associated with GPCRs of the invention; methods of screening for pectoritis, Parkinson's disease.

XX PS Claim 151, SEQ ID NO 701; 542DP; English.

XX The invention relates to human and mouse G protein-coupled receptors CC (GPCRs) and nucleic acids encoding them. The invention also relates to CC sequences at least 90% identical to the GPCR proteins and nucleic acids CC of the invention; methods of treating, preventing or diagnosing diseases CC associated with GPCRs of the invention; methods of screening for CC pectoritis, Parkinson's disease.

XX PS Claim 151, SEQ ID NO 701; 542DP; English.

XX The invention relates to human and mouse G protein-coupled receptors CC (GPCRs) and nucleic acids encoding them. The invention also relates to CC sequences at least 90% identical to the GPCR proteins and nucleic acids CC of the invention; methods of treating, preventing or diagnosing diseases CC associated with GPCRs of the invention; methods of screening for CC pectoritis, Parkinson's disease.

XX PS Claim 151, SEQ ID NO 701; 542DP; English.

XX The invention relates to human and mouse G protein-coupled receptors CC (GPCRs) and nucleic acids encoding them. The invention also relates to CC sequences at least 90% identical to the GPCR proteins and nucleic acids CC of the invention; methods of treating, preventing or diagnosing diseases CC associated with GPCRs of the invention; methods of screening for CC pectoritis, Parkinson's disease.

XX PS Claim 151, SEQ ID NO 701; 542DP; English.

XX The invention relates to human and mouse G protein-coupled receptors CC (GPCRs) and nucleic acids encoding them. The invention also relates to CC sequences at least 90% identical to the GPCR proteins and nucleic acids CC of the invention; methods of treating, preventing or diagnosing diseases CC associated with GPCRs of the invention; methods of screening for CC pectoritis, Parkinson's disease.

XX PS Claim 151, SEQ ID NO 701; 542DP; English.

XX The invention relates to human and mouse G protein-coupled receptors CC (GPCRs) and nucleic acids encoding them. The invention also relates to CC sequences at least 90% identical to the GPCR proteins and nucleic acids CC of the invention; methods of treating, preventing or diagnosing diseases CC associated with GPCRs of the invention; methods of screening for CC pectoritis, Parkinson's disease.

XX PS Claim 151, SEQ ID NO 701; 542DP; English.

XX The invention relates to human and mouse G protein-coupled receptors CC (GPCRs) and nucleic acids encoding them. The invention also relates to CC sequences at least 90% identical to the GPCR proteins and nucleic acids CC of the invention; methods of treating, preventing or diagnosing diseases CC associated with GPCRs of the invention; methods of screening for CC pectoritis, Parkinson's disease.

XX PS Claim 151, SEQ ID NO 701; 542DP; English.

XX The invention relates to human and mouse G protein-coupled receptors CC (GPCRs) and nucleic acids encoding them. The invention also relates to CC sequences at least 90% identical to the GPCR proteins and nucleic acids CC of the invention; methods of treating, preventing or diagnosing diseases CC associated with GPCRs of the invention; methods of screening for CC pectoritis, Parkinson's disease.

XX PS Claim 151, SEQ ID NO 701; 542DP; English.

XX The invention relates to human and mouse G protein-coupled receptors CC (GPCRs) and nucleic acids encoding them. The invention also relates to CC sequences at least 90% identical to the GPCR proteins and nucleic acids CC of the invention; methods of treating, preventing or diagnosing diseases CC associated with GPCRs of the invention; methods of screening for CC pectoritis, Parkinson's disease.

XX PS Claim 151, SEQ ID NO 701; 542DP; English.

XX The invention relates to human and mouse G protein-coupled receptors CC (GPCRs) and nucleic acids encoding them. The invention also relates to CC sequences at least 90% identical to the GPCR proteins and nucleic acids CC of the invention; methods of treating, preventing or diagnosing diseases CC associated with GPCRs of the invention; methods of screening for CC pectoritis, Parkinson's disease.

XX PS Claim 151, SEQ ID NO 701; 542DP; English.

CC diseases); and disorders of the kidney, liver, lung, breast, ovary and
 CC prostate, testis, skin, stomach, pancreas, spleen, thymus and
 CC thyroid (e.g., cancers). The present sequence represents a GPCR of the
 CC invention. Note: The full sequence data for this patent did not form part
 CC of the printed specification; those sequences not shown were obtained in
 CC electronic format directly from WIPO at
 CC ftp://wipo.int/pub/published_pct_sequences.
 XX

Sequence 361 AA:

```
Query Match 80.3%; Score 11561; DB 8; Length 361;
Best Local Similarity 80.8%; Pred. No. 9_66-162;
Matches 295; Conservative 20; Mismatches 46; Indels 4; Gaps 1;
Db 1 MASTESSLRLSGLSPGPSSSEVLDCWFDDEDPKFILLPVSYAVVFGNAPTLWLF 60
Db 1 MTSADSLLPLTSLGSPSSSDG---DCKENEEFPILPLPSYAVVFGNAPTLWLF 56
Qy 61 IFLRARPMDATATYMFHIALSDPTLYVLSPLTLLYYAANHWPCTEICKFPLFLYNY 120
Db 57 LFRARPMDATATYMFHIALSDPTLYVLSPLTLLYYAANHWPCTEICKFPLFLYNY 116
Qy 121 CSVFLTCISVARYLGICPPLRAIRWRPLLAGLCLAWLWVAGLIVPNLFFVITNSKG 180
Db 117 CSVFLTCISVARYMGICPPLRAIRWRPLRPGALCLGWLWVAGLIVPNLFFVITANG 176
Qy 181 TTFLCHDFTTRPEEFDDHYTHFESSAVMGFLFGVPCLVLTVCYGLMARRLYQPLGSAQSSR 240
Db 177 TTFLCHDFTLPESBDHYTFSSSTIMVLFGFPFLITLCYGLMARRLYRPLGAGESSR 236
Qy 241 LRSLRITAVLVLTIVAVCFVCPFHITRTIYTILARLEADPVLATIVVVKTPPLASNSC 300
Qy 242 LRSLRITAVLVLTIVAVCFVCPFHITRTIYTILARLNAECSVTVVVVKKTPPLASNSC 296
Db 237 LRSLRITAVLVLTIVAVCFVCPFHITRTIYTILARLNAECSVTVVVVKKTPPLASNSC 296
Qy 301 LDGVLYLTGDKYRQLQQLCGGSKPQRTAASSLALYSLPESSCRWAATPQDSCSTP 360
Db 297 LDGVLYLTGDKYRNLQQLCGGSKPQRTTASSLALYSLPESSCRWAATPQDSCSTP 356
*Qy 361 RADRL 365
Db 357 EGDRL 361
```

RESULT 14

AAE04390 standard; protein, 374 AA.

AC AAE04390;

DT 04-SEP-2001 (first entry)

DE Turkey P2Y nucleotide receptor.

KW Turkey; P2-purinergic receptor; P2Y12; vasotroptic; thrombolytic;
 cerebroprotective; gynaecological; ADP; adenosine 5'-diphosphate; angina;
 myocardial infarction; ischaemic attack; preeclampsia; bleeding disorder;
 carotid endarterectomy; vascular graft surgery; brain disorder; migraine;
 vascular injury; schizophrenia; eating disorder; depression; restenotic;
 peripheral vascular disease; platelet aggregation; stroke; embolism;
 thrombocytopaenic purpura; stroke; pertussis toxin-sensitive G protein;
 Gi; disseminated intravascular coagulation; P2Y nucleotide receptor;
 cardiot; thrombosis.
 XX Melegria gallopatho.
 XX WO200146454-A1.

XX 28-JUN-2001.

XX PP 26-DEC-2000; 2000WO-US034998.

XX PR 23-DEC-1999; 99US-0171622P.

PA (CORT-) COR THERAPEUTICS INC.

XX Conley PB, Jantzen H, Ramakrishnan-Dubridge V, Julius DJ;

CC Hollereter G;

CC DR WPI; 2001-418082/44.

XX Novel isolated ADP receptor, termed P2Y12 receptor polypeptide, useful
 PT for identifying binding partners and for diagnostic applications.
 XX Disclosure; Page 95-96; 108pp; English.

PS The invention relates to ADP (adenosine 5'-diphosphate) receptor, termed
 XX CC as P2Y12 receptor and its corresponding cDNA molecule. P2Y12 receptor is expressed
 CC as the subtype of P2-purinergic receptor. The P2Y12 receptor is a G protein-coupled receptor
 CC selectively in the platelets and brain, and couples to a pertussis toxin-
 CC sensitive G protein (Gi). P2Y12 receptor is a G protein-coupled receptor
 CC that responds to ADP. The invention also relates to a method for
 CC identifying an agent which is useful for modulating acute myocardial
 CC infarction, unstable angina, chronic stable angina, transient ischaemic
 CC attacks, strokes, peripheral vascular disease, preeclampsia, deep venous
 CC thrombosis, embolism, disseminated intravascular coagulation, thrombotic
 CC thrombocytopenic purpura or a bleeding disorder; thrombotic and
 CC complications following angioplasty, carotid endarterectomy,
 CC post CABG (coronary artery bypass graft) surgery, vascular graft surgery,
 CC stent placement or insertion of endovascular devices and prostheses.
 CC P2Y12 receptor is useful for identifying binding partners and for
 CC diagnostic applications. P2Y12 receptor provides targets for screening
 CC synthetic small molecules and combinatorial or naturally occurring
 CC compound libraries to regulate platelet aggregation, vascular injury, or
 CC disease as well as schizophrenia, eating disorders, depression, migraine
 CC and other brain disorders. The present sequence is turkey P2Y nucleotide
 CC receptor related to the invention

XX Sequence 374 AA:

```
Query Match 58.0%; Score 1127.5; DB 4; Length 374;
Best Local Similarity 59.3%; Pred. No. 3e-114;
Matches 208; Conservative 56; Mismatches 70; Indels 17; Gaps 4;
Qy 9 LRSGLGSP-----GPGSSEYELDCWFDDEDPKFILLPVSYAVVFGNAPTLW 58
Db 5 VRMFSLAPWPTPPTPMGGNTTAAEAKCVENEEPKPLPISGYVFWVPLNSWAMW 64
```

Qy 59 LFIFPLRBPNTATYMFHIALSDPTLYVLSPLTLLYYAANHWPCTEICKFPLFLYNY 118
Db 65 IFVSRGRPRWNNATTTMFLNLSIDDTIVXESPLTVYYADRNWNPCKVFKIVRFAYN 124
Qy 119 LYCSYTFELTCISVARYLGICPPLRAIRWRPLLAGLCLAWLWVAGLIVPNLFFVTTSN 178
Db 125 LYSSSFLFCTISVARYMGICPPLRAIRWRPLLAGLCLAWLWVAGLIVPNLFFVTTSN 184
Qy 179 KGTTVLCHDTDRPBFEDHYTHFSSAVMGFLFGVPCLVLTVCYGLMARRLYQ--PLPGSA 235
Db 185 KDNSTLICHDTKPFEDHYTHFSSSIMALFGIPPLVIVCYCLAKRLCKRSFPSPSR 244
Qy 236 QSSSLRSLSLTIAVLTIVAVCFVCPFHITRTIYTILARLEADPVLATIVVVKTPRPLA 295
Db 245 VPSYKRSRSMIIILTVFAICFVPHITLTLYTSRYFOADCQTININFTYKTPRPLA 304
Qy 296 SANSCDPLVYLTDKTYRQLRQJGGKQPQPRTAASSLALYSLPESSCRWAATPQDSCSTP 345
Db 305 SINSCDPLVYLTDKTYRQLRQJGGKQPQPRTAASSLALYSLPESSCRWAATPQDSCSTP 352

RESULT 15
 ADI16982

ID ADI16982 standard; protein, 374 AA.

XX AC ADI16982;

XX DT 15-APR-2004 (first entry)

XX XX

DE Turkey NOVX protein homologue SegID 518.
 XX turkey; NOVX; cardiomyopathy; atherosclerosis; cancer; diabetes;
 KW inflammation; autoimmune disorder; allergy; blood disorder;
 KW acquired immunodeficiency syndrome; AIDS; obesity; asthma;
 KW immunoglobulin (Ig)A nephropathy; cirrhosis; arthritis;
 KW Alzheimer's disease; infection; str.
 XX OS Meleagridis galloppavo.
 XX WO200266649-A2.
 PN PD-SEP-2002.
 XX XX 31-JAN-2002; 2002AO-US002785.
 PP XX 31-JAN-2001; 2001US-0265395P.
 PR 31-JAN-2001; 2001US-0265412P.
 PR 31-JAN-2001; 2001US-0265514P.
 PR 31-JAN-2001; 2001US-0265517P.
 PR 05-FEB-2001; 2001US-0266406P.
 PR 05-FEB-2001; 2001US-0266767P.
 PR 07-FEB-2001; 2001US-0266975P.
 PR 07-FEB-2001; 2001US-0267057P.
 PR 08-FEB-2001; 2001US-0267459P.
 PR 09-FEB-2001; 2001US-0267823P.
 PR 15-FEB-2001; 2001US-0268974P.
 PR 26-FEB-2001; 2001US-0271664P.
 PR 27-FEB-2001; 2001US-0271839P.
 PR 02-MAR-2001; 2001US-0271855P.
 PR 02-MAR-2001; 2001US-0272788P.
 PR 14-MAR-2001; 2001US-0273046P.
 PR 14-MAR-2001; 2001US-0275925P.
 PR 14-MAR-2001; 2001US-0275947P.
 PR 14-MAR-2001; 2001US-0275950P.
 PR 15-MAR-2001; 2001US-0275989P.
 PR 15-MAR-2001; 2001US-0276448P.
 PR 16-MAR-2001; 2001US-0276450P.
 PR 16-MAR-2001; 2001US-0276397P.
 PR 20-MAR-2001; 2001US-0276768P.
 PR 26-MAR-2001; 2001US-0278652P.
 PR 26-MAR-2001; 2001US-0278778P.
 PR 29-MAR-2001; 2001US-0279882P.
 PR 29-MAR-2001; 2001US-0279883P.
 PR 30-MAR-2001; 2001US-0280147P.
 PR 11-APR-2001; 2001US-0282992P.
 PR 11-APR-2001; 2001US-0283133P.
 PR 20-APR-2001; 2001US-0283133P.
 PR 23-APR-2001; 2001US-0285749P.
 PR 03-MAY-2001; 2001US-0288327P.
 PR 03-MAY-2001; 2001US-0288504P.
 PR 29-MAY-2001; 2001US-0294047P.
 PR 30-JUN-2001; 2001US-0294947P.
 PR 08-JUN-2001; 2001US-0296964P.
 PR 18-JUN-2001; 2001US-0298959P.
 PR 19-JUN-2001; 2001US-0298959P.
 PR 13-AUG-2001; 2001US-0312020P.
 PR 16-AUG-2001; 2001US-0312889P.
 PR 16-AUG-2001; 2001US-0312908P.
 PR 21-AUG-2001; 2001US-0313390P.
 PR 28-AUG-2001; 2001US-0315470P.
 PR 31-AUG-2001; 2001US-031647P.
 PR 07-SEP-2001; 2001US-0318115P.
 PR 07-SEP-2001; 2001US-0318118P.
 PR 12-SEP-2001; 2001US-0318740P.
 PR 19-SEP-2001; 2001US-0323379P.
 PR 18-OCT-2001; 2001US-033245P.
 PR 14-NOV-2001; 2001US-0333038P.
 PR 14-NOV-2001; 2001US-0332701P.
 XX

Tchernev VT, Spytek KA, Zerhusen BD, Paturajan M, Shimkets RA,
 Li L, Gangolfi BA, Padigaru M, Anderson DW, Restelli L, Miller CE;
 Gerlach VL, Taupier RJ, Gusev VI, Colman SD, Rieger DM, Lepley DR, Burgess CB;
 Furtak K, Gross WM, Alsobrook JP, Lepley DM, Rieger DK, Burgess CB;
 XX DR WPI: 2002-706998/76.
 XX PT New NOVX polypeptides and nucleic acids, useful for preventing or
 PT treating NOVX-associated disorders, e.g. cancer, cardiomyopathy, tissue typing or
 PT atherosclerosis, or diabetes, and in chromosome mapping, tissue mapping, or
 PT pharmacogenomics.
 XX PS Disclosure; SEQ ID NO 518; 1498PP; English.
 XX CC This invention relates to a novel nucleic acids, and encoded polypeptides
 CC thereof, which have properties related to the stimulation of biochemical
 CC or physiological responses in a cell, tissue, organ or organism.
 CC Specifically, it refers to the use of biologically active fragments for
 CC diagnostic and prognostic assays and furthermore in the treatment of
 CC diverse pathological conditions. The present invention describes novel
 CC human and murine NOVX proteins, as well as methods to modulate their
 CC expression using antisense oligos, ribozymes and peptide nucleic acids.
 CC The NOVX polypeptides, polymucleotides and antibodies are useful in
 CC treating or preventing NOVX-associated disorders, e.g. cardiomyopathy,
 CC atherosclerosis, cancer and diabetes. Furthermore, they may be used in
 CC treating or preventing diseases such as inflammation, autoimmune
 CC disorders, allergies, blood disorders, acquired immunodeficiency syndrome
 CC (AIDS), obesity, asthma, immunoglobulin (Ig)A nephropathy, cirrhosis,
 CC arthritis, Alzheimer's disease, infections, stroke, muscular dystrophy
 CC and epilepsy. Accordingly, these molecules have many activities including
 CC cytostatic, cardiant, antiinflammatory, immunosuppressive, anti-allergic,
 CC haemostatic, anti-HIV, antidiabetic, antiarteriosclerotic, anorectic,
 CC antiarrhythmic, nephrotoxic, antiarthritic, hepatotoxic,
 CC neuroprotective, nootropic, antibacterial, virucide, antiparasitic,
 CC relaxant and anticonvulsant. In addition, they are useful in screening
 CC assays to identify small molecules that modulate or inhibit, for example,
 CC neurogenesis, wound healing and angiogenesis. The nucleic acids are also
 CC used as in chromosome mapping, tissue typing, preventive medicine and
 CC pharmacogenomics. This polypeptide is a homologue of a human NOVX protein
 CC of the invention.
 XX SQ Sequence 374 AA:

Query	Match	Score	Length
9 LRSIGLSP-----	58.0%	1127.5;	DB 5;
5 VAMFSLAPWPTPTPWLGNTAAEAKCVPNEEFKFTLPLPSYGVvGvPLNSWMM	59.3%	Pred. No. 3e-114;	;
QY	56;	Mismatches 70;	Indels 17; GapS 4;
Db	208;	Conservative	;
Matches	;	;	;

QY 59 LPFPLREWDATYTMFLALDSTLTVLSLPLTLYYYAHNEWPPGFEICKYVRFELVWN 58
 QY 65 IFVSRMRPWNATTYTMFLAISDPLTYESLPLTLYYYADRNWWPGKVFCKLVRFELVAN 124
 QY 119 LYCSVLFLTCISVRYLGICHPLRALKWRGRPLAGLCLAVLNLYVAGELVNPNUFVTISN 178
 QY 125 LYSILFLICISVRYMGICHPLRALKWRGRPLAGLCLAVLNLYVAGELVNPNUFVTIS 184
 QY 179 KGTTVLCHDTTRPEFDHYVHFSSAVNGCLLFGYPCLYLVCYGMARLLYQ--PLPGSA 235
 QY 185 KONSTLCHDTTRPEFDIVVHYSIMALLFGIPFLVVCYCLAMAKLCKRSFPSPSR 244
 QY 236 QSSRLSLRTIAVLTIVPAVCFVPEFHTRTYLARLEADERVNLNTVVYKVTRPLA 295
 QY 245 VPSYKRSRDKPVTFHTRTYLTSYRFQADCTLNTINFTYKTRPLA 304
 QY 296 SANSCLDPVLYLJTGDKYRQLQCGKGPDTAAS-LANSLPEDSS 345
 QY 305 SINGCLDPVLYMAGDKTRGLRR--GAAQRPRPVPTSLLVSPSVDS 352
 Db

Wed Apr 5 13:47:54 2006

us-10-811-198-2.rag

Page 13

Job time : 193 secs